

5

10

15

20

APPLICATION FOR UNITED STATES LETTERS PATENT

for

LPS-RESPONSE GENE COMPOSITIONS AND METHODS

by

Bruce A. Beutler

and

Alexander Poltorak

EXPRESS MAIL MAILING LABEL

NUMBER: EL259185441US

DATE OF DEPOSIT: September 15, 1999

BACKGROUND OF THE INVENTION

This application claims priority to and specifically incorporates by reference, the content of U.S. Provisional Application Serial No. 60/100,403 filed September 15, 1998 and U.S. Provisional Application Serial No. 60/102,392 filed September 29, 1998. The entire text of each of the above-referenced disclosures is specifically incorporated by reference herein without disclaimer.

1. Field of the Invention

The present invention relates generally to the fields of microbiology and immunology. More particularly, it concerns the response of macrophages to endotoxin exposure from Gram-negative bacteria and methods of detecting and treating individuals at high risk for infection by Gram-negative bacteria and inhibiting sepsis and septic shock.

2. Description of Related Art

"Innate" or "natural" immunity is largely subserved by macrophages and NK cells. These cells lack the huge repertoire of pathogen receptors that comprise the afferent limb of "specific" immunity, *e.g.*, the receptors found on T-cells and B-cells. Rather, they rely upon very broadly effective mechanisms for the recognition of invasive organisms. An important case in point concerns Gram-negative bacteria, all of which bear endotoxin (lipopolysaccharide, LPS) molecules in their outer membrane, which trigger a strong immune response on the part of the host which produces a shock-like syndrome, characterized by low blood pressure and hyporeactivity to vasoconstrictor agents.

When macrophages are exposed to pure preparations of endotoxin, they secrete numerous cytokine mediators, including tumor necrosis factor (TNF, TNF α), interleukin-1 (IL-1), interferon- α/β , GM-CSF, IL-8 and ultimately smaller "autocoid" molecules, all of which mediate an intense inflammatory reaction. Endotoxin recognition acts as an early warning signal through which a host may mount a timely defense against invasion by Gram-negative organisms.

However, widespread activation of macrophages by endotoxin results in the development of septic shock. By most estimates, Gram-negative septic shock is responsible for 100,000 deaths per year in the United States alone. The entire syndrome of hypotension, coagulopathy, pulmonary edema and acute renal failure results, in large part, from the release of TNF and other cytokines in response to exposure to endotoxin.

TNF is probably the most important mediator of local inflammatory processes as well as septic endotoxin shock. It is produced quickly and in large amounts by macrophages that encounter endotoxin (Beutler *et al.*, 1985a). TNF causes shock when administered to animals (Tracey *et al.*, 1986), and blockade of TNF synthesis or activity markedly attenuates the lethal effect of endotoxin (Beutler *et al.*, 1985b). The relationship between endotoxin and TNF is therefore directly correlated. Surprisingly, however, little is known about the mechanism by which endotoxin triggers host cells to release TNF.

The cognate receptor for endotoxin, complexed with lipopolysaccharide binding protein (LBP) in plasma, is the GPI-linked cell surface membrane protein CD14. CD14 effectively concentrates endotoxin onto the surface of macrophages and other defensive cells of the host (Wright *et al.*, 1990). However, it does not actually signal the presence of endotoxin, as CD14 has no cytoplasmic component with which to do so.

Endotoxin is known to trigger both tyrosine and serine phosphorylation events within the macrophage cell, and at least in part, *ras*, *raf*, *MEK*, and members of the MAP kinase family are also involved in signal transduction (Geppert *et al.*, 1994). The endpoints of endotoxin signaling include activation of the transcription of TNF and various genes, and activation of the translation of TNF mRNA (Beutler *et al.*, 1986; Han *et al.*, 1990). At the protein level, this stimulation by endotoxin leads to a several thousand-fold augmentation of cytokine biosynthesis by a macrophage cell. But the initial controlling element and event in the signaling pathway of macrophage response to endotoxin has not been identified. Thus, in spite of its importance, most of the endotoxin signaling pathway remains relatively unknown. Recently however, the

Toll-like receptor 2 (TLR2) has been suggested to partially mediate lipopolysaccharide-induced cellular signaling (Gerard, 1998; Yang *et al.*, 1998).

Thirty years ago, mice of the C3H/HeJ strain were noted to be specifically and globally unresponsive to endotoxin, while closely related animals of the C3H/HeN or C3H/OuJ substrains exhibited normal responses (Sultzter, 1968). The median lethal dose of endotoxin is more than 100-fold higher in C3H/HeJ mice than in either of these other strains. Macrophages of C3H/HeJ mice fail to produce cytokines in response to endotoxin, and B-lymphocytes of C3H/HeJ mice are not driven to proliferate by endotoxin. While C3H/HeJ mice are highly resistant to the lethal effect of endotoxin, they are unusually sensitive to infection by gram-negative organisms. The mean lethal inoculum with *Salmonella typhimurium*, for example, is two organisms in C3H/HeJ mice, whereas several thousand organisms are required to kill mice of the C3H/HeN strain. Hence, the ability to sense the presence of endotoxin is required for defense against gram-negative organisms and it is speculated that individuals that suffer from sepsis and septic shock have a similar genetic mutation which causes them to be more susceptible to infection.

These defective responses by the C3H/HeJ mice are the result of a single, codominant mutation, which maps to a position between the widely separated *Mup-I* (Major urinary protein) and *Ps* (polysyndactyly) loci on mouse chromosome IV (Watson *et al.*, 1978). Mice homozygous for the mutant allele of the “*Lps* gene” are unresponsive to endotoxin, whereas homozygotes for the common allele are normally responsive, whether lethality or cell-based assays are employed as an index. Heterozygotes exhibit intermediate levels of response. The protein encoded by this mutant gene is the most important known determinant of endotoxin-induced TNF biosynthesis, and indeed, of all reactions to endotoxin.

Many attempts to identify the product of the *Lps* gene, or to clone it have been made. With the recognition that CD14 serves as the principle cell-surface receptor for endotoxin, it was proposed that the *Lps* gene might encode an associated polypeptide chain with signal

transducing potential, or more broadly, an early component of the signal transduction apparatus. Attempts to identify a CD14 binding molecule, which might be the product of the *Lps* gene, have been pursued by several investigators. Two-hybrid screening, affinity chromatography, and cross linking approaches have thus far each failed to pinpoint a protein that specifically engages
5 CD14. Expression cloning strategies have also been applied in the search for the *Lps* gene product without success.

Given the occurrence of gram-negative bacteremia and the high and rising incidence of gram-negative nosocomial infections, a certain subset of the population appears to be at high
10 risk to develop endotoxic shock even if adequate antimicrobial therapy is instituted. It would be useful to know which patients are at high risk for gram-negative bacterial infections and sepsis in advance of its onset. Diagnostic methods that predict the risk of infection as well as the clinical course of sepsis could be reasonably applied to most hospitalized patients. In addition, it is clear that there is an immediate and increasing need for new drugs and treatment methods that
15 regulate macrophage response to gram-negative bacterial infections. Unfortunately, given the current lack of understanding of the regulation of the macrophage response to endotoxin, these drugs and methods have not been developed, and patients continue to be at risk for these life-threatening infections.

SUMMARY OF THE INVENTION

The present invention relates in part to methods for screening for susceptibility to infection. These methods are based on the Inventors' discovery that the Toll-4 or TLR-4 polypeptide plays a role as the LPS receptor and is, therefore, involved in the pathway leading to
25 immune responses in response to certain infections, including especially, certain infection involving Gram negative bacteria. In particular embodiments, the invention provides screening methods for identifying individuals at risk for certain infections. Testing positive for such screens would permit proactive counseling and/or treatment of susceptible individuals. For example, in particular circumstances an individual may be taking immunosuppressive drugs or

be immunodeficient. It would be advantageous in this, and in other instances, for the individual susceptible to infection, to be apprised of the risk to Gram negative bacterial infection. Recently the nomenclature for the Toll-4 protein has been changed to TLR-4 (Toll-like receptor 4). Thus, in the context of the present invention it is important to note that Toll-4 and TLR-4 are used interchangeably. The new nomenclature will be used herein, unless such designation leads to ambiguity in certain textual embodiments.

Such methods for screening for the susceptibility to infection generally comprise: obtaining sample nucleic acid from an animal; and analyzing the sample nucleic acid to detect a mutation in a gene encoding a TLR-4 polypeptide relative to a sequence of a gene encoding a native TLR-4 polypeptide; wherein a mutation in the gene encoding the TLR-4 polypeptide is indicative of susceptibility to infection. In most cases, the nucleic acid analyzed is DNA, and the step of analyzing the TLR-4-encoding nucleic acid comprises sequencing the TLR-4-encoding nucleic acid to obtain a sequence. In order to determine whether a mutation exists in the obtained sequence of the TLR-4-encoding nucleic acid, the sequence may be compared to a native nucleic acid sequence of TLR-4. For example, the native nucleic acid sequence of TLR-4 may have a sequence set forth in SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:46, SEQ ID NO:47 or SEQ ID NO:48. In another example, the native TLR-4 polypeptide may have an amino acid sequence set forth in SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:98 or SEQ ID NO:99. Of course, any methods of determining whether a mutation is present in the gene encoding the TLR-4 polypeptide is within the scope of the invention.

In cases where the TLR-4-encoding nucleic acid comprises a mutation, that mutation may be a point mutation, or any other type of mutation. The step of analyzing the TLR-4-encoding nucleic acid may comprise PCR, an RNase protection assay, or an RFLP procedure. Alternatively, an antibody that discriminates wild-type TLR-4 from mutant TLR-4 nucleic acid or TLR-4 polypeptide may be used in an immunodetection format or the TLR-4 polypeptide may be directly sequenced.

It is contemplated that the mutation in the TLR-4 encoding nucleic acid may arise through deletion mutations, insertion mutations, frameshift mutations, nonsense mutations, missense mutations or splice mutations. In particularly preferred embodiments, the sample nucleic acid comprises a mutation that results in a change from PRO to HIS at residue 712 of a TLR-4 protein of SEQ ID NO:99. In other preferred embodiments, the sample nucleic acid comprises a mutation that results in a change from GLU to LYS at residue 178, a change from ARG to HIS at residue 763, a change from GLN to ARG at residue 188, a change from ASP to GLY at residue 299, a change from ASN to SER at residue 329, a change from GLU to LYS at residue 474, a change from ARG to HIS at residue 763, a change from TYR to CYS at residue 46, a change from PRO to HIS at residue 145, a change from CYS to TYR at residue 281, a change from ASN to HIS at residue 624, or a change from THR to ILE at residue 399 of the native TLR-4 polypeptide amino acid sequence of SEQ ID NO:98. In yet other embodiments, the sample nucleic acid comprises at least a second mutation, wherein the second mutation results in a deletion of VAL-GLY-THR at residues 827-829 of the native TLR-4 polypeptide amino acid sequence of SEQ ID NO:98.

In particular embodiments of the invention, the sample nucleic acid comprises at least one point mutation relative to a nucleic acid sequence from a gene encoding a native TLR-4 polypeptide, wherein the mutation is in nucleotide 2342 of the nucleic acid sequence of SEQ ID NO:46. In further embodiments, the sample nucleic acid comprises at least two point mutations relative to a nucleic acid sequence from a gene encoding a native TLR-4 polypeptide, wherein at least one mutation is a change from nucleotide C to nucleotide A at position 2342 of the nucleic acid sequence of SEQ ID NO:46.

In other cases, at least one mutation is in Exon 2, Exon 3 or Intron 2 of the sequence of SEQ ID NO:47, wherein said at least one mutation is a change from nucleotide A to nucleotide G at position 8457, a change from nucleotide G to nucleotide A at position 8612, a change from nucleotide A to nucleotide G at position 8631, a change from nucleotide A to nucleotide G at position 12245, a change from nucleotide T to nucleotide C at position 12293, a change from

In some cases, the methods of reducing susceptibility to an infection involve diagnosing an animal with susceptibility to infection via analysis of an TLR-4-encoding nucleic acid sequence for a mutation, in any of the manners discussed above.

5 Additional aspects of the invention relate to methods of screening for modulators of an LPS mediated response comprising the steps of: a) obtaining a TLR-4 polypeptide; b) determining a standard activity profile of the TLR-4 polypeptide; c) contacting the TLR-4 polypeptide with a putative modulator; and d) assaying for a change in the standard activity profile. In these cases, the TLR-4 polypeptide may have the amino acid sequence of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:98 or SEQ ID NO:99. The standard activity profile of the TLR-4 polypeptide is determined by determining the ability of the TLR-4 polypeptide to stimulate transcription of a reporter gene, the reporter gene operatively positioned under control of a nucleic acid segment comprising a promoter from a TLR-4 gene

15 In other embodiments, a method of modulating an LPS mediated response comprising modulating TLR-4 function in an animal is provided, often further comprising the step of diagnosing the animal for susceptibility to infection via analysis of a TLR-4-encoding nucleic acid sequence for a mutation relative to a sequence of a gene encoding a native TLR-4 polypeptide. In certain embodiments, the animal susceptible to infection is provided a TLR-4 polypeptide, wherein the TLR-4 polypeptide is a TLR-4 polypeptide that has the sequence of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:98 or SEQ ID NO:99. In specific embodiments, the provision of a TLR-4 polypeptide is accomplished by inducing expression of a TLR-4 polypeptide in the animal, introduction of a TLR-4-encoding nucleic acid to the animal or by injecting a TLR-4 polypeptide into the animal. In other embodiments, the step of modulating TLR-4 function in the animal comprises providing a modulator of TLR-4 to the animal, wherein the modulator of TLR-4 may be an agonist of TLR-4 or antagonist of TLR-4, wherein the agonist of TLR-4 or antagonist of TLR-4 modulates transcription or translation of a TLR-4-encoding nucleic acid.

In some preferred embodiments, the invention contemplates methods of screening for modulators of an LPS mediated response comprising: a) obtaining a TLR-4-encoding nucleic acid segment; b) determining a standard transcription and translation activity of the TLR-4-encoding nucleic acid sequence; c) contacting the TLR-4-encoding nucleic acid segment with a putative modulator; d) maintaining the nucleic acid segment and putative modulator under conditions that normally allow for TLR-4 transcription and translation; and e) assaying for a change in the transcription and translation activity of TLR-4.

Yet other embodiments relate to modulators of an LPS mediated response prepared by a process comprising screening for modulators of an LPS mediated response comprising: a) obtaining a TLR-4 polypeptide; b) determining a standard activity profile of the TLR-4 polypeptide; c) contacting the TLR-4 polypeptide with a putative modulator; and d) assaying for a change in the standard activity profile. Such modulators may be prepared by a process comprising screening for modulators of an LPS mediated response comprising: a) obtaining a TLR-4-encoding nucleic acid segment; b) determining a standard transcription and translation activity of the TLR-4 nucleic acid sequence; c) contacting the TLR-4-encoding nucleic acid segment with a putative modulator; d) maintaining the nucleic acid segment and putative modulator under conditions that normally allow for TLR-4 transcription and translation; and e) assaying for a change in the transcription and translation activity.

The invention further relates to methods of treating Gram-negative bacterial infections comprising administration of an agent that modulates the recognition of endotoxin through an LPS mediated response. For example, the agent may simulate or inhibit the activity of a TLR-4 polypeptide.

Other objects, features and advantages of the present invention will become apparent from the following detailed description. It should be understood, however, that the detailed description and the specific examples, while indicating preferred embodiments of the invention, are given by way of illustration only, since various changes and modifications within the spirit

and scope of the invention will become apparent to those skilled in the art from this detailed description.

Other objects, features and advantages of the present invention will become apparent from the following detailed description. It should be understood, however, that the detailed description and the specific examples, while indicating preferred embodiments of the invention, are given by way of illustration only, since various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description.

BRIEF DESCRIPTION OF THE DRAWINGS

The following drawings form part of the present specification and are included to further demonstrate certain aspects of the present invention. The invention may be better understood by reference to one or more of these drawings in combination with the detailed description of specific embodiments presented herein.

FIG. 1. Coarse genetic map of the *Lps* locus with respect to D4MIT markers. 493 meioses from an (SWR X C3H/HeJ) X C3H/HeJ backcross were examined, and crossovers used to map the locus with respect to eleven markers, including the D4MIT markers shown and a single marker derived from the interferon- α locus. Numbers above double arrows indicate centimorgan distances. The gene was confined to a region between a cluster of four inseparable markers (D4MIT244, 218,82, and 325) and the single marker D4MIT80.

FIG. 2A and FIG. 2B. Identification of novel microsatellite markers, and mapping of the *Lps* locus with respect to these markers. FIG. 2A, Map based on 493 meioses analyzed in the SWR backcross. FIG. 2B, Map based on 1600 meioses analyzed in the C57BL/6 backcross. Scale refers to physical distances (note 1 Mb bar), determined on the basis of fluorescence *in situ* hybridization data and pulse-field gel electrophoresis, performed using

YACs and BACs that span the critical region (FIG. 4 and FIG. 5). Though only one of the markers (7.3) could be used in both analyses, the maps shown in FIG. 2A and FIG. 2B are perfectly aligned and drawn to the same scale. Interruptions in map FIG. 2B indicate that D4MIT164 and D4MIT27 are quite remote from the region of interest. Numerals above brackets refer to the number of crossovers within each mapping panel that separate individual polymorphic markers from the *Lps^d* mutation. D4MIT markers are shown in shaded circles; novel markers defined in Table I are placed in the correct physical order (centromere is on the left), and indicated by non-shaded circles. The heavily shaded bar coinciding with the zero region of each map refers to an area in which no crossover events were observed, between any of the markers themselves, or between the markers and *Lps^d*. The location of the *Lps^d* mutation is necessarily bounded by markers B and 83.3, as indicated by the heavy bar at the bottom of the Figure.

FIG. 3A and FIG. 3B. Primary biological assay data used in defining crossovers between *Lps^d* and B (FIG. 3A), and between *Lps^d* and 83.3 (FIG. 3B). Assays of LPS response were performed on seven separate days. On each of these days, control assays of TNF production by macrophages (FIG. 3A) or splenocyte proliferation (FIG. 3B) from obligate heterozygotes and obligate homozygotes for the *Lps^d* allele were performed in parallel with assays performed on samples from the seven mice known to have recombination in the interval between B and 83.3. Results of assays performed on obligate heterozygotes are shown as blue circles; obligate homozygote results are shown as red circles. The LPS responses of the seven mice with a recombination event between markers B and 83.3 are represented as black squares. Four of these mice (FIG. 3A) showed recombination between B and *Lps^d*, and three mice (FIG. 3B) showed recombination occurred between *Lps^d* and 83.3. No overlap was apparent between the range of values obtained with obligate homozygotes and obligate heterozygotes, and the mice bearing recombination could be unambiguously categorized as responders or nonresponders. Each point represents the mean of four replicate cytotoxicity assays (FIG. 3A) or splenocyte proliferation assays (FIG. 3B). Error bars are omitted for simplicity, but were generally in the range of 10% of the mean value.

FIG. 4A and FIG. 4B. FIG. 4A: Centromere is to the left. Sixty-three BACs are included in this contig. A gap of small size (probably less than 100 kb) separates BACs 24 and 25. The remainder of the contig is seamless. The apparent gap between BACs 58 and 59 is covered by YAC clone 100E4. Vertical lines indicate the ends of selected BACs contacting SP6 or T7 primer sites within the BAC cloning vector. Tic marks indicate specific unique markers listed above the contig. Microsatellite markers are given alphabetical or numerical designations. D4MIT markers (325, 25, 178, 7, 132, and 83) are shown in large type. Circled C3H/HeJ and C57BL/6 (orange). Double arrows at the top of the Figure indicate physical distances estimated by interphase FISH analysis (numbers indicate megabases; margin of error = $\pm 10\%$). Vertical lines separating arrows point to the center of the BACs used for FISH distance measurements (L22, 297O12, 259N13 346B6, 217B22, 215K4, and 293L15). All BACs are drawn to scale, based on sizes obtained through pulsed-field gel electrophoresis.

FIG. 4B: Bars indicate genetic distances assigned by means of two independent back-crosses¹. A backcross involving SWR mice yielded 493 meaningful meioses. Three crossovers were observed between marker 83.3 and marker 7.11, corresponding to a genetic distance of 0.6 cM, and one crossover was observed between marker D4MIT325 and marker 25.5, corresponding to a genetic distance of 0.2 cM (magenta bars). A backcross involving C57BL/6 mice yielded 1600 meaningful meioses. Four crossovers were observed between marker B and marker A, corresponding to a genetic distance of 0.25 cM and 13 crossovers were observed between marker C and marker B, corresponding to a genetic distance to 0.8 cM (orange bar). On 2093 meioses, the mutation is therefore confined to an interval between markers B and 83.3. This corresponds to a physical distance of 2.6 Mb (denoted by the blue bar). Complete absence of crossovers (the zero region) was observed in the composite of the two crosses over a 1.2 Mb interval extending from marker A through marker 7.11 (denoted by the black bar). No polymorphic markers capable of distinguishing C57BL/6 from C3H/HeJ were

identified distal to marker 7.11 in the critical region. The BACs represented in this Figure are as follows:

- (1. 4L22 2. 329E1 3. 331E22 4. 18J9 5. 259B3 6. 147P7 7. 179M4 8. 297O12 9. 363L11 10. 353J12 11. 151O8 12. 312J8 13. 358P4 14. 327O21 15. 297N10 16. 92G10 17. 259N13 18. 243O20 19. 216C14 20. 131M6 21. 49K20 22. 135O17 23. 274K20 24. 336A11 25. 309I17 26. 152C16 27. 352P10 28. 58H7 29. 84C8 30. 346B6 31. 373I18 32. 288K23 33. 291G16 34. 276O8 35. 340I16 36. 269E13 37. 62A9 38. 389F15 39. 353O21 40. 197M3 41. 293J8 42. 220E13 43. 181N19 44. 369F7 45. 430N20 46. 370J14 47. 213O15 48. 265H22 49. 20B5 50. 175I18 51. 247P7 52. 264N15 53. 204O1 54. 217B22 55. 178D24 56. 300H9 57. 188A22 58. 289J11 59. 152B3 60. 288O20 61. 216K4 62. 293L15 63. 147M3)

All BAC designations refer to the Research Genetics mouse BAC library, with the exception of BACs 84C8 and 389F15, which were obtained from Genome Systems (mouse C57BL/6 BAC library).

FIG. 5. Minimal contig of BACs and a single YAC, sequenced in the search for *Lps*. BACs sequenced to completion or to the point of finishing are shown in blue ("complete"). BACs sequenced to a high density, but not yet at the point of finishing, are shown in red ("in progress"). YAC clone 100E4 has also been partially sequenced. BACs 293L15 and 147M3 have not been sequenced. Bar at the top of the figure refers to genetic distances from limiting markers B and 83.3 to *Lps*^d. The zero recombination area is shown in black. Several of the polymorphic markers used in mapping (circled) are included as landmarks. The positions of the pseudogenes detected are shown at BAC-level resolution; sequences from TLR-4, considered the prime candidate gene, were detected in BAC 309I17 and in BAC 152C16.

FIG. 6. TLR-4 receptor locus and a portion of the *Pappa* locus. The two genes were identified by GRAIL and BLAST analysis. The orientation and location of TLR-4 and *Pappa* are shown with respect to the nearest genetic markers.

B
 FIGS. 7A-7B
 FIG. 7A: Amino acid sequences of mouse mutant J-Toll-4, mouse N-Toll-4, rat TLR-4 and human TLR-4. The mutant mouse J-toll TLR-4 amino acid sequence contains a point mutation at residue 712 (proline to histidine), not found in the amino acid sequences of N-Toll-4, rat TLR-4 or human TLR-4. The numbering system in this figure does not take into account the spacing to maximize the sequence alignment.

B
 FIG. 7B: Sequencing of amplified DNA from the C3H/HeJ, C3H/HeN, SWR, C57BL/6, and DBA-2 mice genomes.

10

FIG. 8A. Amplification of low abundance control cDNAs from HeN, HeJ, ScSn, ScCr, HeN, HeJ, ScSn and ScCr.

15

FIG. 8B. TLR-4 mRNA detected by Northern blots using total RNA from macrophages.

FIG. 9. TLR-4 mRNA induced by LPS in lymphoid tissues.

20

FIG. 10. Spatially conserved representation of coding mutations found in TLR4 of 102 human subjects. Each lightly shaded dot refers to a mutation affecting a residue that is relatively conserved (either invariant among six mammalian species, or extant in two forms). Each black dot refers to a less conserved residue (three or more variants among species). Twelve individuals were found to be heterozygous for a double amino acid substitution. One individual was found to be heterozygous at only one of the mutant sites. Introns are shortened, and non-coding regions are not shown, but the coding region of the three principal human exons is drawn to an equivalent scale at all points in the illustration.

25

FIG. 11. Spatially conserved representation of coding mutations found in *Tlr4* of 35 *Mus musculus* strains. As in FIG. 10, each lightly shaded dot refers to a mutation that is relatively conserved, and each black dot refers to a less conserved mutation.

FIG. 12. Genetic distance and probable ancestral relationships among *Tlr4* genes of 35 *Mus musculus* strains. Numbers within circles denote strains, in accordance with the legend of Table IV. Numbers within parentheses indicate the mutational distance (number of mutations separating each strain from its presumed ancestor), with reference to both coding and non-coding substitutions listed in Table IV. Arrows point in the direction of descent, and in length are proportionate to distance. Dashed arrows suggest that mice of a given genotype evidently contributed genetic information to mice of another strain, given the similarity of the mutations observed, though unique mutations are also observed in the latter strain, and not all of the mutations observed in the former strain are present. The symbol “?” denotes the likelihood of an intermediate form prior to interbreeding of strains.

FIG. 13. Spline curve illustrating interspecific sequence variation across the *Tlr4* protein. A multiple alignment of *Tlr4* sequences from three rodent species (mouse, rat, and hamster) and three primate species (human, chimpanzee, and baboon) was generated using the GCG program pileup. The number of amino acids observed at each residue was plotted using the program Prism 3.0 (a value of 1 was assigned if a single amino acid was observed among the six species; a value of 5 was assigned if five forms were observed among the six species; etc). The points were then connected using a cubic spline curve. Ecto, the extracellular domain; TM, the transmembrane domain; Prox, the proximal cytoplasmic domain; Dist, the distal cytoplasmic domain. Numbering refers to the human sequence. Where a deletion was introduced by pileup,

a single mismatch was assumed. Where the sequence was truncated, each absent residue was tabulated as a separate mismatch.

Sub 02

5 **FIG. 14. Schematic illustration of recombinant proteins expressed in RAW 264.7 cells.** Constructs were made by PCR, using cDNA derived from C3H/HeJ and C3H/HeN mice.

The primers (5' _3'):

ATC GAT ACC AGG AGG CTT GAA TCC C

and

TAT CGA TAC CAG GAA GCT TGA ATC CC

10 were used to generate the full-length amplified products, which were cloned into the vector pFLAG-CMV-1 (Sigma) using ClaI and KpnI sites. The native signal peptide was thus removed, and an alternative signal peptide, followed by the flag sequence, was provided by the vector. The ectodomain construct was produced using the downstream primer (5' _3'):

CAG GGT ACC TCA CAG GTG AAA ATA GAA GTG GTA T,

15 whereas the two cytoplasmic domain constructs were produced using the upstream primer (5' _3'):

GCC GAA TTC AAT GTA CAA GAC AAT CAT CAG T.

20 The latter two constructs were cloned into pFLAG-CMV-1 using EcoRI and KpnI sites. All constructs were verified by DNA sequencing on both strands. All expression constructs were shown to yield products of anticipated size in COS cells, after Western blot detection with M2 monoclonal antibody (not shown).

FIG. 15A. Saturation isotherm of monoclonal antibody M2 binding to a single clone of RAW 264.7 cells transfected with an expression vector encoding Tlr4^{Lps-d}. M2 antibody was labeled to a specific activity of 3.0×10^6 cpm/ μ g using ¹²⁵I, by means of the iodogen technique³⁵. Labeled antibody (concentration range 50 ng/ml to 20 μ g/ml) was added in a volume of 1.0 ml to monolayers of 2.0×10^6 cells in Hank's balanced salt solution, supplemented with 10% fetal bovine serum and buffered with 50 mM HEPES, pH 7.4. The cells

were maintained at 0_ C for a period of 4 hours. Performed as such, 56.4% saturation of the surface receptor was achieved at equilibrium using the highest concentration of antibody. Nonlinear regression analysis, based on the assumption of hyperbolic binding kinetics, suggested a Kd of $1.0 \times 10^{-7} \text{ \AA}$ $3.0 \times 10^{-8} \text{ M}^{-1}$ and the presence of $2.81 \times 10^4 \text{ \AA}$ 4.99×10^3 binding sites per cell. R² for the analysis was 0.9576. Controls, performed for all plates, included the addition of the flag peptide to the system at a $10 \cdot \text{M}$ concentration in order to block specific binding, and only specific binding (in general, approximately 80% of total binding) is presented here. Mathematical analysis was performed using using the program Prism 3.0 (GraphPad Software Inc).

10

FIG. 15B. The expression level of each construct (copy number per cell) was determined by direct measurement of equilibrium M2 monoclonal antibody binding at a fixed concentration, with reference to the nonlinear regression analysis of saturation isotherms presented in FIG 15A. Each point represents the result of duplicate determinations of specific binding. Cells transfected with vector alone had zero specific binding (not shown).

15

FIG. 15C. Composite analysis of the shift in EC50 caused by expression of Tlr4^{Lps-n} and Tlr4^{Lps- d} in RAW 264.7 cells. Each point represents an EC50 determination performed on ten independent clones at the stated LPS concentration. For each clone, four replicate assays were performed at each concentration. Hence, each curve represents the composite analysis of 240 assays. Transfected macrophages were plated in 24 well plates at a density of 5×10^5 cells per well, and covered with 1.0 ml of DMEM supplemented with 10% FBS. LPS was added to each well at the concentration indicated. After 15 hours of incubation the medium was harvested, and TNF concentration was assayed in the standard L-929 cytotoxicity system³⁶, using cycloheximide at a concentration of $100 \cdot \text{g/ml}$ to potentiate killing. After 15 hours of exposure to diluted macrophage medium or to mouse TNF applied at a range of 8 standard concentrations, the number of viable cells was determined by staining with crystal violet. A standard curve relating % cytotoxicity to TNF concentration (not shown) was generated using Prism 3.0, and was based on an assumption of sigmoidicity. Variance among

20

25

replicate samples was typically beneath 5% of the mean, and departures of individual samples from the sigmoid plot were typically smaller still. Linear estimates of TNF concentration in unknown samples were based on non-linear interpolation from the standard curve (also performed using Prism 3.0). The curves shown were generated assuming sigmoidicity of response with variable slope for each curve, and further assigning a maximum response value of 1760 pg TNF, which yielded an optimal fit for the most responsive curve. Error bars indicate standard deviation among clones at each LPS concentration. Log EC50 values and standard error values are shown in the inset table.

FIG. 15D. Shifts of the log EC50, determined for individual clones. A more conservative approach, in which log EC50 values were determined for individual clones transfected with vector alone, or with the Tlr4^{Lps-n} or Tlr4^{Lps-d} constructs. The log EC50 data were then represented as a scatter plot, in which each point represents the log EC50 determination of a single clone (confidence limits not shown for the sake of simplicity), and is derived from 24 separate TNF assays performed on samples stimulated over a 10⁴-fold range of LPS concentration (100 pg/ml to 1 • g/ml, as well as an unstimulated control). In most instances, two determinations of log EC50 were made independently for each clone. The mean and standard error of each cluster is shown in the inset, together with p values defining the likelihood that the EC50 displacements are attributable to chance. Data were analyzed by means of a one-tailed t test, using Welch's correction for unequal variance.

FIG. 15E. Lack of correlation between level of recombinant receptor expression and the magnitude of effect on EC50. Plotting the EC50 of Tlr4^{Lps-n} transfected cells (nine clones; duplicate assays) and Tlr4^{Lps-d} transfected cells (eight clones; duplicate assays) vs. the receptor number measured for each clone (shown separately in Figures 2b and 2d), it is apparent that no correlation exists over the range of receptor number surveyed. Inset: p values calculated to assess the significance of departure of the slope (determined by linear regression for each set of points) from zero.

bioRxiv preprint doi: <https://doi.org/10.1101/2017.04.01.128000>; this version posted April 1, 2017. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.

FIG. 16A. Over-expression of the Tlr4 ectodomain fails to inhibit LPS signaling.

Composite analysis of the shift in EC50 caused by expression of the Tlr4 ectodomain (no cytoplasmic domain) or the full-length Tlr4^{Lps-d} protein in RAW 264.7 cells. Control cells were transfected with the empty vector. Analysis was carried out in a manner identical to that described in Figure 2c. Inset: log EC50 for each curve, and standard error.

FIG. 16B. Distribution of individual log EC50 data for clones expressing the Tlr4 ecotodomain, the full-length Tlr4^{Lps-d} protein, or no recombinant receptor (transfected with empty vector). Inset: the mean and standard error of each cluster, together with p values defining the likelihood that the EC50 displacements are attributable to chance. Data were analyzed by means of a t test, using Welch's correction for unequal variance.

FIG. 17A. Over-expression of the Tlr4 cytoplasmic domain, either with or without the Lps-d mutation, impairs signal transduction in RAW 264.7 cells. Composite analysis of the shift in EC50 caused by expression of the Tlr4 ectodomain (no cytoplasmic domain) or the full-length Tlr4^{Lps-d} protein in RAW 264.7 cells. Control cells were transfected with the empty vector. Analysis was carried out in a manner identical to that described in Figure 2c. Inset: log EC50 for each curve, and standard error.

FIG. 17B. Distribution of individual log EC50 data for clones expressing the cytoplasmic domain of the Tlr4^{Lps-d} protein, the Tlr4^{Lps-n} protein, or no recombinant protein (transfected with empty vector). Inset: the mean and standard error of each cluster, together with p values defining the likelihood that the EC50 displacements are attributable to chance. Data were analyzed by means of a t test, using Welch's correction for unequal variance.

DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS

Bacterial infections represent a significant challenge in the treatments of a wide variety of disease. Structurally disparate LPS molecules, produced by many different species of Gram-negative bacteria, are engaged on the macrophage surface by CD14 and ultimately trigger the release of cytokines such as tumor necrosis factor (TNF) and interleukin-1 (IL-1). These cytokines orchestrate the inflammatory response, with its attendant beneficial and harmful effects.

Given the ubiquitous presence of Gram-negative bacteria and the high incidence of Gram-negative mediated infections, certain individuals are at high risk to develop endotoxic shock even if adequate antimicrobial therapy is instituted. Methods for diagnosing patients at high risk for Gram-negative bacterial infections and sepsis in advance of its onset would be beneficial. Further, there is a need to determine whether a particular individual may be susceptible to Gram-negative bacterial infection, in determining the course of treatment for any number of diseases. For example, it will be beneficial to test individuals who are candidates for immuno-suppressive drug therapy, for susceptibility to Gram-negative bacteria in order to assess the risks of immunosuppressive treatment. Such diagnostic methods to predict the risk of infection as well as the clinical course of sepsis could be reasonably applied to most hospitalized patients. The present invention is directed towards addressing these needs.

The claimed invention also provides methods of identifying agents which stimulate endotoxin signaling such that TNF and other cytokines are released from macrophages. It is envisioned that such agents will be of therapeutic use in the treatment of individuals who are insensitive to endotoxin, either through genetic defect, disease or other condition, and whose immune system requires external stimulation to recognize infection from Gram-negative bacteria.

A. The Present Invention

In broad aspects, the present invention provides methods for screening for susceptibility to infection. On the basis of 2093 meioses analyzed in two separate intraspecific backcrosses, the location of the mouse *Lps^d* mutation has been circumscribed to a genetic interval 0.9 cM in size. To identify gene candidates, nearly 40,000 sequencing runs were performed across the critical region. Selective hybridization and exon trapping were also employed to identify genes throughout the “zero” region. These studies revealed that only a single intact gene was identified within the entire critical region. This gene encodes the TLR-4 receptor, a member of the IL-1 family of receptors. Thus, the present inventors demonstrate that there is a mutation in the TLR-4-encoding gene that appears to provide a predisposition to infection.

In these studies a total of 19 genetic markers that lie in close proximity to the mutation were examined in mapping. Most of these were previously unpublished polymorphic microsatellites, identified by fragmentation of YAC and BAC clones spanning the region of interest. *Lps^d* was found to be inseparable from the microsatellite marker D4MIT178, and from three novel polymorphic microsatellites identified near D4MIT178. The mutation was confined between two novel microsatellite markers, herein designated “B” and “83.3.” B lies centromeric to the mutation, and was separated by four crossovers in a panel of 1600 mice; 83.3 lies distal to the mutation and was separated by three crossovers in a panel of 493 mice. 66 BAC clones and one YAC clone were assembled to cover >95% of the critical region. Estimates based on pulsed field gel electrophoresis and fluorescence in situ hybridization indicate that the B→83.3 interval is about 3.2 Mb in length. A minimal area of zero recombinational distance from *Lps^d* was also assigned, and found to occupy approximately 1.2 Mb of physical size.

It was found that in the macrophages of mice that are susceptible to bacterial infection there is a genetic mutation in the *lps* locus. Specifically, there is a mutation in the TLR-4 receptor that is expressed by the macrophages of these compromised mice and this mutation leads to a reduced recognition of endotoxin. As the endotoxin is not recognized by these defense cells, there is a lack of immune response mounted against the invading bacteria which

results in the deleterious effect of the infection. The present invention suggest that similar mechanisms work in other mammalian cells and as such in a broad sense the present invention provides methods of preventing a bacterial infection of a host comprising ensuring that the macrophages of the host express a function TLR-4 or Toll-like receptor. By providing such a functional receptor, the present invention ensures that the endotoxin signal is recognized by the immune system of the host. Conversely, in those instances in which widespread activation of macrophages by endotoxin results in the overproduction of TNF leading to the development of septic shock, it may be desirable to down-regulate the TLR-4 receptor.

Thus, the present invention also provides a method of treating gram-negative bacterial infections comprising administration of an agent that stimulates the recognition of endotoxin. In specific circumstances such an agent is likely to be a candidate substance that stimulates the expression, activity or function of the TLR-4 receptor that is expressed by the macrophages of the host. Similarly, methods and compositions for treating endotoxin related symptoms comprising administration of an agent that reduces the recognition of endotoxin also are provided by the present invention. A useful compound that may be identified by the present invention is one which inhibits endotoxin signaling by binding to a TLR-4 receptor and competing with endotoxin for the binding. Particularly preferred agents would be those that modulate the stimulation of TNF and cytokine secretion. Such a modulation may be an increase in secretion in circumstances where the endotoxin has not been recognized or a decrease in secretion in circumstances where there has been a deleterious production of TNF and/or other cytokines.

Thus, as outlined above and described in detail herein below, the TLR-4 sequence will find utility in a variety of applications in bacterial infection susceptibility detection, diagnosis, prognosis and treatment. Examples of such applications within the scope of the present invention include amplification of markers of LPS mediated infections using specific primers; detection of markers of TLR-4 by hybridization with oligonucleotide probes; incorporation of isolated nucleic acids into vectors and expression of vector-incorporated nucleic acids as RNA and protein;

development of immunologic reagents corresponding to gene encoded products; and therapeutic treatment for the identified infection using these reagents as well as, anti-sense nucleic acids, or other inhibitors specific for the identified disease. The present invention further discloses screening assays for compounds to upregulate gene expression or to combat the effects of the mutant TLR-4 genes.

B. LPS Mutation is Responsible for Susceptibility to Bacterial Infection

The *Lps* is an important susceptibility locus, influencing the propensity to develop a disseminated Gram negative infection, or the outcome of such an infection. Hence, C3H/HeJ mice, while highly resistant to LPS, show exaggerated susceptibility to infection by Gram negative organisms (O'Brien *et al.*, 1980; Macela *et al.*, 1996). In birds, resistance to *Salmonella typhimurium* is linked to a polymorphism at the tenascin locus (Hu *et al.*, 1997); tenascin is closely linked to the *Lps* gene, and it may be assumed that a mutation of the avian *Lps* locus lies in linkage disequilibrium with the tenascin marker, yielding the reported association. From these investigations it is likely that mutations at the equivalent locus in humans also will influence the course of Gram negative infection.

The *Lps* critical region is remarkably gene-poor. While the average megabase of mammalian DNA contains approximately 30 genes, only one authentic gene (and a portion of a second gene) have been detected within 2.6 Mb of DNA flanking *Lps*. As virtually all of the *Lps* critical region was sequenced herein, and no other plausible candidates were found, it must be considered that the lone candidate, encoding the toll-like receptor 4 (TLR-4; Tlr-4; TIL4) of mice, very likely represents the *Lps* locus. Moreover, the inventors suggest that a specific mutation of this gene is responsible for the endotoxin-unresponsive phenotype witnessed in C3H/HeJ mice.

The *toll* family of receptors (Chaudhary *et al.*, 1998; Rock *et al.*, 1998) is defined by homology to the *Drosophila toll* protein, a plasma membrane receptor which engages an extracellular mediator encoded by *spätzle*, leading to activation of a *rel* gene family member, by

inducing its dissociation from *cactus*. This sequence of events is important for induction of the drosomycin antifungal response in *Drosophila* (Rosetto *et al.*, 1995; Lemaitre *et al.*, 1996). The mammalian IL-1 receptor is a member of the toll family of proteins, and four other mammalian family members (Toll-like receptors 1 through 4) have been identified by molecular cloning, though their function is uncertain. IL-1 signaling involves, among other events, the activation of NF- κ B, which like *dorsal*, is a member of the *rel* family. LPS signaling also entails activation of NF- κ B. As such, it is plausible to consider that LPS signaling might involve transduction via a toll family member. The present invention, for the first time shows that TLR-4 is the receptor for LPS.

Further evidence consistent with this hypothesis may be seen in the clinical observation of Kuhns and coworkers, who determined that a profound immunodeficiency results from a conjoint defect in responses to IL-1 and LPS (Kuhns *et al.*, 1997). In view of the inventor's findings, the fact that a single mutation may block signal transduction initiated by both IL-1 and LPS may be taken to indicate that a common (proximal) mediator serves both the IL-1 receptor and the LPS receptor. This, in turn, would suggest the existence of structural similarity between the IL-1 and LPS receptors. While the details of signal transduction via toll family members have not been fully elucidated, the involvement of MyD88, IRAK, and TRAF6 has recently been proposed in the case of the TLR-4 receptor (Muzio *et al.*, 1998).

The *Lps^d* mutation has a codominant character, and attempts to identify the product of *Lps* through expression cDNA cloning in C3H/HeJ macrophages were unsuccessful. Blockade of endotoxin signal transduction in the C3H/HeJ mice may therefore reflect the expression of a protein with dominant negative characteristics. As CD14 serves as the physical receptor for LPS on the cell surface yet lacks a transmembrane domain, it would seem likely that CD14 engages TLR-4, and that the latter protein acts to transduce the LPS signal across the membrane. It is possible that the *Lps^d* mutation leads to unproductive interaction between CD14 and an TLR-4, preventing signal transduction through other components of the signaling pathway. Alternatively, the mutation may merely abolish signal transduction through TLR-4 itself.

Examination of these hypotheses will depend upon the demonstration of a mutational difference between the TLR-4 gene in C3H/HeJ mice and in C3H/HeN animals.

C. TLR-4 Polypeptides

5 TLR-4 may be obtained according to various standard methodologies that are known to those of skill in the art. For example, antibodies specific for TLR-4 may be used in immunoaffinity protocols to isolate TLR-4 from cells. Antibodies are advantageously bound to supports, such as columns or beads, and the immobilized antibodies can be used to pull the TLR-4 target out of the cell lysate. Size fractionation (chromatography, centrifugation), ion
10 exchange or affinity chromatograph, and even gel purification may be used for purification as well.

TLR-4, according to the present invention, may advantageously be cleaved into fragments for use in further structural or functional analysis, or in the generation of reagents such as TLR-4-
15 related polypeptides and TLR-4-specific antibodies. This can be accomplished by treating purified or unpurified TLR-4 with a peptidase such as endoproteinase glu-C (Boehringer, Indianapolis, IN). Treatment with CNBr is another method by which TLR-4 fragments may be produced from natural TLR-4. Recombinant techniques also can be used to produce specific fragments of TLR-4.

20 In addition to the peptidyl compounds described herein, the inventors also contemplate that other sterically similar compounds may be formulated to mimic the key portions of the peptide structure, called peptidomimetics. Mimetics are peptide-containing molecules which mimic elements of protein secondary structure. See, for example, Johnson *et al.* (1993). The underlying rationale behind the use of peptide mimetics is that the peptide backbone of proteins exists chiefly
25 to orient amino acid side chains in such a way as to facilitate molecular interactions, such as those of receptor and ligand.

Successful applications of the peptide mimetic concept have thus far focused on mimetics of β -turns within proteins. Likely β -turn structures within TLR-4 can be predicted by computer-

based algorithms as discussed above. Once the component amino acids of the turn are determined, mimetics can be constructed to achieve a similar spatial orientation of the essential elements of the amino acid side chains, as discussed in Johnson *et al.* (1993).

5 D. DNA Segments

Important aspects of the present invention concern isolated DNA segments and recombinant vectors encoding TLR-4, and the creation and use of recombinant host cells through the application of DNA technology, that express TLR-4 for the purposes of increasing the recognition of endotoxin by a host cell. The present invention shows that the long sought
10 after gene at the *lps* locus is TLR-4. The TLR-4 a receptor for LPS and is thus the protein that binds to and recognizes LPS from the bacteria cell wall. It is recognition of the endotoxin by the TLR-4 that allows an animal to mount an immune response against the invading bacteria. If the TLR-4 peptide is mutated such that it is unable to recognize the LPS the animal will not be able to mount an immune response.

15 TLR-4 is a member of the IL-1 family of receptors. U. S. Patent 5,786,331; U. S. Patent 5,776,731; U. S. Patent 5,767,234; U. S. Patent 5,767,064; U. S. Patent 5,726,148; U. S. Patent 5,608,035; U. S. Patent 5,508,262; U. S. Patent 5,488,032; U. S. Patent 5,464,937 each specifically incorporated herein by reference, describe the IL-1 receptor and methods and
20 compositions related to modulating the activity thereof. The present invention contemplates using techniques and compositions similar to those described in these patents for use with the TLR-4 receptor of the present invention.

DNA segments, recombinant vectors, recombinant host cells and expression methods
25 using sequences of the human TLR-4 (SEQ ID NO:1, SEQ ID NO:3 and SEQ ID NO:47), rat (SEQ ID NO:5) and mouse (SEQ ID NO:45, SEQ ID NO:46 and SEQ ID NO:48) also are provided. These sequences express human polypeptides of SEQ ID NO:2, SEQ ID NO:4 and SEQ ID NO:98, rat polypeptide of SEQ ID NO:6, and mouse polypeptide of SEQ ID NO:99, respectively. Each of the foregoing genes are included within all aspects of the following

description. The present invention concerns DNA segments, isolatable from mammalian and human cells, that are free from total genomic DNA and that are capable of expressing a functional TLR-4 protein. As used herein, the term "DNA segment" refers to a DNA molecule that has been isolated free of other genomic DNA of a particular species. Therefore, a DNA segment encoding a TLR-4 protein refers to a DNA segment that contains TLR-4 protein coding sequences yet is isolated away from, or purified free from, total mammalian or human genomic DNA. Included within the term "DNA segment", are DNA segments and smaller fragments of such segments, and also recombinant vectors, including, for example, plasmids, cosmids, phage, viruses, and the like.

Similarly, a DNA segment comprising an isolated or purified TLR-4 protein or subunit gene refers to a DNA segment including purified TLR-4 protein or subunit protein coding sequences and, in certain aspects, regulatory sequences, isolated substantially away from other naturally occurring genes or protein encoding sequences. In this respect, the term "gene" is used for simplicity to refer to a functional protein, polypeptide or peptide encoding unit. As will be understood by those in the art, this functional term includes both genomic sequences, complementary DNA (cDNA) sequences and smaller engineered gene segments that express, or may be adapted to express, TLR-4 proteins, polypeptides, domains, peptides, fusion proteins and mutants.

"Isolated substantially away from other coding sequences" means that the gene of interest, in this case a TLR-4 protein gene, forms the significant part of the coding region of the DNA segment, and that the DNA segment does not contain large portions of naturally-occurring coding DNA, such as large chromosomal fragments or other functional genes or cDNA coding regions. Of course, this refers to the DNA segment as originally isolated, and does not exclude genes or coding regions later added to the segment by the hand of man.

In particular embodiments, the invention concerns isolated DNA segments and recombinant vectors incorporating DNA sequences that encode a TLR-4 protein or subunit that

includes within its amino acid sequence a contiguous amino acid sequence in accordance with, or essentially as set forth in, SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:98 or SEQ ID NO:99 corresponding to TLR-4 in humans, rat and mouse, respectively. Moreover, in other particular embodiments, the invention concerns isolated DNA segments and recombinant
5 vectors that encode a TLR-4 protein or subunit that includes within its amino acid sequence the substantially full length protein sequence of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:98 or SEQ ID NO:99.

The term "a sequence essentially as set forth in SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:98 or SEQ ID NO:99 " means that the sequence substantially corresponds to
10 a portion of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:98 or SEQ ID NO:99 and has relatively few amino acids that are not identical to, or a biologically functional equivalent of, the amino acids of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:98 or SEQ ID NO:99. The term "biologically functional equivalent" is well understood in the art and is further defined in detail herein. Accordingly, sequences that have between about 85% and about 90%;
15 or more preferably, between about 91% and about 95%; or even more preferably, between about 96% and about 99%; of amino acids that are identical or functionally equivalent to the amino acids of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:98 or SEQ ID NO:99 will be sequences that are "essentially as set forth in SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:98 or SEQ ID NO:99 ", provided the biological activity of the protein is maintained.

In certain other embodiments, the invention concerns isolated DNA segments and recombinant vectors that include within their sequence a nucleic acid sequence essentially as set forth in SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47 and SEQ ID NO:48. The term "essentially as set forth in SEQ ID NO:1, SEQ ID NO:3,
25 SEQ ID NO:5, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47 and SEQ ID NO:48" is used in the same sense as described above and means that the nucleic acid sequence substantially corresponds to a portion of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47 or SEQ ID NO:48 and has relatively few codons that are not identical, or functionally equivalent, to the codons of SEQ ID NO:1, SEQ ID NO:3, SEQ ID

NO:5, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47 or SEQ ID NO:48. Again, DNA segments that encode TLR-4 or related proteins or subunits will be most preferred.

5 The term "functionally equivalent codon" is used herein to refer to codons that encode the same amino acid, such as the six codons for arginine or serine, and also refers to codons that encode biologically equivalent amino acids (see Codon Table, below).

665760" 53636360

CODON TABLE

Amino Acids			Codons					
Alanine	Ala	A	GCA	GCC	GCG	GCU		
Cysteine	Cys	C	UGC	UGU				
Aspartic acid	Asp	D	GAC	GAU				
Glutamic acid	Glu	E	GAA	GAG				
Phenylalanine	Phe	F	UUC	UUU				
Glycine	Gly	G	GGA	GGC	GGG	GGU		
Histidine	His	H	CAC	CAU				
Isoleucine	Ile	I	AUA	AUC	AUU			
Lysine	Lys	K	AAA	AAG				
Leucine	Leu	L	UUA	UUG	CUA	CUC	CUG	CUU
Methionine	Met	M	AUG					
Asparagine	Asn	N	AAC	AAU				
Proline	Pro	P	CCA	CCC	CCG	CCU		
Glutamine	Gln	Q	CAA	CAG				
Arginine	Arg	R	AGA	AGG	CGA	CGC	CGG	CGU
Serine	Ser	S	AGC	AGU	UCA	UCC	UCG	UCU
Threonine	Thr	T	ACA	ACC	ACG	ACU		
Valine	Val	V	GUA	GUC	GUG	GUU		
Tryptophan	Trp	W	UGG					
Tyrosine	Tyr	Y	UAC	UAU				

It will also be understood that amino acid and nucleic acid sequences may include additional residues, such as additional N- or C-terminal amino acids or 5' or 3' sequences, and yet still be essentially as set forth in one of the sequences disclosed herein, so long as the sequence meets the criteria set forth above, including the maintenance of biological protein activity where protein expression is concerned. The addition of terminal sequences particularly applies to nucleic acid sequences that may, for example, include various non-coding sequences flanking either of the 5' or 3' portions of the coding region or may include various internal sequences, *i.e.*, introns, which are known to occur within genes.

Excepting intronic or flanking regions, and allowing for the degeneracy of the genetic code, sequences that have between about 75% and about 79%; or more preferably, between

about 80% and about 89%; or even more preferably, between about 90% and about 99%; of nucleotides that are identical to the nucleotides of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:45 or SEQ ID NO:46 will be sequences that are "essentially as set forth in SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47 or SEQ ID NO:48."

Sequences that are essentially the same as those set forth in SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47 or SEQ ID NO:48 may also be functionally defined as sequences that are capable of hybridizing to a nucleic acid segment containing the complement of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47 or SEQ ID NO:48 under relatively stringent conditions. Suitable relatively stringent hybridization conditions will be well known to those of skill in the art.

Suitable standard hybridization conditions for the present invention include, for example, hybridization in 50% formamide, 5× Denhardts' solution, 5× SSC, 25 mM sodium phosphate, 0.1% SDS and 100 µg/ml of denatured salmon sperm DNA at 42°C for 16 hours followed by 1 hour sequential washes with 0.1× SSC, 0.1% SDS solution at 60°C to remove the desired amount of background signal. Lower stringency hybridization conditions for the present invention include, for example, hybridization in 35% formamide, 5× Denhardts' solution, 5× SSC, 25 mM sodium phosphate, 0.1% SDS and 100 µg/ml denatured salmon sperm DNA or *E. coli* DNA at 42°C for 16 hours followed by sequential washes with 0.8× SSC, 0.1% SDS at 55°C. Those of skill in the art will recognize that conditions can be readily adjusted to obtain the desired level of stringency.

Naturally, the present invention also encompasses DNA segments that are complementary, or essentially complementary, to the sequence set forth in SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47 or SEQ ID NO:48. Nucleic acid sequences that are "complementary" are those that are capable of base-pairing

according to the standard Watson-Crick complementarity rules. As used herein, the term "complementary sequences" means nucleic acid sequences that are substantially complementary, as may be assessed by the same nucleotide comparison set forth above, or as defined as being capable of hybridizing to the nucleic acid segment of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47 or SEQ ID NO:48, under relatively stringent conditions such as those described immediately above.

The nucleic acid segments of the present invention, regardless of the length of the coding sequence itself, may be combined with other DNA sequences, such as promoters, polyadenylation signals, additional restriction enzyme sites, multiple cloning sites, other coding segments, and the like, such that their overall length may vary considerably. It is therefore contemplated that a nucleic acid fragment of almost any length may be employed, with the total length preferably being limited by the ease of preparation and use in the intended recombinant DNA protocol.

For example, nucleic acid fragments may be prepared that include a short contiguous stretch identical to or complementary to SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47 or SEQ ID NO:48, such as about 22-27 or about 32-36 nucleotides, and that are up to about 30,000 or 20,000, or about 10,000, or about 5,000 base pairs in length, with segments of about 3,000 being preferred in certain cases. DNA segments with total lengths of about 1,000, about 500, about 200, about 100 and about 50 base pairs in length (including all intermediate lengths) are also contemplated to be useful.

It will be readily understood that "intermediate lengths," in these contexts, means any length between the quoted ranges, such as 22, 23, 24, 25, 26, 27, 28, 29, etc; 30, 31, 32, 33, 34, etc.; 50, 51, 52, 53, etc.; 100, 101, 102, 103, etc.; 150, 151, 152, 153, etc.; including all integers through the 200-500; 500-1,000; 1,000-2,000; 2,000-3,000; 3,000-5,000; 5,000-10,000 ranges, up to and including sequences of about 12,001, 12,002, 13,001, 13,002, 15,000, 20,000, 30,000 and the like.

The various probes and primers designed around the disclosed nucleotide sequences of the present invention may be of any length. By assigning numeric values to a sequence, for example, the first residue is 1, the second residue is 2, *etc.*, an algorithm defining all primers can be proposed:

$$n \text{ to } n + y$$

where n is an integer from 1 to the last number of the sequence and y is the length of the primer minus one, where n + y does not exceed the last number of the sequence. Thus, for a 25-mer, the probes correspond to bases 1 to 25, 2 to 26, 3 to 27 ... and so on. For a 30-mer, the probes correspond to bases 1 to 30, 2 to 31, 3 to 32 ... and so on. For a 35-mer, the probes correspond to bases 1 to 35, 2 to 36, 3 to 37 ... and so on.

It will also be understood that this invention is not limited to the particular nucleic acid and amino acid sequences of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47 or SEQ ID NO:48. Recombinant vectors and isolated DNA segments may therefore variously include these coding regions themselves, coding regions bearing selected alterations or modifications in the basic coding region, or they may encode larger polypeptides that nevertheless include such coding regions or may encode biologically functional equivalent proteins or peptides that have variant amino acids sequences.

The DNA segments of the present invention encompass biologically functional equivalent TLR-4 proteins. Such sequences may arise as a consequence of codon redundancy and functional equivalency that are known to occur naturally within nucleic acid sequences and the proteins thus encoded. Alternatively, functionally equivalent proteins or peptides may be created via the application of recombinant DNA technology, in which changes in the protein structure may be engineered, based on considerations of the properties of the amino acids being exchanged. Changes designed by man may be introduced through the application of site-

directed mutagenesis techniques, *e.g.*, to introduce improvements to the antigenicity of the protein or to test mutants in order to examine transcription, elongation or Tat binding activity at the molecular level.

5 One may also prepare fusion proteins and peptides, *e.g.*, where the TLR-4 protein coding regions are aligned within the same expression unit with other proteins or peptides having desired functions, such as for purification or immunodetection purposes (*e.g.*, proteins that may be purified by affinity chromatography and enzyme label coding regions, respectively).

10 Encompassed by the invention are DNA segments encoding relatively small peptides, such as, for example, peptides of from about 15 to about 50 amino acids in length, and more preferably, of from about 15 to about 30 amino acids in length; and also larger polypeptides up to and including proteins corresponding to the full-length sequences set forth in SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:98 and SEQ ID NO:99 6.

15 It is proposed that the DNA segments of the present invention may be employed for a variety of applications. For example, a particularly useful application concerns the recombinant production of the individual subunits or proteins or peptides whose structure is derived from that of the subunits, or in the recombinant production of the holoenzyme following co-expression of
20 the two subunits. Additionally, the TLR-4 -encoding DNA segments of the present invention can also be used in the preparation of nucleic acid probes or primers, which can, for example, be used in the identification and cloning of TLR-4 genes or related genomic sequences, or in the study of subunit(s) expression, and the like.

25 **E. Immunologic Detection Methods**

 In one embodiment, the diagnostic approach will be immunologic. The reagents will include antibodies to the TLR-4 and TLR-4 mutants, or fragments thereof, and will further include reagents capable of detecting an antibody immunoreactive with an such compound. Detection

methods include, but are not limited to ELISA, RIA and immunoblots, as discussed elsewhere in the specification.

Antibodies against TLR-4 and TLR-4 mutants isolated using the methodology described will be useful in the present invention, primarily in assays for the detection of individuals susceptible to Gram-negative infection. Means for preparing and characterizing antibodies are well known in the art (see, *e.g.*, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, 1988; incorporated herein by reference).

The methods for generating monoclonal antibodies (MAbs) generally begin along the same lines as those for preparing polyclonal antibodies. Briefly, a polyclonal antibody is prepared by immunizing an animal with an immunogenic composition in accordance with the present invention and collecting antisera from that immunized animal. A wide range of animal species can be used for the production of antisera. Typically the animal used for production of anti-antisera is a rabbit, a mouse, a rat, a hamster, a guinea pig or a goat.

Immunogenic compositions of the invention include TLR-4, TLR-4 mutants or fragments and the like. As is well known in the art, a given composition may vary in its immunogenicity. It is often necessary therefore to boost the host immune system, as may be achieved by coupling a peptide or polypeptide immunogen to a carrier. Exemplary and preferred carriers are keyhole limpet hemocyanin (KLH) and bovine serum albumin (BSA). Other albumins such as ovalbumin, mouse serum albumin or rabbit serum albumin can also be used as carriers. Means for conjugating a compound to a carrier protein are well known in the art and include glutaraldehyde, m-maleimidobenzoyl-N-hydroxysuccinimide ester, carbodiimide and bis-biazotized benzidine.

As is also well known in the art, the immunogenicity of a particular immunogen composition can be enhanced by the use of non-specific stimulators of the immune response, known as adjuvants. Exemplary and preferred adjuvants include complete Freund's adjuvant (a

non-specific stimulator of the immune response containing killed *Mycobacterium tuberculosis*), incomplete Freund's adjuvants and aluminum hydroxide adjuvant.

5 The amount of immunogen composition used in the production of polyclonal antibodies varies upon the nature of the immunogen as well as the animal used for immunization. A variety of routes can be used to administer the immunogen (subcutaneous, intramuscular, intradermal, intravenous and intraperitoneal). The production of polyclonal antibodies may be monitored by sampling blood of the immunized animal at various points following immunization. A second, booster injection, also may be given. The process of boosting and titering is repeated until a
10 suitable titer is achieved. When a desired level of immunogenicity is obtained, the immunized animal can be bled and the serum isolated and stored, and/or the animal can be used to generate MAbs.

15 MAbs may be readily prepared through use of well-known techniques, such as those exemplified in U.S. Patent 4,196,265, incorporated herein by reference. Typically, this technique involves immunizing a suitable animal with a selected immunogen composition, *e.g.*, a purified or partially purified protein, polypeptide or peptide. The immunizing composition is administered in a manner effective to stimulate antibody producing cells. Rodents such as mice and rats are preferred animals, however, the use of rabbit, sheep frog cells is also possible. The
20 use of rats may provide certain advantages, but mice are preferred, with the BALB/c mouse being most preferred as this is most routinely used and generally gives a higher percentage of stable fusions.

25 Following immunization, somatic cells with the potential for producing antibodies, specifically B lymphocytes (B cells), are selected for use in the MAb generating protocol. These cells may be obtained from biopsied spleens, tonsils or lymph nodes, or from a peripheral blood sample. Spleen cells and peripheral blood cells are preferred, the former because they are a rich source of antibody-producing cells that are in the dividing plasmablast stage, and the latter because peripheral blood is easily accessible. Often, a panel of animals will have been

immunized and the spleen of animal with the highest antibody titer will be removed and the spleen lymphocytes obtained by homogenizing the spleen with a syringe. Typically, a spleen from an immunized mouse contains approximately 5×10^7 to 2×10^8 lymphocytes.

5 The antibody-producing B lymphocytes from the immunized animal are then fused with cells of an immortal myeloma cell, generally one of the same species as the animal that was immunized. Myeloma cell lines suited for use in hybridoma-producing fusion procedures preferably are non-antibody-producing, have high fusion efficiency, and enzyme deficiencies that render them incapable of growing in certain selective media which support the growth of
10 only the desired fused cells (hybridomas).

Any one of a number of myeloma cells may be used, as are known to those of skill in the art (Campbell, pp. 75-83, 1984). For example, where the immunized animal is a mouse, one may use P3-X63/Ag8, X63-Ag8.653, NS1/1.Ag 4 1, Sp210-Ag14, FO, NSO/U, MPC-11,
15 MPC11-X45-GTG 1.7 and S194/5XX0 Bul; for rats, one may use R210.RCY3, Y3-Ag 1.2.3, IR983F and 4B210; and U-266, GM1500-GRG2, LICR-LON-HMy2 and UC729-6 are all useful in connection with human cell fusions.

Methods for generating hybrids of antibody-producing spleen or lymph node cells and
20 myeloma cells usually comprise mixing somatic cells with myeloma cells in a 2:1 proportion, though the proportion may vary from about 20:1 to about 1:1, respectively, in the presence of an agent or agents (chemical or electrical) that promote the fusion of cell membranes. Fusion methods using Sendai virus have been described by Kohler and Milstein (1975; 1976), and those using polyethylene glycol (PEG), such as 37% (v/v) PEG, by Gefter *et al.* (1977). The use of
25 electrically induced fusion methods is also appropriate.

Fusion procedures usually produce viable hybrids at low frequencies, about 1×10^{-6} to 1×10^{-8} . However, this does not pose a problem, as the viable, fused hybrids are differentiated from the parental, unfused cells (particularly the unfused myeloma cells that would normally

continue to divide indefinitely) by culturing in a selective medium. The selective medium is generally one that contains an agent that blocks the *de novo* synthesis of nucleotides in the tissue culture media. Exemplary and preferred agents are aminopterin, methotrexate, and azaserine. Aminopterin and methotrexate block *de novo* synthesis of both purines and pyrimidines, whereas
5 azaserine blocks only purine synthesis. Where aminopterin or methotrexate is used, the media is supplemented with hypoxanthine and thymidine as a source of nucleotides (HAT medium). Where azaserine is used, the media is supplemented with hypoxanthine.

The preferred selection medium is HAT. Only cells capable of operating nucleotide
10 salvage pathways are able to survive in HAT medium. The myeloma cells are defective in key enzymes of the salvage pathway, e.g., hypoxanthine phosphoribosyl transferase (HPRT), and they cannot survive. The B cells can operate this pathway, but they have a limited life span in culture and generally die within about two weeks. Therefore, the only cells that can survive in the selective media are those hybrids formed from myeloma and B cells.

This culturing provides a population of hybridomas from which specific hybridomas are selected. Typically, selection of hybridomas is performed by culturing the cells by single-clone dilution in microtiter plates, followed by testing the individual clonal supernatants (after about two to three weeks) for the desired reactivity. The assay should be sensitive, simple and rapid.
15
20 Radioimmunoassays, enzyme immunoassays, cytotoxicity assays, plaque assays, dot immunobinding assays, and the like, may be used.

Where one desires to generate an antibody with defined activity, one would generally screen the candidate hybridomas to identify those hybridomas that produce antibodies that have
25 the desired inhibitory or stimulatory properties. Any selected hybridomas would then be serially diluted and cloned into individual antibody-producing cell lines, which clones can then be propagated indefinitely to provide MAbs. The cell lines may be exploited for MAb production in two basic ways. A sample of the hybridoma can be injected (often into the peritoneal cavity) into a histocompatible animal of the type that was used to provide the somatic and myeloma

cells for the original fusion. The injected animal develops tumors secreting the specific monoclonal antibody produced by the fused cell hybrid. The body fluids of the animal, such as serum or ascites fluid, can then be tapped to provide MAbs in high concentration. The individual cell lines could also be cultured *in vitro*, where the MAbs are naturally secreted into the culture medium from which they can be readily obtained in high concentrations. MAbs produced by either means may be further purified, if desired, using filtration, centrifugation and various chromatographic methods such as HPLC or affinity chromatography.

Certain aspects of the present invention relates to the detection of TLR-4 and mutants thereof. One method of detecting such compounds uses immunoassays for agents of the present invention. Antibodies that recognize TLR-4 or TLR-4 mutants of the present invention are contemplated to be useful in these immunoassays.

Immunoassays encompassed by the present invention include, but are not limited to those described in U.S. Patent No. 4,367,110 (double monoclonal antibody sandwich assay) and U.S. Patent No. 4,452,901 (western blot). Other assays include immunoprecipitation of labeled ligands and immunocytochemistry, both *in vitro* and *in vivo*.

Immunoassays, in their most simple and direct sense, are binding assays. Certain preferred immunoassays are the various types of enzyme linked immunosorbent assays (ELISAs) and radioimmunoassays (RIA) known in the art. Immunohistochemical detection using tissue sections is also particularly useful.

In one exemplary ELISA, the antibodies of the invention are immobilized onto a selected surface exhibiting protein affinity, such as a well in a polystyrene microtiter plate. Then, a test composition suspected of containing the desired antigen, such as a clinical sample, is added to the wells. After binding and washing to remove non-specifically bound immune complexes, the bound antigen may be detected. Detection is generally achieved by the addition of another antibody, specific for the desired antigen, that is linked to a detectable label. This type of ELISA

is a simple "sandwich ELISA". Detection may also be achieved by the addition of a second antibody specific for the desired antigen, followed by the addition of a third antibody that has binding affinity for the second antibody, with the third antibody being linked to a detectable label.

5

In another exemplary ELISA, the samples suspected of containing the desired antigen are immobilized onto the well surface and then contacted with the antibodies of the invention. After binding and appropriate washing, the bound immune complexes are detected. Where the initial antigen specific antibodies are linked to a detectable label, the immune complexes may be detected directly. Again, the immune complexes may be detected using a second antibody that has binding affinity for the first antigen specific antibody, with the second antibody being linked to a detectable label.

10

Competition ELISAs are also possible in which test samples compete for binding with known amounts of labeled antigens or antibodies. The amount of reactive species in the unknown sample is determined by mixing the sample with the known labeled species before or during incubation with coated wells. The presence of reactive species in the sample acts to reduce the amount of labeled species available for binding to the well and thus reduces the ultimate signal.

15

20

Irrespective of the format employed, ELISAs have certain features in common, such as coating, incubating or binding, washing to remove non-specifically bound species, and detecting the bound immune complexes. These are described as below.

25

Antigen or antibodies may also be linked to a solid support, such as in the form of plate, beads, dipstick, membrane or column matrix, and the sample to be analyzed applied to the immobilized antigen or antibody. In coating a plate with either antigen or antibody, one will generally incubate the wells of the plate with a solution of the antigen or antibody, either overnight or for a specified period. The wells of the plate will then be washed to remove

incompletely adsorbed material. Any remaining available surfaces of the wells are then "coated" with a nonspecific protein that is antigenically neutral with regard to the test antisera. These include bovine serum albumin (BSA), casein and solutions of milk powder. The coating allows for blocking of nonspecific adsorption sites on the immobilizing surface and thus reduces the background caused by nonspecific binding of antisera onto the surface.

In ELISAs, it is probably more customary to use a secondary or tertiary detection means rather than a direct procedure. Thus, after binding of the antigen or antibody to the well, coating with a non-reactive material to reduce background, and washing to remove unbound material, the immobilizing surface is contacted with the clinical or biological sample to be tested under conditions effective to allow immune complex (antigen/antibody) formation. Detection of the immune complex then requires a labeled secondary binding ligand or antibody, or a secondary binding ligand or antibody in conjunction with a labeled tertiary antibody or third binding ligand.

"Under conditions effective to allow immune complex (antigen/antibody) formation" means that the conditions preferably include diluting the antigens and antibodies with solutions such as BSA, bovine gamma globulin (BGG) and phosphate buffered saline (PBS)/Tween. These added agents also tend to assist in the reduction of nonspecific background.

The suitable conditions also mean that the incubation is at a temperature and for a period of time sufficient to allow effective binding. Incubation steps are typically from about 1 to 2 to 4 hours, at temperatures preferably on the order of 25° to 27°C, or may be overnight at about 4°C or so.

Following all incubation steps in an ELISA, the contacted surface is washed so as to remove non-complexed material. Washing often includes washing with a solution of PBS/Tween, or borate buffer. Following the formation of specific immune complexes between

the test sample and the originally bound material, and subsequent washing, the occurrence of even minute amounts of immune complexes may be determined.

To provide a detecting means, the second or third antibody will have an associated label
5 to allow detection. Preferably, this will be an enzyme that will generate color development upon incubating with an appropriate chromogenic substrate. Thus, for example, one will desire to contact and incubate the first or second immune complex with a urease, glucose oxidase, alkaline phosphatase or hydrogen peroxidase-conjugated antibody for a period of time and under conditions that favor the development of further immune complex formation, *e.g.*, incubation for
10 2 hours at room temperature in a PBS-containing solution such as PBS-Tween.

After incubation with the labeled antibody, and subsequent to washing to remove unbound material, the amount of label is quantified, *e.g.*, by incubation with a chromogenic substrate such as urea and bromocresol purple or
15 2,2'-azino-di-(3-ethyl-benzthiazoline-6-sulfonic acid (ABTS) and H₂O₂, in the case of peroxidase as the enzyme label. Quantification is then achieved by measuring the degree of color generation, *e.g.*, using a visible spectra spectrophotometer.

Alternatively, the label may be a chemiluminescent one. The use of such labels is
20 described in U.S. Patent Nos. 5,310,687, 5,238,808 and 5,221,605.

Assays for TLR-4 and TLR-4 mutants of the present invention also can determine normal/abnormal tissue distribution for diagnostic purposes. Methods for *in vitro* and *in situ* analysis are well known and involve assessing binding of antigen-specific antibodies to tissues,
25 cells or cell extracts. These are conventional techniques well within the grasp of those skilled in the art. For example, the antibodies of the present invention may be used in conjunction with both fresh-frozen and formalin-fixed, paraffin-embedded tissue blocks prepared for study by immunohistochemistry (IHC). Each tissue block may consist of 50 mg of residual "pulverized" prostate tumor. The method of preparing tissue blocks from these particulate specimens has

been successfully used in previous IHC studies of various prognostic factors, *e.g.*, in breast cancer, and is well known to those of skill in the art. (Abbondanzo *et al.*, 1990; Allred *et al.*, 1990; Brown *et al.*, 1990)

5 Briefly, frozen-sections may be prepared by rehydrating 50 ng of frozen pulverized tumor at room temperature in PBS in small plastic capsules; pelleting the particles by centrifugation; resuspending them in a viscous embedding medium (OCT); inverting the capsule and pelleting again by centrifugation; snap-freezing in -70°C isopentane; cutting the plastic capsule and removing the frozen cylinder of tissue; securing the tissue cylinder on a cryostat microtome
10 chuck; and cutting 25-50 serial sections containing an average of about 500 remarkably intact tumor cells.

Permanent-sections may be prepared by a similar method involving rehydration of the 50 mg sample in a plastic microfuge tube; pelleting; resuspending in 10% formalin for 4 hours
15 fixation; washing/pelleting; resuspending in warm 2.5% agar; pelleting; cooling in ice water to harden the agar; removing the tissue/agar block from the tube; infiltrating and embedding the block in paraffin; and cutting up to 50 serial permanent sections.

F. Nucleic Acid Detection

20 In addition to their use in directing the expression of the TLR-4 protein, the nucleic acid sequences disclosed herein also have a variety of other uses. For example, they also have utility as probes or primers in nucleic acid hybridization embodiments.

i. Hybridization

25 The use of a hybridization probe of between 20 and 100 nucleotides in length allows the formation of a duplex molecule that is both stable and selective. Molecules having complementary sequences over stretches greater than 20 bases in length are generally preferred, in order to increase stability and selectivity of the hybrid, and thereby improve the quality and degree of particular hybrid molecules obtained. One will generally prefer to design nucleic acid molecules having

stretches of 20 to 30 nucleotides, or even longer where desired. Such fragments may be readily prepared by, for example, directly synthesizing the fragment by chemical means or by introducing selected sequences into recombinant vectors for recombinant production. These chemical means can include PCR TM technology of U.S. Patent 4,603,102 (herein incorporated by reference) or by
5 introducing selected sequences into recombinant vectors for recombinant production.

Accordingly, the nucleotide sequences of the invention may be used for their ability to selectively form duplex molecules with complementary stretches of genes or RNAs or to provide primers for amplification of DNA or RNA from tissues. Depending on the application envisioned,
10 one will desire to employ varying conditions of hybridization to achieve varying degrees of selectivity of probe towards target sequence.

For certain applications, for example, substitution of nucleotides by site-directed mutagenesis, it is appreciated that lower stringency conditions are required. Under these
15 conditions, hybridization may occur even though the sequences of probe and target strand are not perfectly complementary, but are mismatched at one or more positions. Conditions may be rendered less stringent by increasing salt concentration and decreasing temperature. For example, a low stringency hybridization conditions for the present invention of hybridization in 35% formamide, 5× Denhardts' solution, 5× SSC, 25 mM sodium phosphate, 0.1% SDS and 100
20 µg/ml denatured salmon sperm DNA or *E. coli* DNA at 42°C for 16 hours followed by sequential washes with 0.8× SSC, 0.1% SDS at 55°C allows for cross-species hybridization to homologous proteins to occur. Thus, hybridization conditions can be readily manipulated depending on the desired results.

25 In other embodiments, hybridization may be achieved under conditions of, for example, 50% formamide, 5× Denhardts' solution, 5× SSC, 25 mM sodium phosphate, 0.1% SDS and 100 µg/ml of denatured salmon sperm DNA at 42°C for 16 hours followed by 1 hour sequential washes with 0.1× SSC, 0.1% SDS solution at 60°C to remove the desired amount of background signal.

In certain embodiments, it will be advantageous to employ nucleic acid sequences of the present invention in combination with an appropriate means, such as a label, for determining hybridization. A wide variety of appropriate indicator means are known in the art, including fluorescent, radioactive, enzymatic or other ligands, such as avidin/biotin, which are capable of being detected. In preferred embodiments, one may desire to employ a fluorescent label or an enzyme tag such as urease, alkaline phosphatase or peroxidase, instead of radioactive or other environmentally undesirable reagents. In the case of enzyme tags, colorimetric indicator substrates are known that can be employed to provide a detection means visible to the human eye or spectrophotometrically, to identify specific hybridization with complementary nucleic acid-containing samples.

In general, it is envisioned that the hybridization probes described herein will be useful both as reagents in solution hybridization, as in PCR™, for detection of expression of corresponding genes, as well as in embodiments employing a solid phase. In embodiments involving a solid phase, the test DNA (or RNA) is adsorbed or otherwise affixed to a selected matrix or surface. This fixed, single-stranded nucleic acid is then subjected to hybridization with selected probes under desired conditions. The selected conditions will depend on the particular circumstances based on the particular criteria required (depending, for example, on the G+C content, type of target nucleic acid, source of nucleic acid, size of hybridization probe, *etc.*). Following washing of the hybridized surface to remove non-specifically bound probe molecules, hybridization is detected, or even quantified, by means of the label.

ii. Amplification and PCR™

Nucleic acid used as a template for amplification is isolated from cells contained in the biological sample, according to standard methodologies (Sambrook *et al.*, 1989). The nucleic acid may be genomic DNA or fractionated or whole cell RNA. Where RNA is used, it may be desired to convert the RNA to a cDNA.

Pairs of primers that selectively hybridize to nucleic acids corresponding to a TLR-4 protein or a mutant thereof are contacted with the isolated nucleic acid under conditions that permit selective hybridization. The term "primer", as defined herein, is meant to encompass any nucleic acid that is capable of priming the synthesis of a nascent nucleic acid in a template-
5 dependent process. Typically, primers are oligonucleotides from ten to twenty base pairs in length, but longer sequences can be employed. Primers may be provided in double-stranded or single-stranded form, although the single-stranded form is preferred.

Once hybridized, the nucleic acid:primer complex is contacted with one or more
10 enzymes that facilitate template-dependent nucleic acid synthesis. Multiple rounds of amplification, also referred to as "cycles," are conducted until a sufficient amount of amplification product is produced.

Next, the amplification product is detected. In certain applications, the detection may be
15 performed by visual means. Alternatively, the detection may involve indirect identification of the product via chemiluminescence, radioactive scintigraphy of incorporated radiolabel or fluorescent label or even via a system using electrical or thermal impulse signals (Affymax technology).

A number of template dependent processes are available to amplify the marker sequences
20 present in a given template sample. One of the best known amplification methods is the polymerase chain reaction (referred to as PCR™) which is described in detail in U.S. Patent Nos. 4,683,195, 4,683,202 and 4,800,159, and each incorporated herein by reference in entirety.

Briefly, in PCR™, two primer sequences are prepared that are complementary to regions
25 on opposite complementary strands of the marker sequence. An excess of deoxynucleoside triphosphates are added to a reaction mixture along with a DNA polymerase, *e.g.*, *Taq* polymerase. If the marker sequence is present in a sample, the primers will bind to the marker and the polymerase will cause the primers to be extended along the marker sequence by adding

on nucleotides. By raising and lowering the temperature of the reaction mixture, the extended primers will dissociate from the marker to form reaction products, excess primers will bind to the marker and to the reaction products and the process is repeated.

5 A reverse transcriptase PCR™ (RT-PCR™) amplification procedure may be performed in order to quantify the amount of mRNA amplified or to prepare cDNA from the desired mRNA. Methods of reverse transcribing RNA into cDNA are well known and described in Sambrook *et al.*, 1989. Alternative methods for reverse transcription utilize thermostable, RNA-dependent DNA polymerases. These methods are described in WO 90/07641, filed December 21, 1990,
10 incorporated herein by reference. Polymerase chain reaction methodologies are well known in the art.

15 Another method for amplification is the ligase chain reaction ("LCR"), disclosed in EPA No. 320 308, incorporated herein by reference in its entirety. In LCR, two complementary probe pairs are prepared, and in the presence of the target sequence, each pair will bind to opposite complementary strands of the target such that they abut. In the presence of a ligase, the two probe pairs will link to form a single unit. By temperature cycling, as in PCR™, bound ligated units dissociate from the target and then serve as "target sequences" for ligation of excess probe pairs. U.S. Patent 4,883,750 describes a method similar to LCR for binding probe pairs to a
20 target sequence.

 Qbeta Replicase, described in PCT Application No. PCT/US87/00880, incorporated herein by reference, may also be used as still another amplification method in the present invention. In this method, a replicative sequence of RNA that has a region complementary to
25 that of a target is added to a sample in the presence of an RNA polymerase. The polymerase will copy the replicative sequence that can then be detected.

 An isothermal amplification method, in which restriction endonucleases and ligases are used to achieve the amplification of target molecules that contain nucleotide 5'-[alpha-thio]-

triphosphates in one strand of a restriction site may also be useful in the amplification of nucleic acids in the present invention.

5 Strand Displacement Amplification (SDA) is another method of carrying out isothermal amplification of nucleic acids which involves multiple rounds of strand displacement and synthesis, *i.e.*, nick translation. A similar method, called Repair Chain Reaction (RCR), involves annealing several probes throughout a region targeted for amplification, followed by a repair reaction in which only two of the four bases are present. The other two bases can be added as biotinylated derivatives for easy detection. A similar approach is used in SDA. Target
10 specific sequences can also be detected using a cyclic probe reaction (CPR). In CPR, a probe having 3' and 5' sequences of non-specific DNA and a middle sequence of specific RNA is hybridized to DNA that is present in a sample. Upon hybridization, the reaction is treated with RNase H, and the products of the probe identified as distinctive products that are released after digestion. The original template is annealed to another cycling probe and the reaction is
15 repeated.

Still another amplification methods described in GB Application No. 2 202 328, and in PCT Application No. PCT/US89/01025, each of which is incorporated herein by reference in its entirety, may be used in accordance with the present invention. In the former application,
20 "modified" primers are used in a PCR™-like, template- and enzyme-dependent synthesis. The primers may be modified by labeling with a capture moiety (*e.g.*, biotin) and/or a detector moiety (*e.g.*, enzyme). In the latter application, an excess of labeled probes are added to a sample. In the presence of the target sequence, the probe binds and is cleaved catalytically. After cleavage, the target sequence is released intact to be bound by excess probe. Cleavage of the labeled probe
25 signals the presence of the target sequence.

Other nucleic acid amplification procedures include transcription-based amplification systems (TAS), including nucleic acid sequence based amplification (NASBA) and 3SR Gingeras *et al.*, PCT Application WO 88/10315, incorporated herein by reference. In NASBA,

the nucleic acids can be prepared for amplification by standard phenol/chloroform extraction, heat denaturation of a clinical sample, treatment with lysis buffer and minispin columns for isolation of DNA and RNA or guanidinium chloride extraction of RNA. These amplification techniques involve annealing a primer which has target specific sequences. Following polymerization, DNA/RNA hybrids are digested with RNase H while double stranded DNA molecules are heat denatured again. In either case the single stranded DNA is made fully double stranded by addition of second target specific primer, followed by polymerization. The double-stranded DNA molecules are then multiply transcribed by an RNA polymerase such as T7 or SP6. In an isothermal cyclic reaction, the RNA's are reverse transcribed into single stranded DNA, which is then converted to double stranded DNA, and then transcribed once again with an RNA polymerase such as T7 or SP6. The resulting products, whether truncated or complete, indicate target specific sequences.

Davey *et al.*, EPA No. 329 822 (incorporated herein by reference in its entirety) disclose a nucleic acid amplification process involving cyclically synthesizing single-stranded RNA ("ssRNA"), ssDNA, and double-stranded DNA (dsDNA), which may be used in accordance with the present invention. The ssRNA is a template for a first primer oligonucleotide, which is elongated by reverse transcriptase (RNA-dependent DNA polymerase). The RNA is then removed from the resulting DNA:RNA duplex by the action of ribonuclease H (RNase H, an RNase specific for RNA in duplex with either DNA or RNA). The resultant ssDNA is a template for a second primer, which also includes the sequences of an RNA polymerase promoter (exemplified by T7 RNA polymerase) 5' to its homology to the template. This primer is then extended by DNA polymerase (exemplified by the large "Klenow" fragment of *E. coli* DNA polymerase I), resulting in a double-stranded DNA ("dsDNA") molecule, having a sequence identical to that of the original RNA between the primers and having additionally, at one end, a promoter sequence. This promoter sequence can be used by the appropriate RNA polymerase to make many RNA copies of the DNA. These copies can then re-enter the cycle leading to very swift amplification. With proper choice of enzymes, this amplification can be

done isothermally without addition of enzymes at each cycle. Because of the cyclical nature of this process, the starting sequence can be chosen to be in the form of either DNA or RNA.

Miller *et al.*, PCT Application WO 89/06700 (incorporated herein by reference in its entirety) disclose a nucleic acid sequence amplification scheme based on the hybridization of a promoter/primer sequence to a target single-stranded DNA ("ssDNA") followed by transcription of many RNA copies of the sequence. This scheme is not cyclic, *i.e.*, new templates are not produced from the resultant RNA transcripts. Other amplification methods include "RACE" and "one-sided PCR" (Frohman, 1990, incorporated by reference).

Methods based on ligation of two (or more) oligonucleotides in the presence of nucleic acid having the sequence of the resulting "di-oligonucleotide", thereby amplifying the di-oligonucleotide, may also be used in the amplification step of the present invention.

Following any amplification, it may be desirable to separate the amplification product from the template and the excess primer for the purpose of determining whether specific amplification has occurred. In one embodiment, amplification products are separated by agarose, agarose-acrylamide or polyacrylamide gel electrophoresis using standard methods. See Sambrook *et al.*, 1989.

Alternatively, chromatographic techniques may be employed to effect separation. There are many kinds of chromatography which may be used in the present invention: adsorption, partition, ion-exchange and molecular sieve, and many specialized techniques for using them including column, paper, thin-layer and gas chromatography.

Amplification products must be visualized in order to confirm amplification of the marker sequences. One typical visualization method involves staining of a gel with ethidium bromide and visualization under UV light. Alternatively, if the amplification products are integrally labeled with radio- or fluorometrically-labeled nucleotides, the amplification products

can then be exposed to x-ray film or visualized under the appropriate stimulating spectra, following separation.

5 In one embodiment, visualization is achieved indirectly. Following separation of amplification products, a labeled, nucleic acid probe is brought into contact with the amplified marker sequence. The probe preferably is conjugated to a chromophore but may be radiolabeled. In another embodiment, the probe is conjugated to a binding partner, such as an antibody or biotin, and the other member of the binding pair carries a detectable moiety.

10 In one embodiment, detection is by Southern blotting and hybridization with a labeled probe. The techniques involved in Southern blotting are well known to those of skill in the art and can be found in many standard books on molecular protocols. See Sambrook *et al.*, 1989. Briefly, amplification products are separated by gel electrophoresis. The gel is then contacted with a membrane, such as nitrocellulose, permitting transfer of the nucleic acid and non-covalent
15 binding. Subsequently, the membrane is incubated with a chromophore-conjugated probe that is capable of hybridizing with a target amplification product. Detection is by exposure of the membrane to x-ray film or ion-emitting detection devices.

20 One example of the foregoing is described in U.S. Patent No. 5,279,721, incorporated by reference herein, which discloses an apparatus and method for the automated electrophoresis and transfer of nucleic acids. The apparatus permits electrophoresis and blotting without external manipulation of the gel and is ideally suited to carrying out methods according to the present invention.

25 All the essential materials and reagents required for detecting TLR-4 protein markers in a biological sample may be assembled together in a kit. This generally will comprise preselected primers for specific markers. Also included may be enzymes suitable for amplifying nucleic acids including various polymerases (RT, Taq, *etc.*), deoxynucleotides and buffers to provide the necessary reaction mixture for amplification.

Such kits generally will comprise, in suitable means, distinct containers for each individual reagent and enzyme as well as for each marker primer pair. Preferred pairs of primers for amplifying nucleic acids are selected to amplify the sequences specified in SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47 or SEQ ID NO:48.

In another embodiment, such kits will comprise hybridization probes specific for TLR-4 protein chosen from a group including nucleic acids corresponding to the sequences specified in SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47 or SEQ ID NO:48. Such kits generally will comprise, in suitable means, distinct containers for each individual reagent and enzyme as well as for each marker hybridization probe.

iii. Other Assays

Other methods for genetic screening to accurately detect genetic changes which may be caused by disease, such as bacterial infections that alter normal cellular production and processing, in genomic DNA, cDNA or RNA samples may be employed, depending on the specific situation.

For example, one method of screening for genetic variation is based on RNase cleavage of base pair mismatches in RNA/DNA and RNA/RNA heteroduplexes. As used herein, the term "mismatch" is defined as a region of one or more unpaired or mispaired nucleotides in a double-stranded RNA/RNA, RNA/DNA or DNA/DNA molecule. This definition thus includes mismatches due to insertion/deletion mutations, as well as single and multiple base point mutations.

U.S. Patent No. 4,946,773 describes an RNase A mismatch cleavage assay that involves annealing single-stranded DNA or RNA test samples to an RNA probe, and subsequent treatment of the nucleic acid duplexes with RNase A. After the RNase cleavage reaction, the

The RNase Protection assay was adapted for detection of single base mutations. In this type of RNase A mismatch cleavage assay, radiolabeled RNA probes transcribed *in vitro* from wild type sequences, are hybridized to complementary target regions derived from test samples.

- 5 The test target generally comprises DNA (either genomic DNA or DNA amplified by cloning in plasmids or by PCRTM), although RNA targets (endogenous mRNA) have occasionally been used. If single nucleotide (or greater) sequence differences occur between the hybridized probe and target, the resulting disruption in Watson-Crick hydrogen bonding at that position ("mismatch") can be recognized and cleaved in some cases by single-strand specific
10 ribonuclease. To date, RNase A has been used almost exclusively for cleavage of single-base mismatches, although RNase I has recently been shown as useful also for mismatch cleavage. There are recent descriptions of using the MutS protein and other DNA-repair enzymes for detection of single-base mismatches.

15 **G. Recombinant Vectors, Host Cells and Expression**

- Recombinant vectors form important further aspects of the present invention. The term "expression vector or construct" means any type of genetic construct containing a nucleic acid coding for a gene product in which part or all of the nucleic acid encoding sequence is capable of being transcribed. The transcript may be translated into a protein, but it need not be. Thus, in
20 certain embodiments, expression includes both transcription of a gene and translation of a RNA into a gene product. In other embodiments, expression only includes transcription of the nucleic acid, for example, to generate antisense constructs.

- Particularly useful vectors are contemplated to be those vectors in which the coding
25 portion of the DNA segment, whether encoding a full length protein or smaller peptide, is positioned under the transcriptional control of a promoter. A "promoter" refers to a DNA sequence recognized by the synthetic machinery of the cell, or introduced synthetic machinery, required to initiate the specific transcription of a gene. The phrases "operatively positioned", "under control" or "under transcriptional control" means that the promoter is in the correct

location and orientation in relation to the nucleic acid to control RNA polymerase initiation and expression of the gene.

5 The promoter may be in the form of the promoter that is naturally associated with a TLR-4 protein gene, as may be obtained by isolating the 5' non-coding sequences located upstream of the coding segment or exon, for example, using recombinant cloning and/or PCR™ technology, in connection with the compositions disclosed herein (PCR™ technology is disclosed in U.S. Patent 4,683,202 and U.S. Patent 4,682,195, each incorporated herein by reference). Additionally, the toll-like receptors from *Drosophila* are well known to those of skill in the art.

10 The promoter regions of these nucleic acids may be useful herein.

In other embodiments, it is contemplated that certain advantages will be gained by positioning the coding DNA segment under the control of a recombinant, or heterologous, promoter. As used herein, a recombinant or heterologous promoter is intended to refer to a promoter that is not normally associated with a TLR-4 protein gene in its natural environment.

15 Such promoters may include promoters normally associated with other genes, and/or promoters isolated from any other bacterial, viral, eukaryotic, or mammalian cell.

Naturally, it will be important to employ a promoter that effectively directs the expression of the DNA segment in the cell type, organism, or even animal, chosen for expression. The use of promoter and cell type combinations for protein expression is generally known to those of skill in the art of molecular biology, for example, see Sambrook *et al.* (1989), incorporated herein by reference. The promoters employed may be constitutive, or inducible, and can be used under the appropriate conditions to direct high level expression of the

20 introduced DNA segment, such as is advantageous in the large-scale production of recombinant proteins or peptides.

25

At least one module in a promoter functions to position the start site for RNA synthesis. The best known example of this is the TATA box, but in some promoters lacking a TATA box,

such as the promoter for the mammalian terminal deoxynucleotidyl transferase gene and the promoter for the SV40 late genes, a discrete element overlying the start site itself helps to fix the place of initiation.

5 Additional promoter elements regulate the frequency of transcriptional initiation. Typically, these are located in the region 30-110 bp upstream of the start site, although a number of promoters have been shown to contain functional elements downstream of the start site as well. The spacing between promoter elements frequently is flexible, so that promoter function is preserved when elements are inverted or moved relative to one another. In the thymidine kinase
10 (tk) promoter, the spacing between promoter elements can be increased to 50 bp apart before activity begins to decline. Depending on the promoter, it appears that individual elements can function either co-operatively or independently to activate transcription.

15 The particular promoter that is employed to control the expression of a nucleic acid is not believed to be critical, so long as it is capable of expressing the nucleic acid in the targeted cell. Thus, where a human cell is targeted, it is preferable to position the nucleic acid coding region adjacent to and under the control of a promoter that is capable of being expressed in a human cell. Generally speaking, such a promoter might include either a human or viral promoter. Preferred promoters include those derived from HSV, including the HNF1 α promoter. Another
20 preferred embodiment is the tetracycline controlled promoter.

In various other embodiments, the human cytomegalovirus (CMV) immediate early gene promoter, the Simian virus 40 (SV40) early promoter and the Rous sarcoma virus long terminal repeat can be used to obtain high-level expression of transgenes. The use of other viral or
25 mammalian cellular or bacterial phage promoters which are well-known in the art to achieve expression of a transgene is contemplated as well, provided that the levels of expression are sufficient for a given purpose. The following tables list several elements/promoters which may be employed, in the context of the present invention, to regulate the expression of TLR-4 protein

or subunit gene. This list is not intended to be exhaustive of all the possible elements involved in the promotion of transgene expression but, merely, to be exemplary thereof.

Enhancers were originally detected as genetic elements that increased transcription from a promoter located at a distant position on the same molecule of DNA. This ability to act over a large distance had little precedent in classic studies of prokaryotic transcriptional regulation. Subsequent work showed that regions of DNA with enhancer activity are organized much like promoters. That is, they are composed of many individual elements, each of which binds to one or more transcriptional proteins.

The basic distinction between enhancers and promoters is operational. An enhancer region as a whole must be able to stimulate transcription at a distance; this need not be true of a promoter region or its component elements. On the other hand, a promoter must have one or more elements that direct initiation of RNA synthesis at a particular site and in a particular orientation, whereas enhancers lack these specificities. Promoters and enhancers are often overlapping and contiguous, often seeming to have a very similar modular organization.

Additionally any promoter/enhancer combination (as per the Eukaryotic Promoter Data Base EPDB) could also be used to drive expression of a transgene. Use of a T3, T7 or SP6 cytoplasmic expression system is another possible embodiment. Eukaryotic cells can support cytoplasmic transcription from certain bacterial promoters if the appropriate bacterial polymerase is provided, either as part of the delivery complex or as an additional genetic expression construct.

PROMOTER TABLE

PROMOTER	REFERENCES
Immunoglobulin Heavy Chain	Hanerji <i>et al.</i> , 1983; Gilles <i>et al.</i> , 1983; Grosschedl and Baltimore, 1985; Imler <i>et al.</i> , 1987; Weinberger <i>et al.</i> , 1988; Kiledjian <i>et al.</i> , 1988; Porton <i>et al.</i> , 1990
Immunoglobulin Light Chain	Queen and Baltimore, 1983; Picard and Schaffner, 1984
T-Cell Receptor	Luria <i>et al.</i> , 1987, Winoto and Baltimore, 1989; Redondo <i>et al.</i> , 1990
HLA DQ α and DQ β	Sullivan and Peterlin, 1987
β -Interferon	Goodbourn <i>et al.</i> , 1986; Fujita <i>et al.</i> , 1987; Goodbourn and Maniatis, 1985
Interleukin-2	Greene <i>et al.</i> , 1989
Interleukin-2 Receptor	Greene <i>et al.</i> , 1989; Lin <i>et al.</i> , 1990
MHC Class II 5	Koch <i>et al.</i> , 1989
MHC Class II HLA-DR α	Sherman <i>et al.</i> , 1989
β -Actin	Kawamoto <i>et al.</i> , 1988; Ng <i>et al.</i> , 1989
Muscle Creatine Kinase	Jaynes <i>et al.</i> , 1988; Horlick and Benfield, 1989; Johnson <i>et al.</i> , 1989a
Prealbumin (Transthyretin)	Costa <i>et al.</i> , 1988
Elastase I	Omitz <i>et al.</i> , 1987
Metallothionein	Karin <i>et al.</i> , 1987; Culotta and Hamer, 1989
Collagenase	Pinkert <i>et al.</i> , 1987; Angel <i>et al.</i> , 1987
Albumin Gene	Pinkert <i>et al.</i> , 1987, Tronche <i>et al.</i> , 1989, 1990
α -Fetoprotein	Godbout <i>et al.</i> , 1988
τ -Globin	Bodine and Ley, 1987; Perez-Stable and Constantini, 1990
β -Globin	Trudel and Constantini, 1987
e-fos	Cohen <i>et al.</i> , 1987
c-HA-ras	Triesman, 1986; Deschamps <i>et al.</i> , 1985
Insulin	Edlund <i>et al.</i> , 1985
Neural Cell Adhesion Molecule (NCAM)	Hirsch <i>et al.</i> , 1990
α ₁ -Antitrypsin	Latimer <i>et al.</i> , 1990
H2B (TH2B) Histone	Hwang <i>et al.</i> , 1990

PROMOTER	REFERENCES
Mouse or Type I Collagen	Ripe <i>et al.</i> , 1989
Glucose-Regulated Proteins (GRP94 and GRP78)	Chang <i>et al.</i> , 1989
Rat Growth Hormone	Larsen <i>et al.</i> , 1986
Human Serum Amyloid A (SAA)	Edbrooke <i>et al.</i> , 1989
Troponin I (TN I)	Yutzey <i>et al.</i> , 1989
Platelet-Derived Growth Factor	Pech <i>et al.</i> , 1989
Duchenne Muscular Dystrophy	Klamut <i>et al.</i> , 1990
SV40	Banerji <i>et al.</i> , 1981; Moreau <i>et al.</i> , 1981; Sleight and Lockett, 1985; Firak and Subramanian, 1986; Herr and Clarke, 1986; Imbra and Karin, 1986; Kadesch and Berg, 1986; Wang and Calame, 1986; Ondek <i>et al.</i> , 1987; Kuhl <i>et al.</i> , 1987 Schaffner <i>et al.</i> , 1988
Polyoma	Swartzendruber and Lehman, 1975; Vasseur <i>et al.</i> , 1980; Katinka <i>et al.</i> , 1980, 1981; Tyndell <i>et al.</i> , 1981; Dandolo <i>et al.</i> , 1983; deVilliers <i>et al.</i> , 1984; Hen <i>et al.</i> , 1986; Satake <i>et al.</i> , 1988; Campbell and Villarreal, 1988
Retroviruses	Kriegler and Botchan, 1982, 1983; Levinson <i>et al.</i> , 1982; Kriegler <i>et al.</i> , 1983, 1984a,b, 1988; Bosze <i>et al.</i> , 1986; Miksicek <i>et al.</i> , 1986; Celander and Haseltine, 1987; Thiesen <i>et al.</i> , 1988; Celander <i>et al.</i> , 1988; Chol <i>et al.</i> , 1988; Reisman and Rotter, 1989
Papilloma Virus	Campo <i>et al.</i> , 1983; Lusky <i>et al.</i> , 1983; Spandidos and Wilkie, 1983; Spalholz <i>et al.</i> , 1985; Lusky and Botchan, 1986; Cripe <i>et al.</i> , 1987; Gloss <i>et al.</i> , 1987; Hirochika <i>et al.</i> , 1987, Stephens and Hentschel, 1987; Glue <i>et al.</i> , 1988
Hepatitis B Virus	Bulla and Siddiqui, 1986; Jameel and Siddiqui, 1986; Shaul and Ben-Levy, 1987; Spandau and Lee, 1988; Vannice and Levinson, 1988
Human Immunodeficiency Virus	Muesing <i>et al.</i> , 1987; Hauber and Cullan, 1988; Jakobovits <i>et al.</i> , 1988; Feng and Holland, 1988; Takebe <i>et al.</i> , 1988; Rowen <i>et al.</i> , 1988; Berkhout <i>et al.</i> , 1989; Laspia <i>et al.</i> , 1989; Sharp and Marciniak, 1989; Braddock <i>et al.</i> , 1989
Cytomegalovirus	Weber <i>et al.</i> , 1984; Boshart <i>et al.</i> , 1985; Foecking and Hofstetter, 1986
Gibbon Ape Leukemia Virus	Holbrook <i>et al.</i> , 1987; Quinn <i>et al.</i> , 1989

ENHANCER TABLE

	Inducer	References
MT II	Phorbol Ester (TFA) Heavy metals	Palmiter <i>et al.</i> , 1982; Haslinger and Karin, 1985; Searle <i>et al.</i> , 1985; Stuart <i>et al.</i> , 1985; Imagawa <i>et al.</i> , 1987; Karin <i>et al.</i> , 1987; Angel <i>et al.</i> , 1987b; McNeall <i>et al.</i> , 1989
MMTV (mouse mammary tumor virus)	Glucocorticoids	Huang <i>et al.</i> , 1981; Lee <i>et al.</i> , 1981; Majors and Varmus, 1983; Chandler <i>et al.</i> , 1983; Lee <i>et al.</i> , 1984; Fonta <i>et al.</i> , 1985; Sakai <i>et al.</i> , 1986
β-Interferon	poly(rI)X poly(rc)	Tavernier <i>et al.</i> , 1983
Adenovirus 5 <u>E2</u>	Ela	Imperiale and Nevins, 1984
Collagenase	Phorbol Ester (TPA)	Angle <i>et al.</i> , 1987a
Stromelysin	Phorbol Ester (TPA)	Angle <i>et al.</i> , 1987b
SV40	Phorbol Ester (TFA)	Angel <i>et al.</i> , 1987b
Murine MX Gene	Interferon, Newcastle Disease Virus	
GRP78 Gene	A23187	Resendez <i>et al.</i> , 1988
α-2-Macroglobulin	IL-6	Kunz <i>et al.</i> , 1989
Vimentin	Serum	Rittling <i>et al.</i> , 1989
MHC Class I Gene H-2kb	Interferon	Blonar <i>et al.</i> , 1989
HSP70	Ela, SV40 Large T Antigen	Taylor <i>et al.</i> , 1989; Taylor and Kingston, 1990a,b
Proliferin	Phorbol Ester-TPA	Mordacq and Linzer, 1989
Tumor Necrosis Factor	FMA	Hensel <i>et al.</i> , 1989
Thyroid Stimulating Hormone α Gene	Thyroid Hormone	Chatterjee <i>et al.</i> , 1989

Turning to the expression of the TLR-4 proteins of the present invention, once a suitable clone or clones have been obtained, whether they be cDNA based or genomic, one may proceed to prepare an expression system. The engineering of DNA segment(s) for expression in a prokaryotic or eukaryotic system may be performed by techniques generally known to those of skill in recombinant expression. It is believed that virtually any expression system may be employed in the expression of the proteins of the present invention.

Both cDNA and genomic sequences are suitable for eukaryotic expression, as the host cell will generally process the genomic transcripts to yield functional mRNA for translation into protein. Generally speaking, it may be more convenient to employ as the recombinant gene a cDNA version of the gene. It is believed that the use of a cDNA version will provide advantages in that the size of the gene will generally be much smaller and more readily employed to transfect the targeted cell than will a genomic gene, which will typically be up to an order of magnitude larger than the cDNA gene. However, the possibility of employing a genomic version of a particular gene where desired is not excluded.

In expression, one will typically include a polyadenylation signal to effect proper polyadenylation of the transcript. The nature of the polyadenylation signal is not believed to be crucial to the successful practice of the invention, and any such sequence may be employed. Preferred embodiments include the SV40 polyadenylation signal and the bovine growth hormone polyadenylation signal, convenient and known to function well in various target cells. Also contemplated as an element of the expression cassette is a terminator. These elements can serve to enhance message levels and to minimize read through from the cassette into other sequences.

A specific initiation signal also may be required for efficient translation of coding sequences. These signals include the ATG initiation codon and adjacent sequences. Exogenous translational control signals, including the ATG initiation codon, may need to be provided. One of ordinary skill in the art would readily be capable of determining this and providing the

necessary signals. It is well known that the initiation codon must be "in-frame" with the reading frame of the desired coding sequence to ensure translation of the entire insert. The exogenous translational control signals and initiation codons can be either natural or synthetic. The efficiency of expression may be enhanced by the inclusion of appropriate transcription enhancer elements.

As used herein, the terms "engineered" and "recombinant" cells are intended to refer to a cell into which an exogenous DNA segment or gene, such as a cDNA or gene encoding a TLR-4 protein has been introduced. Therefore, engineered cells are distinguishable from naturally occurring cells which do not contain a recombinantly introduced exogenous DNA segment or gene. Engineered cells are thus cells having a gene or genes introduced through the hand of man. Recombinant cells include those having an introduced cDNA or genomic gene, and also include genes positioned adjacent to a promoter not naturally associated with the particular introduced gene.

To express a recombinant TLR-4 protein, whether mutant or wild-type, in accordance with the present invention one would prepare an expression vector that comprises a TLR-4 protein-encoding nucleic acid under the control of one or more promoters. To bring a coding sequence "under the control of" a promoter, one positions the 5' end of the transcription initiation site of the transcriptional reading frame generally between about 1 and about 50 nucleotides "downstream" of (*i.e.*, 3' of) the chosen promoter. The "upstream" promoter stimulates transcription of the DNA and promotes expression of the encoded recombinant protein. This is the meaning of "recombinant expression" in this context.

Many standard techniques are available to construct expression vectors containing the appropriate nucleic acids and transcriptional/translational control sequences in order to achieve protein or peptide expression in a variety of host-expression systems. Cell types available for expression include, but are not limited to, bacteria, such as *E. coli* and *B. subtilis* transformed with recombinant bacteriophage DNA, plasmid DNA or cosmid DNA expression vectors.

Certain examples of prokaryotic hosts are *E. coli* strain RR1, *E. coli* LE392, *E. coli* B, *E. coli* X 1776 (ATCC No. 31537) as well as *E. coli* W3110 (F-, lambda-, prototrophic, ATCC No. 27325); bacilli such as *Bacillus subtilis*; and other enterobacteriaceae such as *Salmonella typhimurium*, *Serratia marcescens*, and various *Pseudomonas* species.

In general, plasmid vectors containing replicon and control sequences which are derived from species compatible with the host cell are used in connection with these hosts. The vector ordinarily carries a replication site, as well as marking sequences which are capable of providing phenotypic selection in transformed cells. For example, *E. coli* is often transformed using pBR322, a plasmid derived from an *E. coli* species. pBR322 contains genes for ampicillin and tetracycline resistance and thus provides easy means for identifying transformed cells. The pBR plasmid, or other microbial plasmid or phage must also contain, or be modified to contain, promoters which can be used by the microbial organism for expression of its own proteins.

In addition, phage vectors containing replicon and control sequences that are compatible with the host microorganism can be used as transforming vectors in connection with these hosts. For example, the phage lambda GEMTM-11 may be utilized in making a recombinant phage vector which can be used to transform host cells, such as *E. coli* LE392.

Further useful vectors include pIN vectors and pGEX vectors, for use in generating glutathione S-transferase (GST) soluble fusion proteins for later purification and separation or cleavage. Other suitable fusion proteins are those with β -galactosidase, ubiquitin, the like.

Promoters that are most commonly used in recombinant DNA construction include the β -lactamase (penicillinase), lactose and tryptophan (trp) promoter systems. While these are the most commonly used, other microbial promoters have been discovered and utilized, and details concerning their nucleotide sequences have been published, enabling those of skill in the art to ligate them functionally with plasmid vectors.

The following details concerning recombinant protein production in bacterial cells, such as *E. coli*, are provided by way of exemplary information on recombinant protein production in general, the adaptation of which to a particular recombinant expression system will be known to those of skill in the art.

Bacterial cells, for example, *E. coli*, containing the expression vector are grown in any of a number of suitable media, for example, LB. The expression of the recombinant protein may be induced, *e.g.*, by adding IPTG to the media or by switching incubation to a higher temperature. After culturing the bacteria for a further period, generally of between 2 and 24 hours, the cells are collected by centrifugation and washed to remove residual media.

The bacterial cells are then lysed, for example, by disruption in a cell homogenizer and centrifuged to separate the dense inclusion bodies and cell membranes from the soluble cell components. This centrifugation can be performed under conditions whereby the dense inclusion bodies are selectively enriched by incorporation of sugars, such as sucrose, into the buffer and centrifugation at a selective speed.

If the recombinant protein is expressed in the inclusion bodies, as is the case in many instances, these can be washed in any of several solutions to remove some of the contaminating host proteins, then solubilized in solutions containing high concentrations of urea (*e.g.* 8M) or chaotropic agents such as guanidine hydrochloride in the presence of reducing agents, such as β -mercaptoethanol or DTT (dithiothreitol).

Under some circumstances, it may be advantageous to incubate the protein for several hours under conditions suitable for the protein to undergo a refolding process into a conformation which more closely resembles that of the native protein. Such conditions generally include low protein concentrations, less than 500 mg/ml, low levels of reducing agent, concentrations of urea less than 2 M and often the presence of reagents such as a mixture of

reduced and oxidized glutathione which facilitate the interchange of disulfide bonds within the protein molecule.

The refolding process can be monitored, for example, by SDS-PAGE, or with antibodies specific for the native molecule (which can be obtained from animals vaccinated with the native molecule or smaller quantities of recombinant protein). Following refolding, the protein can then be purified further and separated from the refolding mixture by chromatography on any of several supports including ion exchange resins, gel permeation resins or on a variety of affinity columns.

For expression in *Saccharomyces*, the plasmid YRp7, for example, is commonly used. This plasmid already contains the *trp1* gene which provides a selection marker for a mutant strain of yeast lacking the ability to grow in tryptophan, for example ATCC No. 44076 or PEP4-1. The presence of the *trp1* lesion as a characteristic of the yeast host cell genome then provides an effective environment for detecting transformation by growth in the absence of tryptophan.

Suitable promoting sequences in yeast vectors include the promoters for 3-phosphoglycerate kinase or other glycolytic enzymes, such as enolase, glyceraldehyde-3-phosphate dehydrogenase, hexokinase, pyruvate decarboxylase, phosphofructokinase, glucose-6-phosphate isomerase, 3-phosphoglycerate mutase, pyruvate kinase, triosephosphate isomerase, phosphoglucose isomerase, and glucokinase. In constructing suitable expression plasmids, the termination sequences associated with these genes are also ligated into the expression vector 3' of the sequence desired to be expressed to provide polyadenylation of the mRNA and termination.

Other suitable promoters, which have the additional advantage of transcription controlled by growth conditions, include the promoter region for alcohol dehydrogenase 2, isocytochrome C, acid phosphatase, degradative enzymes associated with nitrogen metabolism, and the

aforementioned glyceraldehyde-3-phosphate dehydrogenase, and enzymes responsible for maltose and galactose utilization.

In addition to microorganisms, cultures of cells derived from multicellular organisms may also be used as hosts. In principle, any such cell culture is workable, whether from vertebrate or invertebrate culture. In addition to mammalian cells, these include insect cell systems infected with recombinant virus expression vectors (*e.g.*, baculovirus); and plant cell systems infected with recombinant virus expression vectors (*e.g.*, cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or transformed with recombinant plasmid expression vectors (*e.g.*, Ti plasmid) containing one or more Toll protein coding sequences.

In a useful insect system, *Autographa californica* nuclear polyhidrosis virus (AcNPV) is used as a vector to express foreign genes. The virus grows in *Spodoptera frugiperda* cells. The TLR-4 protein coding sequences are cloned into non-essential regions (for example the polyhedrin gene) of the virus and placed under control of an AcNPV promoter (for example the polyhedrin promoter). Successful insertion of the coding sequences results in the inactivation of the polyhedrin gene and production of non-occluded recombinant virus (*i.e.*, virus lacking the proteinaceous coat coded for by the polyhedrin gene). These recombinant viruses are then used to infect *Spodoptera frugiperda* cells in which the inserted gene is expressed (*e.g.*, U.S. Patent No. 4,215,051, Smith, incorporated herein by reference).

Examples of useful mammalian host cell lines are VERO and HeLa cells, Chinese hamster ovary (CHO) cell lines, W138, BHK, COS-7, 293, HepG2, 3T3, RIN and MDCK cell lines. In addition, a host cell strain may be chosen that modulates the expression of the inserted sequences, or modifies and processes the gene product in the specific fashion desired. Such modifications (*e.g.*, glycosylation) and processing (*e.g.*, cleavage) of protein products may be important for the function of the protein.

Different host cells have characteristic and specific mechanisms for the post-translational processing and modification of proteins. Appropriate cells lines or host systems can be chosen to ensure the correct modification and processing of the foreign protein expressed.

5 Expression vectors for use in mammalian such cells ordinarily include an origin of replication (as necessary), a promoter located in front of the gene to be expressed, along with any necessary ribosome binding sites, RNA splice sites, polyadenylation site, and transcriptional terminator sequences. The origin of replication may be provided either by construction of the vector to include an exogenous origin, such as may be derived from SV40 or other viral (*e.g.*,
10 Polyoma, Adeno, VSV, BPV) source, or may be provided by the host cell chromosomal replication mechanism. If the vector is integrated into the host cell chromosome, the latter is often sufficient.

15 The promoters may be derived from the genome of mammalian cells (*e.g.*, metallothionein promoter) or from mammalian viruses (*e.g.*, the adenovirus late promoter; the vaccinia virus 7.5K promoter). Further, it is also possible, and may be desirable, to utilize promoter or control sequences normally associated with the desired TLR-4 protein gene sequence, provided such control sequences are compatible with the host cell systems.

20 A number of viral based expression systems may be utilized, for example, commonly used promoters are derived from polyoma, Adenovirus 2, and most frequently Simian Virus 40 (SV40). The early and late promoters of SV40 virus are particularly useful because both are obtained easily from the virus as a fragment which also contains the SV40 viral origin of replication. Smaller or larger SV40 fragments may also be used, provided there is included the
25 approximately 250 bp sequence extending from the *Hind III* site toward the *Bgl I* site located in the viral origin of replication.

In cases where an adenovirus is used as an expression vector, the coding sequences may be ligated to an adenovirus transcription/ translation control complex, *e.g.*, the late promoter and

tripartite leader sequence. This chimeric gene may then be inserted in the adenovirus genome by *in vitro* or *in vivo* recombination. Insertion in a non-essential region of the viral genome (*e.g.*, region E1 or E3) will result in a recombinant virus that is viable and capable of expressing TLR-4 proteins in infected hosts.

5

Specific initiation signals may also be required for efficient translation TLR-4 protein coding sequences. These signals include the ATG initiation codon and adjacent sequences. Exogenous translational control signals, including the ATG initiation codon, may additionally need to be provided. One of ordinary skill in the art would readily be capable of determining this and providing the necessary signals. It is well known that the initiation codon must be in-frame (or in-phase) with the reading frame of the desired coding sequence to ensure translation of the entire insert. These exogenous translational control signals and initiation codons can be of a variety of origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of appropriate transcription enhancer elements, transcription terminators.

10

15

In eukaryotic expression, one will also typically desire to incorporate into the transcriptional unit an appropriate polyadenylation site (*e.g.*, 5'-AATAAA-3') if one was not contained within the original cloned segment. Typically, the poly-A addition site is placed about 30 to 2000 nucleotides "downstream" of the termination site of the protein at a position prior to transcription termination.

20

For long-term, high-yield production of recombinant TLR-4 proteins, stable expression is preferred. For example, cell lines that stably express constructs TLR-4 proteins may be engineered. Rather than using expression vectors that contain viral origins of replication, host cells can be transformed with vectors controlled by appropriate expression control elements (*e.g.*, promoter, enhancer, sequences, transcription terminators, polyadenylation sites, etc.), and a selectable marker. Following the introduction of foreign DNA, engineered cells may be allowed to grow for 1-2 days in an enriched media, and then are switched to a selective media. The selectable marker in the recombinant plasmid confers resistance to the selection and allows cells

25

to stably integrate the plasmid into their chromosomes and grow to form foci which in turn can be cloned and expanded into cell lines.

5 A number of selection systems may be used, including, but not limited, to the herpes simplex virus (HSV) tk, hypoxanthine-guanine phosphoribosyltransferase (hgprt) and adenine phosphoribosyltransferase genes (aprt), in tk-, hgprt- or aprt- cells, respectively. Also, antimetabolite resistance can be used as the basis of selection for *dhfr*, that confers resistance to methotrexate; *gpt*, that confers resistance to mycophenolic acid; *neo*, that confers resistance to the aminoglycoside G-418; and *hygro*, that confers resistance to hygromycin:

10

Animal cells can be propagated *in vitro* in two modes: as non-anchorage dependent cells growing in suspension throughout the bulk of the culture or as anchorage-dependent cells requiring attachment to a solid substrate for their propagation (*i.e.*, a monolayer type of cell growth).

15

Non-anchorage dependent or suspension cultures from continuous established cell lines are the most widely used means of large scale production of cells and cell products. However, suspension cultured cells have limitations, such as tumorigenic potential and lower protein production than adherent cells.

20

Large scale suspension culture of mammalian cells in stirred tanks is a common method for production of recombinant proteins. Two suspension culture reactor designs are in wide use - the stirred reactor and the airlift reactor. The stirred design has successfully been used on an 8000 liter capacity for the production of interferon. Cells are grown in a stainless steel tank with a height-to-diameter ratio of 1:1 to 3:1. The culture is usually mixed with one or more agitators, based on bladed disks or marine propeller patterns. Agitator systems offering less shear forces than blades have been described. Agitation may be driven either directly or indirectly by magnetically coupled drives. Indirect drives reduce the risk of microbial contamination through seals on stirrer shafts.

25

The airlift reactor, also initially described for microbial fermentation and later adapted for mammalian culture, relies on a gas stream to both mix and oxygenate the culture. The gas stream enters a riser section of the reactor and drives circulation. Gas disengages at the culture surface, causing denser liquid free of gas bubbles to travel downward in the downcomer section of the reactor. The main advantage of this design is the simplicity and lack of need for mechanical mixing. Typically, the height-to-diameter ratio is 10:1. The airlift reactor scales up relatively easily, has good mass transfer of gases and generates relatively low shear forces.

It is contemplated that the TLR-4 protein of the invention may be "overexpressed", *i.e.*, expressed in increased levels relative to its natural expression in cells. Such overexpression may be assessed by a variety of methods, including radio-labeling and/or protein purification. However, simple and direct methods are preferred, for example, those involving SDS/PAGE and protein staining or western blotting, followed by quantitative analyses, such as densitometric scanning of the resultant gel or blot. A specific increase in the level of the recombinant protein or peptide in comparison to the level in natural cells is indicative of overexpression, as is a relative abundance of the specific protein in relation to the other proteins produced by the host cell and, *e.g.*, visible on a gel.

H. Kits

All the essential materials and reagents required for detecting TLR-4 polynucleotides or polypeptides may be assembled together in a kit. When the components of the kit are provided in one or more liquid solutions, the liquid solution preferably is an aqueous solution, with a sterile aqueous solution being particularly preferred. Each component preferably is supplied in a separate container.

For therapeutic uses, a polynucleotide or candidate substance, as identified according to the methods disclosed herein, may be formulated into a single or separate pharmaceutically acceptable syringeable composition. In this case, the container means may itself be an inhalant,

syringe, pipette, eye dropper, or other such like apparatus, from which the formulation may be applied to an infected area of the body, injected into an animal, or even applied to and mixed with the other components of the kit.

5 The components of these kits may also be provided in dried or lyophilized forms. When reagents or components are provided as a dried form, reconstitution generally is by the addition of a suitable solvent. It is envisioned that the solvent also may be provided in another container means. The kits of the invention may also include an instruction sheet defining administration of active compounds or explaining assays for detecting TLR-4 or TLR-4 mutants in samples.

10

The kits of the present invention also will typically include a means for containing the vials in close confinement for commercial sale such as, *e.g.*, injection or blow-molded plastic containers into which the desired vials are retained. Irrespective of the number or type of containers, the kits of the invention also may comprise, or be packaged with, an instrument for
15 assisting with the injection/administration or placement of the ultimate complex composition within the body of an animal. Such an instrument may be an inhalant, syringe, pipette, forceps, measured spoon, eye dropper or any such medically approved delivery vehicle. Other instrumentation includes devices that permit the reading or monitoring of reactions *in vitro*.

20 **I. Biological Functional Equivalents**

As will be understood by those of skill in the art, modification and changes may be made in the structure of the TLR-4 protein and subunits and still obtain a molecule having like or otherwise desirable characteristics. For example, certain amino acids may be substituted for other amino acids in a protein structure without appreciable loss of interactive binding capacity.

25 Since it is the interactive capacity and nature of a protein that defines that protein's biological functional activity, certain amino acid sequence substitutions can be made in a protein sequence (or, of course, its underlying DNA coding sequence) and nevertheless obtain a protein with like (agonistic) properties. It is thus contemplated that various changes may be made in the sequence

of TLR-4 proteins or subunits (or underlying DNA) without appreciable loss of their biological utility or activity.

Equally, the same considerations may be employed to create a TLR-4 protein or subunit with countervailing (*e.g.*, antagonistic) properties. This is relevant to the present invention in which TLR-4 analogues without endotoxin recognition activity are contemplated to be useful in inhibiting the secretion of TNF.

In terms of functional equivalents, it is also well understood by the skilled artisan that, inherent in the definition of a biologically functional equivalent protein or peptide, is the concept that there is a limit to the number of changes that may be made within a defined portion of the molecule and still result in a molecule with an acceptable level of equivalent biological activity. Biologically functional equivalent peptides are thus defined herein as those peptides in which certain, not most or all, of the amino acids may be substituted. In particular, where small peptides are concerned, less amino acids may be changed. Of course, a plurality of distinct proteins/peptides with different substitutions may easily be made and used in accordance with the invention.

It is also well understood that where certain residues are shown to be particularly important to the biological or structural properties of a protein or peptide, *e.g.*, residues in the active site of an enzyme or to maintain protein function.

Amino acid substitutions are generally based on the relative similarity of the amino acid side-chain substituents, for example, their hydrophobicity, hydrophilicity, charge, size, and the like. An analysis of the size, shape and type of the amino acid side-chain substituents reveals that arginine, lysine and histidine are all positively charged residues; that alanine, glycine and serine are all a similar size; and that phenylalanine, tryptophan and tyrosine all have a generally similar shape. Therefore, based upon these considerations, arginine, lysine and histidine;

alanine, glycine and serine; and phenylalanine, tryptophan and tyrosine; are defined herein as biologically functional equivalents.

To effect more quantitative changes, the hydropathic index of amino acids may be considered. Each amino acid has been assigned a hydropathic index on the basis of their hydrophobicity and charge characteristics, these are: isoleucine (+4.5); valine (+4.2); leucine (+3.8); phenylalanine (+2.8); cysteine/cystine (+2.5); methionine (+1.9); alanine (+1.8); glycine (-0.4); threonine (-0.7); serine (-0.8); tryptophan (-0.9); tyrosine (-1.3); proline (-1.6); histidine (-3.2); glutamate (-3.5); glutamine (-3.5); aspartate (-3.5); asparagine (-3.5); lysine (-3.9); and arginine (-4.5).

The importance of the hydropathic amino acid index in conferring interactive biological function on a protein is generally understood in the art (Kyte & Doolittle, 1982, incorporated herein by reference). It is known that certain amino acids may be substituted for other amino acids having a similar hydropathic index or score and still retain a similar biological activity. In making changes based upon the hydropathic index, the substitution of amino acids whose hydropathic indices are within ± 2 is preferred, those which are within ± 1 are particularly preferred, and those within ± 0.5 are even more particularly preferred.

It is also understood in the art that the substitution of like amino acids can be made effectively on the basis of hydrophilicity, particularly where the biological functional equivalent protein or peptide thereby created is intended for use in immunological embodiments, as in the present case. U.S. Patent 4,554,101, incorporated herein by reference, states that the greatest local average hydrophilicity of a protein, as governed by the hydrophilicity of its adjacent amino acids, correlates with its immunogenicity and antigenicity, i.e. with a biological property of the protein.

As detailed in U.S. Patent 4,554,101, the following hydrophilicity values have been assigned to amino acid residues: arginine (+3.0); lysine (+3.0); aspartate ($+3.0 \pm 1$); glutamate

(+3.0 \pm 1); serine (+0.3); asparagine (+0.2); glutamine (+0.2); glycine (0); threonine (-0.4); proline (-0.5 \pm 1); alanine (-0.5); histidine (-0.5); cysteine (-1.0); methionine (-1.3); valine (-1.5); leucine (-1.8); isoleucine (-1.8); tyrosine (-2.3); phenylalanine (-2.5); tryptophan (-3.4).

- 5 In making changes based upon similar hydrophilicity values, the substitution of amino acids whose hydrophilicity values are within ± 2 is preferred, those which are within ± 1 are particularly preferred, and those within ± 0.5 are even more particularly preferred.

10 While discussion has focused on functionally equivalent polypeptides arising from amino acid changes, it will be appreciated that these changes may be effected by alteration of the encoding DNA; taking into consideration also that the genetic code is degenerate and that two or more codons may code for the same amino acid. A table of amino acids and their codons is presented hereinabove for use in such embodiments, as well as for other uses, such as in the design of probes and primers and the like.

15

i. Mutagenesis

20 Site-specific mutagenesis is a technique useful in the preparation of individual peptides, or biologically functional equivalent proteins or peptides, through specific mutagenesis of the underlying DNA. The technique further provides a ready ability to prepare and test sequence variants, incorporating one or more of the foregoing considerations, by introducing one or more nucleotide sequence changes into the DNA. Site-specific mutagenesis allows the production of mutants through the use of specific oligonucleotide sequences which encode the DNA sequence of the desired mutation, as well as a sufficient number of adjacent nucleotides, to provide a primer sequence of sufficient size and sequence complexity to form a stable duplex on both
25 sides of the deletion junction being traversed. Typically, a primer of about 17 to 25 nucleotides in length is preferred, with about 5 to 10 residues on both sides of the junction of the sequence being altered.

In general, the technique of site-specific mutagenesis is well known in the art. As will be appreciated, the technique typically employs a bacteriophage vector that exists in both a single stranded and double stranded form. Typical vectors useful in site-directed mutagenesis include vectors such as the M13 phage. These phage vectors are commercially available and their use is generally well known to those skilled in the art. Double stranded plasmids are also routinely employed in site directed mutagenesis, which eliminates the step of transferring the gene of interest from a phage to a plasmid.

In general, site-directed mutagenesis is performed by first obtaining a single-stranded vector, or melting of two strands of a double stranded vector which includes within its sequence a DNA sequence encoding the desired protein. An oligonucleotide primer bearing the desired mutated sequence is synthetically prepared. This primer is then annealed with the single-stranded DNA preparation, and subjected to DNA polymerizing enzymes such as *E. coli* polymerase I Klenow fragment, in order to complete the synthesis of the mutation-bearing strand. Thus, a heteroduplex is formed wherein one strand encodes the original non-mutated sequence and the second strand bears the desired mutation. This heteroduplex vector is then used to transform appropriate cells, such as *E. coli* cells, and clones are selected that include recombinant vectors bearing the mutated sequence arrangement.

The preparation of sequence variants of the selected gene using site-directed mutagenesis is provided as a means of producing potentially useful species and is not meant to be limiting, as there are other ways in which sequence variants of genes may be obtained. For example, recombinant vectors encoding the desired gene may be treated with mutagenic agents, such as hydroxylamine, to obtain sequence variants.

J. Inhibitors, Stimulators and Screening Assays

In still further embodiments, the present invention provides methods for identifying new TLR-4 inhibitory or stimulatory compounds, which may be termed as "candidate substances." It is contemplated that such screening techniques will prove useful in the general identification of

any compound that will serve the purpose of inhibiting or stimulating TLR-4 directed signaling of TNF secretion, and in preferred embodiments, will provide candidate compounds.

It is further contemplated that useful compounds in this regard will in no way be limited to proteinaceous or peptidyl compounds. In fact, it may prove to be the case that the most useful pharmacological compounds for identification through application of the screening assays will be non-peptidyl in nature and, *e.g.*, which will serve to inhibit TNF secretion through a tight binding or other chemical interaction. Candidate substances may be obtained from libraries of synthetic chemicals, or from natural samples, such as rain forest and marine samples.

i. Assay Formats

The present invention provides methods of screening for modulators of LPS mediated response by monitoring the standard activity profile of TLR-4 in the presence and absence of the candidate substance and comparing such results. It is contemplated that this screening technique will prove useful in the general identification of a compound that will serve the purpose of promoting, augmenting or increasing the activity of TLR-4 of a macrophage cell. Such compounds will be useful in the treatment of various bacterial infections.

In these embodiments, the present invention is directed to a method for determining the ability of a candidate substance to stimulate the wild-type TLR-4 of cells that either naturally express TLR-4 or have been engineered to express TLR-4 as described herein. The method including generally the steps of:

- (i) providing a cell expressing a TLR-4 polypeptide;
- (ii) determining the activity of said TLR-4 polypeptide; and
- (iii) contacting said cell with a candidate substance; and
- (iv) comparing the TLR-4 activity of the cell in step (iii) with the TLR-4 activity observed when said candidate substance is not added,

wherein an alteration in the activity indicates that said candidate substance is a modulator of said apoptotic activity.

To identify a candidate substance as being capable of stimulating TLR-4 in the assay above, one would measure or determine the activity in the absence of the added candidate substance. One would then add the candidate substance to the cell and determine the activity in the presence of the candidate substance. A candidate substance which increases the activity or capacity relative to activity observed in its absence is indicative of a candidate substance with stimulatory capability.

In particular embodiments, any compound that stimulates the production of IFN or related cytokines and mediates the inflammatory response to LPS or LPS containing moieties (*e.g.*, Gram negative bacteria). As stated above, a "candidate substance" refers to any molecule that is capable of modulating the activity of TLR-4. The candidate substance may be a protein or fragment thereof, a small molecule inhibitor, or even a nucleic acid molecule. Accordingly, the active compounds may include fragments or parts of naturally-occurring compounds or may be found as active combinations of known compounds which are otherwise inactive.

Accordingly, the present invention provides screening assays to identify agents which stimulate a cellular immune and/or response, it is proposed that compounds isolated from natural sources, such as animals, bacteria, fungi, plant sources, including leaves and bark, and marine samples may be assayed as candidates for the presence of potentially useful pharmaceutical agents. It will be understood that the pharmaceutical agents to be screened could also be derived or synthesized from chemical compositions or man-made compounds.

Thus, it is understood that the candidate substance identified by the present invention may be polypeptide, polynucleotide, small molecule inhibitors or any other compounds that may be designed through rational drug design starting from known stimulators of immune and/or inflammatory response. For example, Barrett *et al.*, describe peptides and compounds that bind

the IL-1 receptor (U.S Patent 5,786,331, specifically incorporated herein by reference) and U.S. Patent 5,508,262 describes an IL-1 receptor agonist. It may be that, as TLR-4 is an analogue of the IL-1 receptor, agonists of IL-1 may also be agonists of TLR-4. Alternatively, known modulators of IL-1 receptors may prove to be a useful starting point in a rational drug design strategy that will yield experimentally, therapeutically or clinically relevant compounds that modulate the activity of TLR-4 and the immune response that TLR-4 mediates.

The candidate screening assays are simple to set up and perform. Thus, in assaying for a candidate substance, after obtaining a cell expressing functional TLR-4, one will admix a candidate substance with the cell, under conditions which would allow measurable TNF secretion to occur. In this fashion, one can measure the ability of the candidate substance to stimulate the TNF secretory response of the cell in the absence of the candidate substance. One would then measure the response in the presence of the candidate substance and determine the effect of the candidate substance.

"Effective amounts" in certain circumstances are those amounts effective to reproducibly stimulate the TNF secretory (inflammatory) response from the cell in comparison to their normal levels. Compounds that achieve significant appropriate changes in activity will be used.

Significant changes in inflammatory response, *e.g.*, as measured TNF production, splenocyte activity and the like are represented by an increase/decrease in the response of at least about 30%-40%, and most preferably, by changes of at least about 50%, with higher values of course being possible.

It will, of course, be understood that all the screening methods of the present invention are useful in themselves notwithstanding the fact that effective candidates may not be found. The invention provides methods for screening for such candidates, not solely methods of finding them.

ii. *Rational Drug Design*

The goal of rational drug design is to produce structural analogs of biologically active polypeptides or compounds with which they interact (agonists, antagonists, inhibitors, binding partners, *etc.*). By creating such analogs, it is possible to fashion drugs which are more active or stable than the natural molecules, which have different susceptibility to alteration or which may affect the function of various other molecules. In one approach, one would generate a three-dimensional structure for TLR-4 or a fragment thereof. This could be accomplished by x-ray crystallograph, computer modeling or by a combination of both approaches. An alternative approach, "alanine scan," involves the random replacement of residues throughout molecule with alanine, and the resulting affect on function determined.

It also is possible to isolate a specific antibody, selected by a functional assay, and then solve its crystal structure. In principle, this approach yields a pharmacore upon which subsequent drug design can be based. It is possible to bypass protein crystallograph altogether by generating anti-idiotypic antibodies to a functional, pharmacologically active antibody. As a mirror image of a mirror image, the binding site of anti-idiotypic would be expected to be an analog of the original antigen. The anti-idiotypic could then be used to identify and isolate peptides from banks of chemically- or biologically-produced peptides. Selected peptides would then serve as the pharmacore. Anti-idiotypes may be generated using the methods described herein for producing antibodies, using an antibody as the antigen.

Thus, one may design drugs which have activity as stimulators, inhibitors, agonists, antagonists of TLR-4 or molecules affected by TLR-4 function. Such rational drug design may start with lead compounds already known to those of skill in the art. By virtue of the availability of cloned TLR-4 sequences, sufficient amounts of these proteins can be produced to perform crystallographic studies. In addition, knowledge of the polypeptide sequences permits computer employed predictions of structure-function relationships. Particularly useful agents that may be found by the present invention will be those agents that stimulate the TLR-4 receptor response to LPS and therefore increase the immune attack against LPS. Such agents may bind to the TLR-4.

K. Formulations and Routes for Administration to Patients

Where clinical applications are contemplated, it will be necessary to prepare the expression vectors or candidate substances of the present invention as pharmaceutical compositions, *i.e.*, in a form appropriate for *in vivo* applications. Generally, this will entail preparing compositions that are essentially free of pyrogens, as well as other impurities that could be harmful to humans or animals.

One will generally desire to employ appropriate salts and buffers to render delivery vectors stable and allow for uptake by target cells. Buffers also will be employed when recombinant cells are introduced into a patient. Aqueous compositions of the present invention comprise an effective amount of the vector to cells, dissolved or dispersed in a pharmaceutically acceptable carrier or aqueous medium. Such compositions also are referred to as inocula. The phrase "pharmaceutically or pharmacologically acceptable" refer to molecular entities and compositions that do not produce adverse, allergic, or other untoward reactions when administered to an animal or a human. As used herein, "pharmaceutically acceptable carrier" includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like. The use of such media and agents for pharmaceutically active substances is well know in the art. Except insofar as any conventional media or agent is incompatible with the vectors or cells of the present invention, its use in therapeutic compositions is contemplated. Supplementary active ingredients also can be incorporated into the compositions.

The active compositions of the present invention include classic pharmaceutical preparations. Administration of these compositions according to the present invention will be *via* any common route so long as the target tissue is available *via* that route. This includes oral, nasal, buccal, rectal, vaginal or topical. Alternatively, administration may be by orthotopic, intradermal, subcutaneous, intramuscular, intraperitoneal or intravenous injection. Such

compositions would normally be administered as pharmaceutically acceptable compositions, described *supra*.

The active compounds may be administered *via* any suitable route, including parenterally or by injection. Solutions of the active compounds as free base or pharmacologically acceptable salts can be prepared in water suitably mixed with a surfactant, such as hydroxypropylcellulose. Dispersions also can be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.

The pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms, such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils. The proper fluidity can be maintained, for example, by the use of a coating, such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. The prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.

Sterile injectable solutions are prepared by incorporating the active compounds in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by

incorporating the various sterilized active ingredients into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum-drying and freeze-drying techniques which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.

As used herein, "pharmaceutically acceptable carrier" includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like. The use of such media and agents for pharmaceutical active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic compositions is contemplated. Supplementary active ingredients also can be incorporated into the compositions.

For oral administration the polypeptides of the present invention may be incorporated with excipients and used in the form of non-ingestible mouthwashes and dentifrices. A mouthwash may be prepared incorporating the active ingredient in the required amount in an appropriate solvent, such as a sodium borate solution (Dobell's Solution). Alternatively, the active ingredient may be incorporated into an antiseptic wash containing sodium borate, glycerin and potassium bicarbonate. The active ingredient may also be dispersed in dentifrices, including: gels, pastes, powders and slurries. The active ingredient may be added in a therapeutically effective amount to a paste dentifrice that may include water, binders, abrasives, flavoring agents, foaming agents, and humectants.

The compositions of the present invention may be formulated in a neutral or salt form. Pharmaceutically-acceptable salts include the acid addition salts (formed with the free amino groups of the protein) and which are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic, oxalic, tartaric, mandelic, and the like. Salts formed with the free carboxyl groups also can be derived from inorganic bases

such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, histidine, procaine and the like.

5 Upon formulation, solutions will be administered in a manner compatible with the dosage formulation and in such amount as is therapeutically effective. The formulations are easily administered in a variety of dosage forms such as injectable solutions, drug release capsules and the like. For parenteral administration in an aqueous solution, for example, the solution should be suitably buffered if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose. These particular aqueous solutions are especially suitable for
10 intravenous, intramuscular, subcutaneous and intraperitoneal administration.

In this connection, sterile aqueous media which can be employed will be known to those of skill in the art in light of the present disclosure. For example, a unit dose could be dissolved in 1 ml of isotonic NaCl solution and either added to 1000 ml of hypodermoclysis fluid or
15 injected at the proposed site of infusion, (see for example, "Remington's Pharmaceutical Sciences" 15th Edition, pages 1035-1038 and 1570-1580). Some variation in dosage will necessarily occur depending on the condition of the subject being treated. The person responsible for administration will, in any event, determine the appropriate dose for the individual subject. Moreover, for human administration, preparations should meet sterility,
20 pyrogenicity, general safety and purity standards as required by FDA Office of Biologics standards.

L. Examples

The following examples are included to demonstrate preferred embodiments of the
25 invention. It should be appreciated by those of skill in the art that the techniques disclosed in the examples which follow represent techniques discovered by the inventor to function well in the practice of the invention, and thus can be considered to constitute preferred modes for its practice. However, those of skill in the art should, in light of the present disclosure, appreciate

that many changes can be made in the specific embodiments which are disclosed and still obtain a like or similar result without departing from the spirit and scope of the invention.

EXAMPLE 1

Materials And Methods

Mice

[SWR x C3H/HeJ] x C3H/HeJ F2 animals. SWR mice were obtained from Jackson Laboratories, and maintained in the Animal Resource Center of the University of TX, Southwestern Medical Center. C3H/HeJ mice were also obtained from Jackson Laboratories (Bar Harbor, ME). F1 mice obtained by the cross of C3H/HeJ males to SWR females were backcrossed at eight weeks of age to C3H/HeJ animals of both sexes. 493 F2 animals were used at six to eight weeks of age for analysis of LPS response phenotype and preparation of genomic DNA. In this panel of animals, both splenocyte responses and macrophage TNF production were assayed as endpoints of endotoxin response determination.

15

[C57BL/6 x C3H/HeJ] x C3H/HeJ F2 animals. 1600 F2 mice were produced at the Jackson Laboratories, and shipped to the Animal Resource Center of the University of TX, Southwestern Medical center at 5 to 8 weeks of age. Animals were immediately ear-tagged for identification and tail cuttings were taken for identification. For this panel of animals, selection of individuals with recombination between markers D4MIT164 and D4MIT27 was made by PCR analysis. All but a few non-recombinants were sacrificed; the remaining non-recombinants were used as controls (obligate *Lps^d* heterozygotes or homozygotes with representative genetic variability at other loci) with each assay series. In this panel of animals, macrophage TNF production was used as the sole endpoint of endotoxin response determination.

25

Preparation of genomic DNA

Tail fragments approximately 5 mm in length were placed in 1.5 ml microcentrifuge tubes containing 650 μ l of SSTE buffer, in which proteinase K had been dissolved at a concentration of 1 mg/ml. SSTE buffer was made by bringing 10 ml of 10% SDS, 2 ml of 5 M

NaCl, 5 ml of 1M tris, pH 8.0, and 3 ml of 0.5 M EDTA, pH 8.0 to a final volume of 100 ml with distilled water. The tissue was digested overnight at 55 °C. 30 µl of RNase T1 (5 U/µl) was then added to each tube, and a second incubation was carried out at 37 °C for one hour. DNA was then extracted with phenol, 1:1 phenol/chloroform solution, and finally chloroform.

5 After addition of 1/10 volume of 3M sodium acetate solution, samples were precipitated with two volumes of ethanol. Pellets were dried and redissolved in 300 µl of TE solution.

Assays for LPS responsiveness

Splenocyte proliferation assays were used to type all 493 animals produced by the backcross of C3H/HeJ mice to SWR mice, and were performed by harvesting 30 to 40 million spleen cells from each animal. Erythrocytes were lysed with ammonium chloride, and the remaining cell population, predominantly lymphocytes, were plated at a density of 1 million cells per well, in triplicate, in round bottom 96-well plates. Cells were stimulated with Con A as a control for viability, and also with LPS at two concentrations (1.0 µg/ml and 5.0 µg/ml) for a period of 72 hours, in the presence of tritiated thymidine. All samples showing Con A responses that exceeded 100,000 CPM were retained for analysis; those occasional samples that had smaller Con A responses were discarded from consideration. A cell harvester was used to collect the lymphocytes, and measurements of thymidine incorporation were made. An index of LPS responsiveness (I) was calculated for each sample as follows:

10
15
20

$$I = [\text{mean CPM of LPS-induced splenocytes}] / [\text{mean CPM of non-induced splenocytes}]$$

For simplicity, only the data pertaining to stimulation with 5 µg/ml LPS are reported in this paper.

TNF production by peritoneal macrophages was used to type all 1600 animals produced by the backcross of C3H/HeJ mice to C57BL/6 mice. TNF mediated cytolytic activity is released by LPS-responsive cells following endotoxin stimulation *in vitro*, and was used to quantitate LPS sensitivity. Eight-week-old mice were injected intraperitoneally with sterile

25

Brewer's thioglycollate broth (3.0 ml). 4 days later, peritoneal exudate macrophages were harvested by peritoneal lavage. 2×10^5 cells from each mouse were plated in 24 well plates, and after adherence, stimulated by LPS at concentrations of 0.01 and 0.5 $\mu\text{g/ml}$. After 16 hours, the medium was harvested and assayed for TNF content. TNF assays were performed using the

5 L929 cell method, in which cells were plated in 96 well plates, exposed to the macrophage medium, and after rinsing, stained with crystal violet. The intensity of staining, measured in a microplate reader at 590 nm, corresponded to the fraction of surviving cells (Cseh and Beutler, 1989). Results were expressed as % cytotoxicity, defined as:

$$10 \quad [1 - \text{OD}_{[\text{sample well}]} / \text{OD}_{[\text{control}]}] \times 100$$

Both the splenocyte proliferation assay and the macrophage response assay permitted unambiguous discrimination between responders (heterozygotes for the *Lps^d* allele) and nonresponders (homozygotes for the *Lps^d* allele), but the macrophage response assay showed

15 less day-to-day variability and was more convenient to perform.

Contig Assembly.

YACs were isolated from the Research Genetics mouse YAC library by PCR-based screening of a matrix consisting of superpools, pools, and plates. The probes initially employed

20 in this process were the map-pair markers: D4MIT82, D4MIT218, D4MIT325, D4MIT244, D4MIT25, NdS9, D4MIT178, D4MIT7, D4MIT132, and D4MIT83. A total of 20YACs were isolated in this manner. All were sized by pulsed-field gel electrophoresis. The ends of all of the YACs were checked by sequencing. In some cases, continuity with adjoining BACs was immediately established. When highly repetitive sequence was present, internal sequences were

25 determined by cloning rather large fragments of the YAC that contained the end. If when no overlap was established, additional YACs were isolated using the end sequence. In several instances, after two such cycles of chromosome walking, it was concluded that the original YACs were chimeric.

Unique sequences derived from shotgun cloning of YACs, as well as the above mentioned D4MIT markers, were used to identify BAC clones, chiefly by screening the Research Genetics mouse BAC library. Two additional clones (BACs 84C8 and 389F15) were obtained by screening BAC libraries maintained at Genome Systems (St. Louis, MO). A
 5 contiguous span of BACs crossing most of the interval was produced, as in the case of the YAC contig, by chromosome walking. Among the BACs that were isolated, only two proved to be chimeric; the chimeric BACs are not presented in any of the Figures.

Novel marker identification.

10 YACs were fragmented by ultrasonic shearing and subcloned for internal sequence analysis. Both random, non-repetitive sequences and novel microsatellite repeats were isolated in this manner. More than 100 such markers were identified across the region in question. These markers were used for PCR-based screening of a mouse BAC library from Research Genetics (Birmingham, AL), and permitted the isolation of BAC clones. The PCR primers
 15 defining all markers relevant to the Figures are presented in Table I.

Table I PCR primers defining relevant markers

Marker designation*	Polymorphism		Primer pairs
	HeJ vs. SWR	HeJ vs. C57BL/6	
D4MIT164	ND	+	1. tgaacacatatataccaaggcagc (SEQ ID NO:7) 2. accagagggtcattctccaa (SEQ ID NO:8)
D4MIT244	+	-	1. caaataatcigacaaaaaagaagtg (SEQ ID NO:9) 2. ggtgtcatcaccatgatgga (SEQ ID NO:10)
D4MIT218	+	-	1. agtaagaatgttcaactccaacc (SEQ ID NO:11) 2. tccagcattgatgctcac (SEQ ID NO:12)
D4MIT82	+	-	1. atgtgtgccatttgcattgt (SEQ ID NO:13) 2. agtattgcttgataaattgcatg (SEQ ID NO:14)
D4MIT325	+	-	1. gttccgtttcttttacaactatgg (SEQ ID NO:15) 2. attgcctatttttatttcattgtg (SEQ ID NO:16)
25.5	+	-	1. ggaagggtgaagcaagac (SEQ ID NO:17) 2. gactcatgatttgataactgac (SEQ ID NO:18)
25.15	+	-	1. gccaaagaaagagcaaatag (SEQ ID NO:19) 2. cgatttcctatggctcagcc (SEQ ID NO:20)
9.2	+	-	1. agtaattcagcttctccaa (SEQ ID NO:21) 2. cagatccatgatacagatatgc (SEQ ID NO:22)
C	ND	+	1. cctccagcacagtgataaatg (SEQ ID NO:23)

Marker designation	Polymorphism		Primer pairs
	HeJ vs. SWR	HeJ vs. C57BL/6	
C'	ND	+	2. gtgtgtgtgtgtgaacttg (SEQ ID NO:24) 1. tagaaagtggaaacatctgac (SEQ ID NO:25) 2. atgtaactcaatcacagaactc (SEQ ID NO:26)
B	ND	+	1. tcaagatccataacctagac (SEQ ID NO:27) 2. agacagacagatagacagaaag (SEQ ID NO:28)
D4MIT178	-	+	1. gccctgaaggtaaatcagtaact (SEQ ID NO:29) 2. gctcaggaggtagattgcct (SEQ ID NO:30)
A	ND	+	1. tcagtttgccttcattctc (SEQ ID NO:31) 2. aagtatggatgtgtgtgaag (SEQ ID NO:32)
D	ND	+	1. tgctaagattgtgatgactg (SEQ ID NO:33) 2. gactaggtgagagaaacagac (SEQ ID NO:34)
E	ND	+	1. ttggcctgatagtaacaataac (SEQ ID NO:35) 2. ggagatttctaattgcttgg (SEQ ID NO:36)
7.1	+	-	1. tggacaaacaccacataaca (SEQ ID NO:37) 2. cagactatcagatgactga (SEQ ID NO:38)
7.3	+	-	1. acattagaatcatttctgca (SEQ ID NO:39) 2. gcaaagtcttgtgagtct (SEQ ID NO:40)
7.11	+	-	1. cttaactggagaggaaagatc (SEQ ID NO:41)

665T60" 58696E60

Marker designation*	Polymorphism		Primer pairs
	HeJ vs. SWR	HeJ vs. C57BL/6	
83.3	+	-	2. cagttctgtttgtatctctg (SEQ ID NO:42) 1. agagagtgagcctcagtct (SEQ ID NO:43) 2. ttgggtgatgatgtgaac (SEQ ID NO:44)

*Presented in centromeric to telomeric order

Shotgun sequencing.

Using a minimal contig containing 24 BACs and one YAC, which together encompassed >95% of the interval between markers B and 83.3, approximately 20 million bases of high-quality sequence were obtained, from bidirectional reads of approximately 20,000 fragments of DNA (i.e., approximately 40,000 reads in all). In this process, all BACs and the YAC clone 100E4 were fragmented by ultrasonic shearing, repaired to a blunt-ended state using Klenow fragment or mung bean nuclease, and subcloned into the vector pBluescript, which was been cut with *Sma*I and treated with calf intestine alkaline phosphatase to prevent self ligation. The average fragment size was about 1.5 kb. Automated sequencing was performed using ABI model 377A sequencers, and chain termination chemistry was used by all four of these sequencing laboratories.

Bioinformatic analysis.

All sequences were hand-edited or processed by Phred and Phrap (obtained from Brent Ewing and Phil Green, respectively; University of Washington Genome Center) to remove vector, and to assemble as completely as possible. Individual reads were stored as a growing database in a single large directory, and subjected to the following tests, all of which were carried out using Genetics Computing Group (GCG) software, or via web or e-mail servers:

1. All sequences were periodically compared to all other sequences in the database using the Fasta search algorithm, in order to establish and display regions of overlap and homology.

2. All sequences were masked to hide common repetitive elements from consideration prior to searches against the large sequence databases listed below. Censoring was usually carried out using the program RepeatMasker (obtained from Arian Smit, University of Washington).

3. All sequences, in censored and uncensored form, were subjected to blastn analysis using the genembl, dbest, and HCD databases, the latter at levels I and II.

4. All sequences, in censored (masked) and uncensored form, were subjected to blastx analysis using the genembl and HCD databases, the latter at levels I and II.

5. In some select instances, sequences were studied locally using the framesearch algorithm to detect open reading frames with homology to components of the Swissprot database.

6. All sequences were analyzed for rare peptide motifs by translating them in all six frames and subjecting them to a local Motif search.

7. All sequences were, at various stages, aligned with others using the GCG program Gelmerge, or using the program Phrap. In this manner, long contiguous sequences were obtained and unambiguous overlap between adjacent BACs, as well as the approximate extent of overlap, could be inferred.

8. Individual sequencing reads, or when possible, contigs of reads, were subjected to analysis by GRAIL 2 in order to identify putative exons.

Exon trapping.

A total of 169 exons were trapped from the “zero area” of the critical region. Exon trapping was performed using the vector pSPL3 (Burn *et al.*, 1995). Digested genomic DNA was ligated into the vector, and pooled clones (generally 20 to 100 at one time) were transfected into COS-7 cells, obtained from the ATCC. Capture of putative exons was accomplished by PCR.

Shotgun sequencing.

Using a minimal contig containing 24 BACs and one YAC, which together encompassed >95% of the interval between markers B and 83.3, approximately 20 million bases of high-quality sequence were obtained, from bidirectional reads of approximately 20,000 fragments of DNA (i.e., approximately 40,000 reads in all). In this process, all BACs and the YAC clone 100E4 were fragmented by ultrasonic shearing, repaired to a blunt-ended state using Klenow fragment or mung bean nuclease, and subcloned into the vector pBluescript, which was been cut with *Sma*I and treated with calf intestine alkaline phosphatase to prevent self ligation. The average fragment size was about 1.5 kb. Automated sequencing was performed using ABI model 377A sequencers, and chain termination chemistry was used by all four of these sequencing laboratories.

Bioinformatic analysis.

All sequences were hand-edited or processed by Phred and Phrap (obtained from Brent Ewing and Phil Green, respectively; University of Washington Genome Center) to remove vector, and to assemble as completely as possible. Individual reads were stored as a growing database in a single large directory, and subjected to the following tests, all of which were carried out using Genetics Computing Group (GCG) software, or via web or e-mail servers:

1. All sequences were periodically compared to all other sequences in the database using the Fasta search algorithm, in order to establish and display regions of overlap and homology.
2. All sequences were masked to hide common repetitive elements from consideration prior to searches against the large sequence databases listed below. Censoring was usually carried out using the program RepeatMasker (obtained from Arian Smit, University of Washington).

3. All sequences, in censored and uncensored form, were subjected to blastn analysis using the geneml, dbest, and HCD databases, the latter at levels I and II.

4. All sequences, in censored (masked) and uncensored form, were subjected to blastx analysis using the geneml and HCD databases, the latter at levels I and II.

5. In some select instances, sequences were studied locally using the framesearch algorithm to detect open reading frames with homology to components of the Swissprot database.

6. All sequences were analyzed for rare peptide motifs by translating them in all six frames and subjecting them to a local Motif search.

7. All sequences were, at various stages, aligned with others using the GCG program Gelmerge, or using the program Phrap. In this manner, long contiguous sequences were obtained and unambiguous overlap between adjacent BACs, as well as the approximate extent of overlap, could be inferred.

8. Individual sequencing reads, or when possible, contigs of reads, were subjected to analysis by GRAIL 2 in order to identify putative exons.

Exon trapping.

A total of 169 exons were trapped from the “zero area” of the critical region. Exon trapping was performed using the vector pSPL3 (Burn *et al.*, 1995). Digested genomic DNA was ligated into the vector, and pooled clones (generally 20 to 100 at one time) were transfected into COS-7 cells, obtained from the ATCC. Capture of putative exons was accomplished by PCR.

Hybridization selection of expressed cDNAs using BACs.

This method was carried out as described by Rommens *et al.* (1998), using cDNA from RAW 264.7 cells (obtained from the ATCC). A total of 538 selected clones from the “zero area” were examined in the course of the present study.

5

Fluorescence in situ hybridization.

Six separate distance measurements were made at Genome Systems, Inc., using interphase nuclei of mouse cells. The measurements included distances between the following BACs, which were used as probes:

10 [L22 and O12], [O12 and N13], [N13 and B6], [B6 and B22], [B22 and K4], [B22 and L15].

15 The minimum distance that may be measured through this approach is 0.2 Mb, and the maximum distance that may be measured is 1.6 Mb. A 10% margin of error is certified for all measurements.

Genetic computation.

20 A 500 Mhz DEC α computer (DCG Viper EV-56) equipped with 63 Gb of hard drive space and 256 Mb of RAM was used in all of these studies. Programs were run under a Digital UNIX operating system. For the design of primer pairs to be used in PCR and sequence extension, the program Gene Runner was used (Hastings Software, Inc). The graphics program used in depiction of the contig was Hijaak Draw (Inset Graphics, Inc). Each of the latter two programs was run under Windows95 using a Pentium Pro computer from Gateway, Inc.

25

EXAMPLE 2

LPS Response Assays and Validation Thereof

Both splenocyte proliferation assays and assays of TNF production were used to distinguish LPS nonresponder mice (*Lps^d* homozygotes) LPS responders (*Lps^d* heterozygotes) were used in analysis of the [SWR x C3H/HeJ]F1 x C3H/HeJ panel. Both assays were carried

out using two separate LPS concentrations. When splenocyte proliferation was used as an endpoint, a simultaneous assay of proliferation occurring in response to concanavalin A was used as a means of controlling for cell viability. In the [SWR x C3H/HeJ]F1 x C3H/HeJ panel, conflict between the two assays was rarely observed, and mice that were felt to be ambiguous in their responsiveness to LPS were discarded from further consideration.

Experience with the two assays of LPS response showed that measurement of TNF production occurring at low (10 ng/ml) concentrations of LPS was a more reliable index of responsiveness than measurement of splenocyte proliferation. Therefore, this assay was used exclusively in analysis of the [C57BL/6 x C3H/HeJ]F1 x C3H/HeJ backcross panel. Since not all of the potential recombinants were assayed for LPS responsiveness on the same day, and since day-to-day variability in TNF measurement might confuse interpretation of the results, a series of obligate *Lps*^d allele homozygotes and heterozygotes were identified by analysis of flanking markers, and included as controls with each assay performed. The distinction between responder and non-responder control groups was in every instance clear and unambiguous. Similarly, the designation of each individual recombinant as homozygous or heterozygous with respect to the *Lps* locus was accomplished without ambiguity.

EXAMPLE 3

[SWR x C3H/HeJ] x C3H/HeJ Backcross

In initial efforts to confine the *Lps*^d mutation to a point between two markers, animals of the [SWR x C3H/HeJ] x C3H/HeJ backcross were examined. Raw data are not presented as this was essentially a range-finding study. A total of eleven D4MIT markers flanking the gene could be used for genotypic analysis, as the two parental genotypes could be distinguished on the basis of length differences. The crossover frequency between each of these markers and the *Lps* gene in a panel of 493 mice is illustrated in Figure 1. A cluster of four markers (D4MIT82, 325, 218, and 244) which underwent no recombination with one another each exhibited a single crossover event with the *Lps* mutation. This cluster of markers lay centromeric to the mutation. On the distal side of the mutation, D4MIT80 was separated from *Lps*^d by 14 recombination events.

From the fact that only a single crossover event was observed between D4MIT82 and *Lps^d*, it was inferred that the mutation might well lie within the proximal half of the D4MIT82 → D4MIT80 interval. Partial ordering of microsatellite markers between D4MIT82 and D4MIT80 was achieved by Bell, et al., who employed a series of deletion mutants to map markers in the region of the *b* locus (Bell *et al.*, 1995). A YAC clone containing D4MIT83 (which was mapped to the middle portion of the interval) was isolated, fragmented, and used to identify fresh microsatellite repeat polymorphisms. One of these, designated CA83.3, lay distal to the mutation and was separated from it by only six crossover events. Moreover a total of six polymorphic microsatellites (designated CA25.5, CA25.15, CA9.2, CA7.1, CA7.3, and CA7.11) were identified in three other YAC clones which were isolated using the markers D4MIT25, NdS9, and D4MIT7. These six new markers all co-localized with the mutation (Figure 2). When physical mapping (detailed below) revealed that some of the new markers were separated from others of the group by as much as 1.6 Mb of DNA, it appeared certain that a second backcross would be required to narrow the interval.

EXAMPLE 4

[C57BL/6 x C3H/HeJ] x C3H/HeJ Cross

A total of 1600 F2 mice made by crossing C57BL/6 x C3H/HeJ and backcrossing to C3H/HeJ were analyzed for recombination in the region of the *Lps* gene. Those mice that showed such recombination were further analyzed for LPS responsiveness, and fine mapping of the recombination events was accomplished using novel microsatellite markers. The inventors examined markers over a relatively broad range in a screen for crossover events. This range spanned the interval D4MIT164 to D4MIT27, and included D4MIT178.

A total of 192 crossovers were observed between D4MIT164 and D4MIT27 in the 1600 meioses studied. 157 of these crossovers occurred between D4MIT178 and D4MIT27, while 35 crossovers occurred between D4MIT164 and D4MIT178. The location of these events could be further assigned based on the identification of six novel polymorphisms within the D4MIT164 →

D4MIT27 interval (Figure 2). Five novel markers (designated A, D, E, 7.3 and 7.11) still co-localized with the *Lps^d* mutation, as did marker D4MIT178. The physical separation between all four of these microsatellite markers (which were isolated from two overlapping BAC clones) was approximately 1.2 Mb, corresponding to the "zero region" of the critical area. Four
5 crossovers were observed between *Lps^d* and marker B. In terms of physical size, the B→ 83.3 interval corresponds to approximately 2.6 Mb. Because the crossovers between B and 83.3 are essential to confinement of *Lps^d*, the primary assay data for each of the seven critical meioses are presented in Figure 3.

10

EXAMPLE 5

The physical map

A map of the entire interval between D4MIT325 and marker 83.3 is shown in Figure 4. A total of 63 BAC clones and 20YAC clones (only one of which is shown, in red) were isolated to span the critical region. Each YAC and BAC clone is drawn to scale according to analysis by
15 pulsed-field gel electrophoresis. A FISH map is drawn above the assembly, and is in approximate agreement with the electrophoretic map. The black bar in Figure 4 indicates the region of zero recombination determined on the basis of 493 meioses analyzed by the cross [SWR x C3H/HeJ] x C3H/HeJ and 1600 meioses analyzed by the cross [C57BL/6 x C3H/HeJ] x C3H/HeJ. This "zero area" is approximately 1.2 Mb in length. The critical region, known with
20 certainty to contain the *Lps^d* mutation, extends over a distance of approximately 2.6 Mb, circumscribed by markers "B" and D4MIT83.3.

25

EXAMPLE 6

Gene identification

169 putative exons were identified throughout the "zero area" of the contig, and in selected portions that lay beyond the zero area, by exon trapping. 538 clones were isolated from the zero area and beyond by hybridization/selection. Some of each of these represented fragments of known genes and pseudogenes, including *Pappa*, HMG-I and KIAA0029 (detected

by both exon trapping and hybridization selection). TCP-1 and BTG-1 were detected by hybridization selection, though not by exon trapping. Most of the sequences identified by the two methods could not be shown to encode authentic, expressed genes despite exhaustive analysis through northern blotting and other techniques.

5

High density sequence analysis was carried out over an interval containing 24 minimally overlapping BACs and one YAC clone. These BACs are depicted in Figure 5. BACs shown in blue were sequenced either to completion or to the point of finishing (*i.e.*, only a few gaps remain between large assemblies of sequence). BACs shown in red were sequenced with to a high density (several hundred reads each) but not to the point of finishing, and are still considered "in progress." YAC 100E4 was analyzed with nearly 1000 reads. The genes and pseudogenes detected within the region by homology searches are indicated as well.

A large number of exons were predicted by GRAIL analysis. However, many of these were of retroviral origin (*e.g.*, exons within L1, B1, Bam5, and IAP repeats). Among those that were not, some belonged to known genes such as *Pappa*. Among all GRAIL-predicted, non-repetitive exons with ratings of "good" to "excellent," none could be demonstrated to encode authentic macrophage-expressed transcripts when used as probes on northern blots.

Pseudogenes encoding fragments of TCP-1, BTG-1, NKR-P12, KIAA0029, HMG-1, and cytochrome P450 were identified within the contig. However, all of these genes were either fragmentary or contained nonsense mutations. Only two authentic genes were identified within the contig. These were the classical marker gene *Pappa*, encoding a plasma metalloproteinase, and the mouse homolog of TLR-4, encoding a transmembrane protein homologous to the IL-1 receptor. The TLR-4 gene resides in BAC clones 309I17 and 152C16. Its sequence (5' → 3') corresponds to a proximal → distal orientation along the chromosome. The complete size and intron-exon boundaries of the gene remain to be determined.

EXAMPLE 7

Identification of the *Lps*^d Mutation that Alters the TLR-4 Protein Cytoplasmic Domain

5 Mutations of the *Lps* gene selectively impede lipopolysaccharide (LPS) signal transduction in C3H/HeJ and C57BL/10ScCR mice. Homozygotes display a phenotype characterized by resistance to all biological effects of endotoxin and exaggerated susceptibility to overwhelming gram-negative infection. The codominant *Lps*^d mutation of C3H/HeJ mice was confined to a 0.9 centiMorgan genetic interval, based on the analysis of 2093 meioses.

10

 A minimal contig, consisting of 20 BAC clones and one YAC clone, was subjected to sequence analysis. Approximately 40,000 sequencing reads were obtained from shotgun-cloned genomic DNA, bringing over 1.6 Mb of the central contig to a near-contiguous state and yielding rather dense coverage of >95% of the entire critical region. BLAST searches performed on masked versions of the sequence disclosed dozens of high-scoring homologies with published expressed sequence tags (ESTs), but these were excluded from consideration as they could not be cloned from macrophage or fetal cDNA libraries of trusted complexity. Several pseudogenes were observed, but dismissed because they were found to be fragmentary. GRAIL analyses, performed on long contiguous sequences of the central contig using X-GRAIL software, revealed an abundance of retroviral repeats and scattered non-retroviral exons, most of which proved to be derived from pseudogenes.

 Two authentic genes (a portion of the *Pappa* locus and the entire TLR-4 receptor locus) were identified in the entire region, by both BLAST and GRAIL analysis. The orientation and location of these genes, with respect to the nearest genetic markers, is presented in Figure 6. Both genes lie at the centromeric end of the critical region, and at most, only a small 5' fragment of *Pappa* lies distal to marker B.

Pappa encodes a secreted metalloproteinase, which lacks any evidence of a transmembrane domain. It is expressed by placental tissue, but not by primary macrophages or macrophage cell lines (not shown), and for these reasons, as well as its extreme proximity to marker B (which is separated from *Lps^d* by four crossovers in a panel of 1600 meioses), it is considered a poor candidate.

In contrast, the TLR-4 locus seemed a particularly attractive candidate, both on the grounds of map position, and because the pro-inflammatory IL-1 receptor is also a member of the toll receptor family. Further, a human mutation causing co-resistance to LPS and IL-1 attests to the likelihood that the IL-1 and LPS signal transduction proteins share a common downstream intermediate. *A priori*, it would therefore seem likely that the IL-1 and LPS transducers are structurally related. Finally, the pro-inflammatory signaling potential of TLR-4 is suggested by studies in which chimeric versions of human TLR-4, bearing a CD4 sequence in place of the native extracellular domain, were shown to be capable of activating NF-6B in human mononuclear cells.

Accordingly, the TLR-4 cDNAs from C3H/HeJ mRNA, and from the mRNA of several LPS-responsive strains of mice (including C3H/HeN) were cloned, by reverse transcription and polymerase chain reaction, using primers derived from the genomic sequence. The amplified product was fragmented by sonication, shotgun cloned into the vector pBluescript, and sequenced using an Applied Biosystems model 373 DNA sequencer. 100 reads were aligned using the programs phred and phrap (obtained from Brent Ewing and Phil Green, University of Washington Genome Center).

A single mutation was observed in the 835 aa coding region of the TLR-4 cDNA derived from C3H/HeJ mice. At position 712 (within the cytoplasmic domain), a histidine is predicted rather than the proline that resides in mouse TLR-4 from C3H/HeN mice, SWR mice, or C57BL/6 mice. Furthermore, the residue is invariant across species, in that endotoxin-responsive mice, rats and humans all display a proline in the relevant position (Figure 7a). The same

mutation was identified in DNA amplified from the C3H/HeJ genome and directly sequenced. It was not observed in DNA amplified from the C3H/HeN genome, nor in DNA from SWR, C57BL/6, 129, or DBA-2 mice (Figure 7b). No other difference in sequence has ever been observed on comparison of any genomic interval from C3H/HeN and C3H/HeJ mice, which were, until recently, a single strain. In Fig. 7A the sequence identified as J-toll is the mutant protein sequence in which the PRO at residue 712 is mutated to HIS.

While the TLR-4 cDNA was readily amplified by RT-PCR from macrophage RNA derived from C3H/HeJ, C3H/HeN, and C57BL/10ScN mice, it could not be amplified from macrophage RNA derived from C57BL/10ScCR mice. On the other hand, several low-abundance control cDNAs could be amplified from all strains without difficulty (Figure 8a). Moreover, though the toll mRNA is relatively scarce, it could be detected on Northern blots prepared using total RNA derived from macrophages of the three former strains; it could not be detected in total RNA obtained from C57BL/10ScCR mice (Figure 8b). Thus, a *cis*-acting mutation- yet to be defined at the genomic level- prevents the expression of processed toll mRNA in C57BL/10ScCR mice.

Since a definable mutation exists within TLR-4 in C3H/HeJ mice, and a severe deficiency or complete absence of TLR-4 mRNA expression is observed in C57BL/10ScCR mice, it is clear that *Lps* is, in fact, the TLR-4 gene.

The *Lps^d* mutation of C3H/HeJ mice was originally described as codominant, in the sense that *Lps^d/Lpsⁿ* heterozygotes show intermediate levels of endotoxin response. The point mutation [⁷³² (pro6 his)] that we have identified exerts a dominant negative effect on LPS signal transduction. Supporting this conclusion, the functionally null (i.e., non-expressed) *Lps* allele represented in C57BL/10ScCR mice is strictly recessive. Since the TLR-4 molecule functions in a dimeric state, it is likely that the *Lps^d* mutation renders interplay between normal and abnormal subunits unproductive; hence the codominant phenotype. Alternatively, the mutation may cause sequestration of a downstream signaling molecule.

Insofar as the cross:

C3H/HeJ X C57BL/10ScCR

5

yields mice that are profoundly unresponsive to LPS, it may also be inferred that a single copy of the *Lps^d* allele (i.e., the genotype *Lps^d/-*) corresponds to a phenotype as unresponsive as that conferred by *Lps^d/Lps^d*. This observation supports the notion that signal transduction proceeds directly through the TLR-4 molecule, and tends to detract from the hypothesis that TLR-4 undergoes interaction with a second plasma membrane protein that acts, in turn, as a primary LPS transducer.

10

005760-53645260

15

TLR-4 mRNA is expressed predominantly in lymphoid tissues, and the TLR-4 mRNA is induced by LPS (Figure 9), suggesting that up-regulation of TLR-4 mRNA may perpetuate cell activation by LPS. Moreover, the well-known phenomenon of endotoxin tolerance is not likely to result from down-regulation of TLR-4.

20

In *Drosophila*, several Toll homologs are now known to exist (including 18-wheeler. Toll itself engages an extracellular protein ligand, *spätzle*, which promotes signal transduction via *tub* and *pelle* gene products, leading to dissociation of the cytoplasmic inhibitor encoded by *cactus* from a yet-unidentified member of the *rel* family of transcription factors. This pathway culminates in activation of the drosomycin gene, and is required for effective protection against fungal infection.

25

The mammalian ligand for TLR-4 has not yet been identified, and while an endogenous ligand may exist, it is equally possible that LPS recognition is the *raison d'être* for TLR-4. CD14, the best characterized cell surface receptor for LPS, is also a member of the toll superfamily, and it is likely that it directly engages TLR-4 upon interaction with LPS, inducing signal transduction through the latter protein.

TLR-4 signal transduction is believed to proceed through activation of MyD88, a cytoplasmic protein bearing homology both to the cytoplasmic domain of toll itself and to a pair of death domain motifs, originally described in the TNF receptor family. In addition, the interleukin-1 receptor associated kinase (IRAK) and TNF-receptor associated factor (TRAF-6) lie on the TLR-4 signaling pathway, leading to the activation of AP-1 and NF-6B. It has been known for some time that NF-6B activation is essential for transcriptional activation of the mouse TNF gene, and that TNF subserves many of the effects of LPS, including the lethal effect.

It has recently been reported that human toll-2 cDNA, transfected into 293 cells, can promote LPS signal transduction, given co-expression of CD14. It was also noted that LPS is directly bound by soluble dimerized versions of toll-2, and that toll-2 mutants bearing truncations in the cytoplasmic domain exert a dominant inhibitory effect on LPS signaling. LPS signal transduction via TLR-4 has never been reported. However, the demonstration that *Lps* is identical to TLR-4 leaves no room for doubt that TLR-4 is essential for LPS signaling. In mice lacking functional TLR-4, toll-2 does not make a substantial contribution to LPS signal transduction; hence C3H/HeJ and C57BL/10ScCR mice are entirely refractory to LPS. Though it is possible that toll-2, or other members of the toll family, might also be required for LPS signaling, the data in hand do not sustain this conclusion. Recently, it was demonstrated that Chinese hamsters lacking a functional copy of a toll-2 gene, still were responsive to endotoxin (Heine *et al.*, 1999), indicating that toll-2 is not essential in LPS signalling.

Several mammalian toll homologs have now been identified, and several more may exist undiscovered. The phenotypic consequences of mutations in genes encoding other members of the family remain to be seen. Remarkably, C3H/HeJ and C57BL/10ScCR mice are developmentally and phenotypically intact, aside from their inability to effectively respond to LPS, and to gram-negative infection. Their response to products of gram-positive organisms and most other microbes is intact. This fact would suggest that TLR-4 has been retained in evolution principally for the purpose of serving the LPS response pathway. Malo and coworkers have

recently adduced evidence to suggest that, in birds, distinct allelic forms of *Lps* may influence survival during gram-negative infection. As such, polymorphisms associated with the tenascin locus predict outcome following infection of outbred chickens with *Salmonella typhimurium*. In mice, and presumably in birds, the tenascin locus is closely linked to *Lps*. It is entirely possible that mutations of the human TLR-4 gene also influence susceptibility to gram-negative infection, or its clinical outcome. As two independent mutations of TLR-4 have thus far become fixed in mice, it is likely that human populations have also retained TLR-4 mutations. A search for such mutations is currently in progress.

EXAMPLE 8

Genetic Variation at the TLR4 Locus

Materials and Methods

Determination of the complete mouse (Tlr4) and human (TLR4) genomic sequences.

The mouse BAC 152C16 (from the 129/J strain; Research Genetics), was earlier shown by the inventors to contain the *Tlr4* gene in entirety, and a small fraction of *Tlr4* was also found to reside in the overlapping BAC 309I17 (Poltorak *et al.*, 1998). Human TLR4 was identified in BAC 110P15 (Genome Systems) by hybridization screening. All three BACs were fragmented by ultrasound, shotgun cloned into the vector pBluescript-KS, and sequenced extensively using ABI model 373 and 377 sequencers. 959 reads were obtained from 390I17, 1503 reads from 110P15, and 2731 reads from 152C16. The average read length was approximately 700 nt. To concentrate data acquisition efforts on the *Tlr4* and TLR4 genes themselves, PCR primers were fashioned to match regions flanking each gene. A 16 kb fragment was amplified from the mouse BAC 152C16, and a 12 kb fragment was amplified from the human BAC 110P15, each containing all exons of the respective gene. These fragments were also shotgun cloned, and sequenced extensively, so that the depth of sequence reached an average of 12 reads over the area of greatest interest. Assembly was performed using the programs phred and Phrap (obtained

from Brent Ewing and Phil Green, University of Washington Genome Center). Interpretation of repetitive elements was achieved with the program RepeatMasker (obtained from Arian Smit, University of Washington Genome Center). A contiguous high-quality sequence 18974 bp in length containing TLR4 was obtained from the human BAC, and a contig 91748 bp in length containing *Tlr4* was obtained from the mouse BAC. Over these intervals, the error rate was estimated at <1 per 10⁴ bp. The sequences have been posted to Genbank in annotated form (accession number AF177767 for the murine sequence, SEQ ID NO:48, and accession number AF177765 for the human sequence, SEQ ID NO:47). All data related to mutations are presented with reference to these sequences.

10

Sequencing DNA from individual human, mouse, chimpanzee, and baboon samples.

Human DNA samples were obtained from blood anticoagulated with EDTA, obtained from healthy laboratory personnel and from non-selected visitors to the Aston Center outpatient clinic in Dallas, TX. The samples, 102 in all, were from a population of mixed ethnicity, but were predominantly obtained from Caucasian donors. Samples were prepared using the Wizard Genomic DNA Purification kit (Promega). Mouse DNA, obtained from animals of 35 *Mus musculus* strains, was ordered from the Jackson Laboratories. Chimpanzee and baboon DNA were obtained from Dr. Kurt Benirschke (U. of CA, San Diego) and Dr. Gregory Delzoppo (Scripps Research Institute), respectively.

20

The three principal exons of *Tlr4* and TLR4 were amplified independently from all human and mouse genomic DNA samples, leaving a margin of approximately 50 bp to each side of the exons so as to identify intronic mutations that might alter splicing. An alternative second exon, apparent in the cDNA sequence has been reported (Rock *et al.*, 1998) (Gb accession number U88880) that specifies a truncated and presumably inactive product. It was not analyzed in the population survey.

25

All exons of the chimpanzee were amplified and sequenced using the same primers used to amplify and sequence the human exons. For the baboon, the first two exons were also amplified using these same primers; however, the third exon of the baboon was amplified with a substituted primer at the 5' end.

The PCR products were isolated by agarose gel electrophoresis. Exons 1 and 2 were sequenced using the same primers that were used for amplification. Exon 3 was sequenced using the flanking primers, as well as a collection of eight internal primers. In this manner, the entire coding region and all splice junctions of the human and mouse sequences could be covered with a total of 14 sequencing reads, given that all reads were of high quality. All primers used for amplification and sequencing are presented in Table II.

TABLE II. Oligonucleotide primers used to amplify and mouse and human Tlr4 genes. \uparrow , primer matches \oplus strand; \downarrow , primer matches \ominus strand.

MOUSE		HUMAN		
AMPLIFICATION				
	SEQ. ID NO.		SEQ. ID NO.	
EXON 1	↑ CAGTCGGTCAGCAACGCCTTCTTC	49	↑ GCTCGGTAAACGGTGATAG	55
	↓ CAAGGCAGGCTAGCAGGAAAGGGTG	50	↓ TGAGAAAGTTCTGGGCAGAAAG	56
EXON 2	↑ TTATTTCATCTTTGGAGAGGAGTGG	51	↑ TCTCTGGTCTAGGAGAGG	57
	↓ AAGGAAAGTTAGTTAGAACCAACCTTG	52	↓ CCAGTCCAATAATGAAATG	58
EXON 3	↑ TCTCCTGCTCACACCATCATCACCTG	53	↑ CCATCACATCTGTATGAAGAGCTGGATGAC	59
	↓ CATGTGTTCCATGGGCTCTCGGTC	54	↓ TGACTTTCTTTGTCATGGGTTCCCTTGACTG	60
SEQUENCING				
EXON 1 SAME AS ABOVE				
EXON 2 SAME AS ABOVE				
EXON 3	1 ↓ ATGCCATGCCCTTGCTCTTC	61	3.1 ↑ GAGCTGGATGACTAGGATTAATATTC	74
	2 ↓ TTTAAATTCTCCCAAG	62	3.1 ↓ TCAAAATTGCACAGGCCCTCTAG	75
	3 ↓ CAGCTCTTCTAGACC	63	3.2 ↑ CAATCTCTCTTTAGACCTGTCC	76
	4 ↑ TGTGAACATCAGAAATTCCT	64	3.2 ↓ AATACITTTAGGCTGGTTGTCCC	77
	5 ↑ TGAGATTGCTCAACATGG	65	3.3 ↑ GAAAGTTGATCTACCAAGCCTTG	78
	6 ↑ TTGAAACAATTGAAGACAAAGGC	66	3.3 ↓ GGAAGTCATTATGTGATTGAGAC	79
	7 ↑ CCTGGCTGGTTTACACGTC	67	3.4 ↑ CTTCCTGGACCTCTCTCAGTGTCAAC	80
	8 ↑ TTTTCATGGGTCTAGAAGAGCTG	68	3.4 ↓ GAAGGCAGAGCTGAAATGGAGG	81
	9 ↓ AAGAACTGCTTCTGTTC	69	3.5 ↑ TCAGATGAATAAGACCATCATTTGGTG	82
	10 ↓ TCAGAAACTGCCATGTTTG	70	3.5 ↓ AACCAAGTTTGGACCCAG	83

665150: 585955

EXON 3 Secondary	5' ↑ TGAGCTGGTAAAGAATTAG	71	1 ↑ GTAAATTGGACAGTTCC	84
	7' ↑ CTGACGAACCTAGTACATGTG	72	2 ↑ TTCAGTATTCCTATCACTCAG	85
	9' ↓ ATGTCAAAGTTTGTGTGTT	73	3 ↑ TTATAAGTGTCTGAACTCCC	86
			4 ↑ TCGGTCCTCAGTGTGCTTG	87
			5 ↑ GTGTCCCAGCAC TTCATC	88
			6 ↑ AACCTCCTGAGGCATTC	89
			7 ↓ GTTCAAAATTGGAATGCTG	90
			8 ↓ AAGGAACGTATCCAATG	91
			9 ↓ AAGCACACTGAGGACCGAC	92
			10 ↓ GATGAAGTGCTGGGACAC	93
			11 ↓ TCCTCTTCAGATAGATGTTG	94
			12 ↓ TTTCTTTGTCA TGGGTTT	95
			0 ↑ TTTAGGTTCTTATTCAGCAG	96
			0 ↓ GCTCTAGATTGGTCAGATTAG	97

Independent assembly of each sample was required as a condition for further analysis, and if such assembly failed, additional reads were executed using a secondary collection of primers. Thereafter, mutations were identified *en mass*, by pooling all of the reads from 25 to 30 samples at a time and reassembling with the program polyphred, using the phredPhrapPoly script (obtained from Natalie Kolker, University of Washington Genome Center). Consed_alpha (obtained from David Gordon, University of Washington Genome Center) was used to visualize reads and mutations.

The annotated chimpanzee exon sequences have been submitted to Genbank with the accession numbers AF179218, AF179219, and AF179220. The baboon sequences have been submitted with the accession numbers [pending]. For the purpose of genetic comparisons, rat and hamster Tlr4 sequences were also used; their Genbank accession numbers are AF057025 and AF153676, respectively.

Genetic computation

A 500 MHz DEC-alpha system equipped with 256 Mbytes of memory was used for direct analysis of sequence data as described above. In addition to the programs already mentioned, the GCG software (version 9.0) was used for alignment analysis. The windows-based program Generunner 3.0 (Hastings Software) was used for the design of oligonucleotide primers. A spline curve describing heterogeneity of the Tlr4 polypeptide sequence from different species was produced using the program Prism 3.0 (Graphpad Software, Inc). Sequences were prepared for submission with the use of the program Sequin 2.90 (obtained from NCBI).

Results

Overall structure of TLR4 and Tlr4.

The mouse *Tlr4* gene is somewhat longer than its human counterpart, owing to the greater length of intronic sequence (15337 bp from beginning to end of transcribed sequence in the mouse, SEQ ID NO:48, as compared to 11467 bp in the human, SEQ ID NO:47). There are three exons in *Tlr4*, and each corresponds to a homologous sequence in the human gene. A human

cDNA sequence (Genbank accession number U88880) that includes a fourth exon, positioned between the “normal” first and second intron has been reported (Rock *et al.*, 1998). When included in the processed transcript, however, this exon specifies early termination of the polypeptide chain. While it is possible that translation is initiated distal to the added stop codon, and that a shorter product results in the human than in the mouse, such a situation would be unusual given the length of the 5'UTR that would then exist, and the presence of multiple upstream initiation codons. Moreover, there is no murine sequence homologous to the alternative second exon of the human gene. The biological significance of this exon is therefore unclear, and in all likelihood, its inclusion in the mRNA leads to the formation of a nonfunctional protein product.

Neither the human nor the mouse gene display a TATA element or CAAT box in the proximal promoter region. A number of conserved promoter and enhancer motifs are apparent on alignment of the murine and human 5' flanking sequences. Both *Tlr4* and TLR4 lie in the midst of repetitive sequences of retroviral origin, and no other genes may be detected in close communication with either of them, using homology searches or the gene prediction algorithm GRAIL.

Genetic variation at the human TLR4 locus

In total, 204 human TLR4 alleles were sequenced in entirety. As such, all but the rarest alleles have likely been encountered. According to the formula:

$$(1-p) = (1-x)^N,$$

where p is the probability of detecting an allele, x is the actual frequency of the allele in population surveyed, and N is the number of alleles examined, there is a 95% chance that any allele with a frequency exceeding 1.46 % was detected through sequencing this population.

In all, 12 mutable sites were found in human TLR4 (Table III, FIG. 10). Of these, most were confined to exon 3, though some were also placed in the second intron. Five changes observed in the coding region were silent (i.e., did not produce an amino acid substitution). Five

changes did cause amino acid substitutions, one of which affected the cytoplasmic domain, and four of which affected the ectodomain.

005T60:58596E60

TABLE III.

^a The complete exonic coding sequence of TLR4, including splice junctions, was determined using samples obtained from 102 anonymous individuals.

[†] It is unclear whether the mutations in these individuals lie in *cis* or in *trans* from one another.

[‡] With one exception (control 18), these mutations constitute a single allele and are always co-inherited.

* Transmembrane domain extends between residues 636 and 662.

[#] Coding limits within exons: Exon 1: (ATG) 4325→4417; Exon 2: 8414→8580; Exon 3: 12239→15625 (14498=TGA). Alternative Exon 2: 8050-8169.

POLYMORPHISM OF THE HUMAN TLR4 LOCUS IN NORMAL INDIVIDUALS OF A MULTI-ETHNIC POPULATION - DALLAS, TX ^b						
Control	Nucleotide (Genomic)	Exon/ Intron #	AA	Receptor Domain*	Conserved	Allele Frequency
12	8612 G → A	Intron 2	-----	-----		0.01
57 [†]	12399 C → T 12510 G → A	Exon 3	----- (178) E → K	-----	No	0.01
19,42,99	12413 C → A	Exon 3	-----	-----		0.03
56 [†]	12413 C → A 14266 G → A	Exon 3	----- (763) R → H	----- Cyto	Yes	0.01
89	12541 A → G	Exon 3	(188) Q → R	Ecto	Yes	0.01
2,4,11,29,31	12874 A → G	Exon 3	(299) D → G	Ecto	Yes	0.12

665T60" 33636E60

43,62,65,70 ,78,87,93 ⁺	13174 C → T		(399) T → I		No	
18	12874 A → G	Exon 3	(299) D → G	Ecto	Yes	0.01
55	12964 A → G	Exon 3	(329) N → S	Ecto	No	0.01
17,67	13398 G → A	Exon 3	(474) E → K	Ecto	No	0.02
68	13769 G → A	Exon 3	-----	-----		0.01
94	13937 G → A	Exon 3	-----	-----		0.01
75	14266 G → A	Exon 3	(763) R → H	Cyto	Yes	0.01

The most common allele in the human population exists at a frequency of 86.3%, and 74.5% of the population is homozygous for this allele. The most common TLR4 polymorphism (designated TLR4-B; Genbank accession number AF177766) exists at an allelic frequency of 6%, and consists of a double amino acid substitution (residues 299 and 399 of the human polypeptide chain; nts 12874 and 13174 of the gene), one of which (residue 299) affects an aspartic acid residue conserved in mice, rats, hamsters, and chimpanzees (though differing in the baboon sequence). Though the mutations are almost always co-inherited, and hence, must lie in *cis* with one another, a single instance of mutation at the 12874 site was observed in the absence of the 13174 mutation. This would suggest that the double mutation may have arisen from an ancestral allele that is now very rare, and conceivably, it may confer an advantage to carriers.

Of the other mutations observed, 3 modified relatively conserved amino acid residues, whereas 4 modified relatively variable residues.

Genetic variation at the mouse Tlr4 locus.

Among 35 strains of *Mus musculus*, 10 different alleles were identified, based on mutations occurring at 22 sites with respect to the reference sequence, 13 of which create amino acid substitutions (Table IV; FIG. 11). Hence, greater variation was observed among mice than among humans, with the most common murine allele represented at a frequency of only 69%. To a far greater extent in mice than in humans, the ancestry of different *Tlr4* alleles may be traced, as many deviations from the reference allele occur in conjunction with one another. A plausible arrangement of strain relationships is presented in FIG 12. Some strains have accumulated many more mutations than others. For example, the P/J strain *Tlr4* gene exhibits eleven mutations that distinguish it from the most common haplotype, six of them specifying changes in the Tlr4 amino acid sequence; the SEA/GnJ strain differs by nine mutations, and the strains NZW/J and VM/Dk, which are identical to one another, differ at six sites. Shared mutations suggest that interbreeding of some strains took place after their initial mutational separation had

occurred, leading to the introduction of groups of mutations by genetic recombination. Hence, mice of the P/J, NZW/J, and VM/Dk strains have several mutations that are observed in the A/J and BALB/c strains, but also lack some of the mutations of the latter strains, and have unique mutations of their own.

5 ¹ LEGEND

1. NZO/HILt 2. SI/Col 3. DBA/J 4. A/J 5. EL/Suz 6. CBA/J 7. AKR/J 8. BALB/Cj 9. Ddy/jCL 10. P/J 11. MRL/MpJ 12. SJL/J 13. NOD/LtJ 14. 129/J 15. FL/Re 16. MA/MyJ 17. SWR/J 18. LP/J 19. PRO/ReJ 20. SODI/Ei 21. SEA/GnJ 22. SM/J 23. KK/HIJ 24. ST/bJ 25. WB/Re 26. YBR/Ei 27. FVB/NJ 28. PL/J 29. LT/ChReSv 30. RIIS/J 31. RF/J 10 32. NZB/BINJ 33. AU/SsJ 34. NZW/LacJ 35. VM/Dk

TABLE IV.

POLYMORPHISM OF THE <i>Tlr4</i> Among Mice					
Mouse ¹	Nucleotide (Genomic)	Exon/ Intron	AA	Receptor Domain*	Conserved
10	26400 A → G	Exon 2	-----	-----	
4,8,21,22	37685: (T) ₁₀	Intron 2	-----	-----	
34,35	37685: (T) ₁₂	Intron 2	-----	-----	
23	37754 G → A	Exon 3	94 D → N	Ecto	Yes
4,8,10,20,2 1,34,35	38101 G → A	Exon 3	209 M → I	Ecto	No
21	38130 A → G	Exon 3	219 D → G	Ecto	No
4,8,21	38234 G → A	Exon 3	254 V → I	Ecto	Yes
10	38584 A → G	Exon 3	-----	-----	
21	38742 A → T	Exon 3	423 Q → L	Ecto	No
10	38794 G → A	Exon 3	-----	-----	
10	38903 G → T	Exon 3	477 A → S	Ecto	Yes
18	39020 A → G	Exon 3	516 T → A	Ecto	No
4,8,10,20,2 1,22,34,35	39199 C → T	Exon 3	-----	-----	

4,8,10,20,2 1,34,35	39253 A → C	Exon 3	593 E → D	Ecto	No
23	39273 A → T	Exon 3	600 N → I	Ecto	No
10	39383 G → A	Exon 3	637 V → I	TM	Yes
19	39604 T → C	Exon 3	-----	-----	
4,8,20,21,3 4,35	39631 C → T	Exon 3	-----	-----	
4,8,20,21,3 4,35	39756 G → A	Exon 3	761 R → H	Cyto	Yes
18	39826 T → C	Exon 3	-----	-----	
10	39907 T → G	Exon 3	811 N → K	Cyto	No

As in the human TLR4 gene, most of the murine mutations reside within exon 3, and only two substitutions are noted to modify the cytoplasmic domain (FIG 12). Of these, however, one mutation (R761H), is fairly common among the strains surveyed, and corresponds exactly to the human mutation (R763H), observed in one individual out of the 102 surveyed. The same residue has been reported as an H in the hamster. A single conservative substitution (V637I) was noted within the transmembrane domain of the P/J strain.

Anthropoid ape and lower primate TLR4 sequences, and their relationship to the human and rodent sequences

The human and chimpanzee amino acid sequences are nearly identical over the interval studied, distinguished only by three amino acid substitutions. The baboon sequence is 93.5% identical to the human in the ectodomain, differs in the transmembrane domain by one substitution out of 30 residues, and differs in the proximal cytoplasmic domain by only 1 residue in 155. At the C-terminus, however, homology is badly disrupted, so that 16 of the last 21 human residues are not replicated in the baboon protein, which is 13 amino acids shorter than the human protein. Similarly, among rodents, the C-terminus of the protein is the least conserved. Overall, the order of conservation with respect to domain is:

proximal cytoplasmic domain > transmembrane domain > ectodomain > distal cytoplasmic domain.

Indeed, interspecific comparisons of complete Tlr4 amino acid sequence confirm the existence of a hypervariable region at the distal end of the Tlr4 cytoplasmic domain (Table V, FIG. 13).

TABLE V.

Homology among functional domains of Tlr4 from six species. Percentages refer to identity on Fast-A comparison. Ecto, residues 1-631; TM, residues 632-662; Proximal, residues 663-819; Distal, residues 820-839.

ECTO

Human	100%					
Chimp	99.6%	100%				
Baboon	91.5%	91.5%	100%			
Rat	61.3%	60.7%	59.4%	100%		
Mouse	61.9%	62.0%	60.1%	82.9%	100%	
Hamster	64.3%	64.2%	62.5%	73.8%	74.8%	100%
	Human	Chimp	Baboon	Rat	Mouse	Hamster

TM

Human	100%					
Chimp	100%	100%				
Baboon	97.1%	97.1%	100%			
Rat	67.7%	67.7%	67.7%	100%		
Mouse	70.6%	70.6%	70.6%	91.2%	100%	
Hamster	73.5%	73.5%	73.5%	79.4%	79.4%	100%
	Human	Chimp	Baboon	Rat	Mouse	Hamster

PROXIMAL

Human	100%					
Chimp	99.4%	100%				
Baboon	99.4%	98.7%	100%			
Rat	91.7%	91.0%	91.0%	100%		
Mouse	90.4%	89.7%	89.7%	98.1%	100%	
Hamster	91.7%	91.0%	91.0%	97.4%	95.5%	100%
	Human	Chimp	Baboon	Rat	Mouse	Hamster

DISTAL

Human	100%					
Chimp	100%	100%				
Baboon	50%	50%	100%			
Rat	38.1%	38.1%	NS	100%		
Mouse	26.3%	26.3%	NS	63.2%	100%	
Hamster	40.9%	40.9%	NS	40.9%	45.5%	100%
	Human	Chimp	Baboon	Rat	Mouse	Hamster

TABLE VI.

Coding limits within exons: Exon 1:(ATG)4325→4417; Exon 2: 8414→8580; Exon 3: 12239→15625 (14498=TGA). Alternative Exon 2: 8050-8169.

POLYMORPHISM OF THE HUMAN TLR4 LOCUS IN PATEINTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS – CONNECTICUT						
Patient	Nucleotide (Genomic)	Exon/ Intron #	AA	Receptor Domain	Conserved	Allele Frequency
22,5,3	12874 A → G	Exon 3	(299) D → G	Ecto	Yes	0.12
22,3	13174 C → T	Exon 3	(399) T → I	Ecto	No	0.08
24	13398 G → A	Exon 3	(474) E → K	Ecto	No	0.04
19,20	14266 G → A	Exon 3	(763) R → H	Cyto	Yes	0.08

TABLE VII.

Coding limits within exons: Exon 1:(ATG) 4325→4417; Exon 2: 8414→8580; Exon 3: 12239→15625 (14498=TGA). Alternative Exon 2:8050-8169.

* locus-equivalents sequenced

POLYMORPHISM OF THE HUMAN TLR4 LOCUS IN PATIENTS WITH MENINGOCOCCAL SEPSIS – HOLLAND, UK, USA						
Patient	Nucleotide (Genomic)	Exon/ Intron	AA	Receptor Domain	Conserved	Allele Frequency
121, 122, 146	8457 A → G	Exon 2	(46) Y → C	Ecto	No	.017
98	8631 A → G	Intron 2	-----	-----	-----	.006
86	12228 ΔT	Intron 2	-----	-----		.006
28	12245 A → G Δ 14453 → 14461	Exon 3	----- Δ (827-829) VGT	----- Cyto	Yes	.006 .006
86	12293 T → C	Exon 3	-----	-----	-----	.006
69, 76, 97, 102, 107, 115, 125, 136	12413 C → A	Exon 3	-----	-----	-----	.045
??136	12412 C → A	Exon 3	(145) P → H	Ecto	No	.006

665760-5869660

17	12820 G → A	Exon 3	(281) C → Y	Ecto	Yes	.006
64, 143	12874 A → G	Exon 3	(299) D → G	Ecto	Yes	.011
11, 75, 113, 116, 120	12874 A → G 13174 C → T	Exon 3	(299) D → G (399) T → I	Ecto	Yes No	.028
70, 138	13174 C → T	Exon 3	(399) T → I	Ecto	No	.011
150	13848 A → C	Exon 3	(624) N → H	Ecto	Yes	.006
62, 85	13937 G → A	Exon 3	-----	-----	-----	.011

EXAMPLE 9

Tlr4-MEDIATED LPS SIGNAL TRANSDUCTION IN MACROPHAGES

5 The mammalian LPS sensor is formed by a complex array of proteins, some of which may as yet be unknown. Complexes of LPS and LBP are initially engaged at the cell surface by CD14, a glycosphosphoinositol-linked protein with no cytoplasmic domain (Wright *et al.*, 1990). The biological relevance of CD14 in LPS signaling, originally deduced from binding and transfection studies (Wright, 1990; Kirkland *et al.*, 10 1990), is supported by gene knockout data, which revealed that CD14 expression is required for normal sensitivity to LPS (Haziot *et al.*, 1996). However, it was assumed that a second, membrane-spanning protein must ultimately transduce the LPS signal, since CD14 lacks a cytoplasmic domain.

15 The protein that likely fulfills this role was identified through studies of mice, wherein mutations of a single gene (*Lps*) have long been known to abolish LPS signal transduction (Sultzter, 1968; Watson *et al.*, 1978). The *Lps^d* allele, represented in C3H/HeJ mice, is codominant in the sense that *Lps^d/Lpsⁿ* heterozygotes exhibit intermediate sensitivity to LPS (Rosenstreich *et al.*, (1978), and their macrophages 20 display intermediate levels of TNF production in response to LPS. The innominate non-responder allele represented in C57BL/10ScCr mice is recessive to the wild-type allele, in that heterozygotes display normal responses to LPS (Coutinho and Meo, 1978). Using positional methods, the inventors have determined that *Lps* encodes the toll-like receptor 4 (Tlr4), a single- spanning transmembrane protein with a leucine-rich ectodomain and a 25 “Toll-like” cytoplasmic domain (Poltorak *et al.*, 1998a; Poltorak *et al.*, 1998b). The *Lps^d* allele bears a missense mutation (2342 C_A; P712H) which lies within the cytoplasmic domain of the polypeptide chain. The mutation in C57BL/10ScCr mice is a null allele. Relying on these data (Qureshi *et al.*, 1999a), other workers confirmed the presence of the mutations (Qureshi *et al.*, 1999b). Moreover, Hoshino and colleagues demonstrated that 30 a *Tlr4* knockout produces an excellent phenocopy of the naturally occurring *Tlr4* mutations (Hoshino *et al.*, 1999).

In order to directly examine the role of Tlr4 as a transducer of the LPS signal in macrophages, the inventors expressed the normal mouse protein- and various mutant forms- in RAW 264.7 macrophages have been expressed (FIG. 14; Table VIII). These
5 cells of murine origin are highly responsive to LPS, and are known to express the Tlr4 mRNA (Poltorak *et al.*, 1998b). Unlike cell lines of non-myeloid origin (i.e., 293 cells or CHO cells), they express all proteins required for the elicitation of a biologically relevant response to LPS (e.g., TNF production). As such, they may be used to determine whether Tlr4 is a limiting factor in the initiation of an LPS signal, and to examine the mechanism
10 by which the *Tlr4*^{Lps-d} allele exerts its dominant inhibitory effect on signaling. This was determined by performing more than 3,000 assays of TNF production, induced over an extensive range of LPS concentrations in numerous stable clones, since individual clones show considerable background variability in LPS responses. Moreover, because culture conditions can affect the sensitivity of the TNF assay and production of TNF by LPS-
15 stimulated cells, all transfected and control clones were induced and assayed in parallel. Statistical analyses of shifts in the EC50 values determined for individual clones were then applied in order to determine the influence of recombinant protein expression.

RAW 264.7 cells were first cotransfected with cDNAs derived from the *Tlr4*^{Lps-n}
20 and *Tlr4*^{Lps-d} alleles and with a vector encoding *neo*. The amino terminus of each protein was flag-tagged to permit measurement of expression at the cell surface using the monoclonal antibody M2 (obtained from Sigma). After G418 selection, stable clones expressing each Tlr4 isoform or transfected with vector alone were examined for LPS signal transduction. The binding isotherm from one such clone, transfected with the
25 *Tlr4*^{Lps-n} construct, is displayed in FIG. 15A, and the flag copy number for clones bearing each construct is displayed in FIG. 15B. Despite the use of a strong promoter, the mean copy number rarely exceeded 3×10^4 per cell, and the range of expression among all clones spanned less than an order of magnitude. The relatively low copy number achieved is consistent with the possibility that surface expression may be limited by the
30 level of co-expression of other proteins (e.g. MD-2 (Shimazu *et al.*, 1999)), and the lower

copy number in clones bearing truncated constructs as compared with full-length constructs may reflect diminished stability.

Composite EC50 analysis revealed strong augmentation of the LPS response (a 30-fold leftward shift of the curve) resulting from modest over-expression of the normal protein; even stronger suppression (a 2600-fold shift to the right) was observed with expression of the mutant isoform. Hence, with respect to the over-expression of Tlr4^{Lps-n} and Tlr4^{Lps-d} proteins, a 74,000-fold difference in the mean response is apparent at the EC50 point (FIG. 15C). A more conservative approach, based on measurement of the LPS EC50 for each individual clone, also revealed that the Tlr4^{Lps-n} isoform strongly enhances LPS sensitivity, while the Tlr4^{Lps-d} isoform strongly suppresses it (FIG. 15D). According to this method of estimation, the composite range of the responsiveness (mean EC50 of Tlr4^{Lps-d} transfected clones/mean EC50 of Tlr4^{Lps-n} transfected clones) was 1120-fold. Taking the dimension of receptor number into account (FIG. 15E), and excluding the statistical contribution of the clones transfected with vector alone, no significant correlation was observed between LPS signal intensity and the absolute number of recombinant Tlr4 molecules on the cell surface. This suggests that the number of artificial receptors expressed (usually $\sim 1-2 \times 10^4$) is well in excess of the number of native receptors, and that maximum augmentation of LPS response is achieved in each clone transfected with Tlr4^{Lps-n}, with variation attributable to other factors. It is interesting in this regard that, on a linear scale, the inhibitory effect of Tlr4^{Lps-d} over-expression vastly exceeds the augmenting effect of Tlr4^{Lps-n} expression. In fact, most of the macrophage clones were rendered virtually unresponsive to LPS through over-expression of Tlr4^{Lps-d} (LPS EC50 > 10 $\mu\text{g/ml}$).

25

Several conclusions can be drawn from these results. First, the dominant effect of the *Tlr4*^{Lps-d} allele may be directly demonstrated through transfection-based expression of the protein at moderate levels in an LPS-responsive macrophage cell line. Second, since over-expression of Tlr4^{Lps-n} augments the LPS response, the intensity of the LPS signal is normally limited by the quantity of Tlr4 protein on the macrophage membrane.

30

Third, since there appears to be little correlation between the absolute number of recombinant receptors expressed and the magnitude of augmentation or inhibition achieved, it may be inferred that saturation of another component of the signaling cascade, either proximal or distal to Tlr4, occurs when the level of Tlr4 expression exceeds a certain threshold: perhaps in the range of several thousand copies per cell. By the same token, the level of endogenous Tlr4 expression is probably very low: perhaps lower than 10 (Michalek *et al.*, 1980) copies per cell (a finding consistent with the fact that Tlr4 mRNA is of very low abundance (Poltorak *et al.*, 1998b), but nonetheless remarkable in view of the global effects wrought by activation of the receptor). Fourth, and perhaps most important of all, since rather modest changes in the level of normal Tlr4 protein expression or the expression of a dominant negative Tlr4 isoform can shift LPS sensitivity over a range that spans three to four orders of magnitude, one may infer that Tlr4 is of preponderant importance in LPS signal transduction: there is little room for the belief that independent pathways act to transduce the LPS signal as well. This last point is fully supported by the observation that mutation or deletion of the *Tlr4* locus can completely abrogate LPS signaling (Sultzer, 1968; Coutinho and Meo, 1978; Poltorak *et al.*, 1998b).

In one model, the dominant suppressive effect of *Tlr4*^{Lps-d} might be ascribed to the postulated multimeric structure of the Tlr4 protein (Schneider *et al.*, 1991; Medzhitov *et al.*, 1997), given that unproductive association between normal and abnormal subunits yields inhibition of signaling. If association between subunits is principally dependent upon ectodomain contacts, one would predict that any mutation that disrupts function of the Tlr4 cytoplasmic domain might impede signal transduction in a dominant fashion, just as observed with Tlr4^{Lps-d}. To examine this hypothesis, the inventors expressed a truncated version of the Tlr4 protein, lacking the entire cytoplasmic domain. This protein was well expressed on the cell surface, but had only a weak inhibitory effect on LPS signaling, which fell short of significance according to the more stringent method of analysis (FIG. 16A and FIG. 16B). Hence, the Tlr4^{Lps-d} isoform exerts a strong dominant effect whereas deletion of the entire cytoplasmic domain does so weakly at most. The

elicit NF- κ B Translocation yield effects that have little or nothing in common with the LPS response in other respects. Moreover, it has recently been shown that mutational inactivation of MyD88, which is known to engage Tlr4, leads to a state of profound LPS unresponsiveness, though permitting NF- κ B Translocation. Finally, given that a response
 5 of any kind is observed in non-macrophage cell lines, there exists no standard for comparison. It has never been clear, for example, that the magnitude of the NF- κ B response approaches that witnessed in a normal macrophage over an identical range of LPS concentrations, nor is it known what effect this might have in a macrophage. These technical issues have, to date, confounded interpretation of which molecule actually does
 10 transduce the LPS signal, a role previously ascribed to Tlr2 (Yang *et al.*, 1998; Kirschning *et al.*, 1998) but now clearly attributable to Tlr4.

The present data reveal that Tlr4 is the limiting factor in LPS signal transduction in LPS responsive macrophages. Over-expression of Tlr4 in cells that already express it
 15 augments the LPS response, by about 30-fold on average. The relationship between the level of Tlr4 expression and biological response indicates that, although other proteins fulfill indispensable functions in LPS signal transduction both upstream (Wright *et al.*, 1990) and downstream (Kawai *et al.*, 1999; Muzio *et al.*, 1998; Medzhitov *et al.*, 1998) from Tlr4, the quantity of Tlr4 expressed is an important limiting factor in the intensity of
 20 the signal that is evoked. Hence, sensitivity to LPS is likely controlled through modulation of Tlr4 biosynthesis or activity. Priming by interferon (Pace *et al.*, 1985; Lau and Livesey, 1989; Hayes and Zoon, 1993) or by treatment with facultative intracellular pathogens (Vogel *et al.*, 1980; Haranaka *et al.*, 1984; Matsuura and Galanos, 1990) can greatly enhance sensitivity to LPS, while corticosteroids create a state of LPS resistance
 25 (Beutler *et al.*, 1986). Such modulation may be achieved through alteration of Tlr4 structure or expression, or alternatively, through changes in sensitivity to the signal that Tlr4 initiates, or changes in the intensity of the signal that Tlr4 receives.

The over-expression of a membrane-anchored Tlr4 ectodomain (lacking any of the
 30 wild-type cytoplasmic domain) inhibited the LPS response only weakly, if at all. This

failure of the overexpressed ectodomain to block signaling by a competitive mechanism implies that upstream components of the signal transduction pathway must either exist in excess with respect to Tlr4, or must interact with Tlr4 at very low affinity. There is now good reason to doubt the proposal (Modlin *et al.*, 1999) that the expression of soluble

5 Tlr4 might prove an effective means of interdicting the LPS signal *in vivo*, particularly in view of the fact that a membrane-anchored form of the protein would be sterically positioned to exert such an effect with maximum efficiency, while a soluble form would not be. It is, for example, possible to calculate the local concentration of Tlr4 ectodomain achieved through over-expression of a membrane-associated version of the protein.

10 Assuming that the Tlr4 ectodomain resides within a space that is 100 Å “deep” from its most apical point to the surface of the membrane, and further assuming that the macrophage is a spherical body with a 15 µM radius, the expression of 2×10^4 receptors per cell corresponds to a protein concentration of 1.2×10^{-6} M, or 840 µg of ectodomain per ml. While it might be possible to achieve such concentrations of soluble ectodomain

15 *in vivo*, it would not be easy to do so, and at that, little or no attenuation of the LPS signal would be anticipated. On the other hand, interventions that inhibit contact between Tlr4 subunits would be likely to have a pronounced impact on signal transduction.

TABLE VIII

Construct	Residues expressed	Copies/cell	Å SD	n
<i>Tlr4</i> ^{Lps-n}	22 - 835	2.1×10^4	4.1×10^3	10
<i>Tlr4</i> ^{Lps-d}	22 - 835 (P712H)	2.0×10^4	1.4×10^4	10
<i>Tlr4</i> ^{Lps-n} Cyt. Dom.	630 - 835	1.2×10^4	3.8×10^3	7
<i>Tlr4</i> ^{Lps-d} Cyt. Dom.	630 - 835 (P712H)	9.9×10^3	4.0×10^3	8
Ectodomain	22 - 660	1.4×10^4	5.1×10^3	9

20

All of the compositions and methods disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure. While the compositions and methods of this invention have been described in terms of preferred embodiments, it will be apparent to those of skill in the art that variations may be applied to the compositions and methods and in the steps or in the sequence of steps of the method described herein without departing from the concept, spirit and scope of the invention. More specifically, it will be apparent that certain agents which are both chemically and physiologically related may be substituted for the agents described herein while the same or similar results would be achieved. All such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the spirit, scope and concept of the invention as defined by the appended claims.

REFERENCES

The following references, to the extent that they provide exemplary procedural or other details supplementary to those set forth herein, are specifically incorporated herein by reference.

- 5 U. S. Patent 5,464,937
U. S. Patent 5,488,032
U. S. Patent 5,508,262
U. S. Patent 5,608,035
10 U. S. Patent 5,726,148
U. S. Patent 5,767,064
U. S. Patent 5,767,234
U. S. Patent 5,776,731
U. S. Patent 5,786,331
15 U.S. Patent 4,215,051,
U.S. Patent 4,554,101
U.S. Patent 4,603,102
U.S. Patent 4,683,195
U.S. Patent 4,683,202
20 U.S. Patent 4,683,202
U.S. Patent 4,800,159,
U.S. Patent 4,883,750
U.S. Patent 4,682,195
WO 90/07641
25
Angle *et al.*, *Cell*. 49(6): 729-739, 1987b
Angle *et al.*, *Mol Cell Biol*. 7(6): 2256-2266, 1987a
Apte *et al.*, *J.Cell.Physiol.* 89, 313-323, 1976
Apte, *et al.*, *J.Immunol.* 119, 1898 1977
30 Banerji *et al.*, *Cell*; 27(2 Pt 1): 299-308, 1981

- Bell, *et al.*, *Mammalian Genome*. 6, 389-395, 1995
- Berkhout *et al.*, *Cell*; 59(2): 273-282, 1989
- Beutler *et al.*, *J. Immunol.*, 135:3972-3977, 1985a.
- Beutler *et al.*, *Science*, 229:869-871, 1985b.
- 5 Beutler *et al.*, *Science*, 232:977-980, 1986.
- Beutler, Krochin, Milsark, Luedke, Cerami, *Science*, 232:977-980, 1986.
- Beutler, Milsark, Cerami, *Science*, 229:869-871, 1985.
- Blonar *et al.*, *Mol Cell Biol*. 1989 Feb; 9(2): 844-846, 1989
- Bodine and Ley, *EMBO J*. 6(10): 2997-3004, 1987
- 10 Boshart *et al.*, *Cell*. 1985 Jun; 41(2): 521-530, 1985
- Bosze *et al.*, *EMBO J*. 1986 Jul; 5(7): 1615-1623, 1986
- Braddock *et al.*, *Cell*. 1989 Jul 28; 58(2): 269-279, 1989
- Bulla and Siddiqui, *Virology*. 1989 May; 170(1): 251-260, 1989
- Burn *et al.*, *Gene*. 161, 183-187, 1995
- 15 Campbell and Villarreal, *Mol Cell Biol*. 1988 May; 8(5): 1993-2004, 1988
- Campo *et al.*, *Nature*. 1983 May 5; 303(5912): 77-80, 1983
- Celander and Haseltine, *J Virol*. 61(2): 269-275, 1987
- Celander *et al.*, *J Virol*. 62(4): 1314-1322, 1988
- Chandler *et al.*, *Cell*. 1983 Jun; 33(2): 489-499, 1983
- 20 Chang *et al.*, *Mol Cell Biol*. 1989 May; 9(5): 2153-2162, 1989
- Chatterjee *et al.*, *Proc Natl Acad Sci U S A*. 1989 Dec; 86(23): 9114-9118, 1989
- Chaudhary *et al.*, *Blood*. 91, 4020-4027, 1998
- Chedid *et al.*, *Infec.Immun.* 13, 722-727, 1976
- Chol *et al.*, *Eur J Biochem*. Aug 1; 239(3): 579-587, 1996
- 25 Cohen *et al.*, 1987
- Costa *et al.*, *Mol Cell Biol*. 8(1): 81-90, 1988
- Coutinho and Meo, *Immunogenetics*, 7:17-24, 1978.
- Coutinho *et al.*, *Eur.J.Immunol*. 7, 325-328, 1977
- Coutinho *et al.*, *Immunogenetics*. 7, 17-24, 1978
- 30 Cripe *et al.*, *EMBO J*. 6(12): 3745-3753, 1987

- Cseh and Beutler, *J.Biol.Chem.* 264, 16256-16260, 1989
Cseh and Beutler, *J.Biol.Chem.*, 264:16256-16260, 1989.
Culotta and Hamer, *Mol Cell Biol*; 9(3): 1376-1380, 1989
Dandolo *et al.*, *J Virol.* 47(1): 55-64, 1983
5 Davey *et al.*, EPA No. 329 822
Deschamps *et al.*, 1985
deVilliers *et al.*, *Nature*. 1984 Nov 15; 312(5991): 242-246, 1984
Edbrooke *et al.*, *Mol Cell Biol.* 1989 May; 9(5): 1908-1916, 1989
Edlund *et al.*, *Science*. 1985 Nov 22; 230(4728): 912-916, 1985
10 EPA No. 320 308
Feng and Holland, *Nature*. 1988 Jul 14; 334(6178): 165-167, 1988
Firak and Subramanian, *Mol Cell Biol.* 1986 Nov; 6(11): 3667-3676, 1986
Foecking and Hofstetter, *Gene*. 1986; 45(1): 101-105, 1986
Fonta *et al.*, *Neuroreport*. 1995 Mar 27; 6(5): 745-749, 1985
15 Fraker and Speck, *Biochem.Biophys.Res.Commun.*, 80:849-857, 1978.
Freudenberg, Keppler, Galanos, *Infec.Immun.*, 51:891-895, 1986.
Frohman, M.A., In: *PCR™ PROTOCOLS: A GUIDE TO METHODS AND APPLICATIONS*, Academic Press, N.Y., 1990
Fujita *et al.*, *Cell*. 1987 May 8; 49(3): 357-367, 1987
20 Geppert *et al.*, *Mol. Med.*, 1:93-103, 1994.
Gerard, *Nature*, 395:217-219, 1998.
Gilles *et al.*, *Nucleic Acids Res.* 1983 Nov 25; 11(22): 7981-7997, 1983
Gloss *et al.*, *EMBO J.* 1987 Dec 1; 6(12): 3735-3743, 1987
Glue *et al.*, 1988
25 Godbout *et al.*, *Genes Dev.* 1988 Aug; 2(8): 949-956, 1988
Goodbourn and Maniatis, *Cell*. 1985 Jun; 41(2): 509-520, 1985
Goodbourn *et al.*, *Cell*. 1986 May 23; 45(4): 601-610, 1986
Greene *et al.*, *Adv Exp Med Biol.* 1989; 254: 55-60, 1989
Grosschedl and Baltimore, *Cell*. 1985 Jul; 41(3): 885-897, 1985
30 Han *et al.*, *J. Exp. Med.*, 171:465-475, 1990.

- Han, Brown, Beutler, *J.Exp.Med.*, 171:465-475, 1990.
- Haranaka, Satomi, Sakurai, Haranaka, *Cancer Immunol.Immunother.*, 18:87-90, 1984.
- Haslinger and Karin, *Proc Natl Acad Sci U S A.* 1985 Dec; 82(24): 8572-8576, 1985
- Hauber and Cullan, 1988
- 5 Hayes and Zoon, *Infec.Immun.*, 61:3222-3227, 1993.
- Haziot, Ferrero, Kontgen *et al.*, *Immunity*, 4:407-414, 1996.
- Heine *et al.*, *J. Immunology*, 162:6971-6975, 1999.
- Hen *et al.*, *Nature.* 1986 May 15; 321(6067): 249-251, 1986
- Hensel *et al.*, 1989
- 10 Herr and Clarke, 1986
- Hirochika *et al.*, *J Virol.* 1987 Aug; 61(8): 2599-2606, 1987
- Hirsch *et al.*, *Mol Cell Biol.* 1990 May; 10(5): 1959-1968, 1990
- Hoffmann *et al.*, *J.Exp.Med.* 146, 1640-1647, 1977
- Holbrook *et al.*, *Virology.* 1987 Mar; 157(1): 211-219, 1987
- 15 Horlick and Benfield, *Mol Cell Biol.* 1989 Jun; 9(6): 2396-2413, 1989
- Hoshino, Takeuchi, Kawai *et al.*, *Journal of Immunology*, 162:3749-3752, 1999.
- Hu *et al.*, *Genome Research.* 7, 693-704, 1997
- Huang *et al.*, 1981
- Hwang *et al.*, 1990
- 20 Imagawa *et al.*, *Cell.* 1987 Oct 23; 51(2): 251-260, 1987
- Imbra and Karin, *Nature.* 1986 Oct 9; 323(6088): 555-558, 1986
- Imler *et al.*, *Mol Cell Biol.* 1987 Jul; 7(7): 2558-2567, 1987
- Imperiale and Nevins, *Mol Cell Biol.* 1984 May; 4(5): 875-882, 1984
- Jakobovits *et al.*, *Mol Cell Biol.* 1988 Dec; 8(12): 5549-5554, 1988
- 25 Jameel and Siddiqui, *Mol Cell Biol.* 1986 Feb; 6(2): 710-715, 1986
- Jaynes *et al.*, *Mol Cell Biol.* 1988 Jan; 8(1): 62-70, 1988
- Johnson *et al.*, *Mol Cell Biol.* 1989 Aug; 9(8): 3393-3399, 1989a
- Kadesch and Berg, *Mol Cell Biol.* 1986 Jul; 6(7): 2593-2601, 1986
- Karin *et al.*, *Mol Cell Biol.* 1987 Feb; 7(2): 606-613, 1987
- 30 Katinka *et al.*, *Cell.* 1980 Jun; 20(2): 393-399, 1980,

Katinka *et al.*, *Nature*. 1981 Apr 23; 290(5808): 720-722, 1981

Kawai, Adachi, Ogawa, Takeda, Akira, *Immunity*, 11(1):115-122, 1999.

Kawamoto *et al.*, *Mol Cell Biol*. 1988 Jan; 8(1): 267-272, 1988

Kirkland, Virca, Kuus-Reichel *et al.*, *J.Biol.Chem.*, 265:9520-9525, 1990.

5 Kirschning, Wesche, Merrill, Rothe, *J.Exp.Med.*, 188:2091-2097, 1998.

Kruys, Kemmer, Shakhov, Jongeneel, Beutler, *Proc.Natl.Acad.Sci. USA*, 89:673-677, 1992.

Kuhns *et al.*, *J.Immunol*. 158, 3959-3964, 1997

Kyte and Doolittle, *J. Mol. Biol.*, 157(1):105-132, 1982.

10 Lau and Livesey, *J.Clin.Invest.*, 84:738-743, 1989.

Lemaitre *et al.*, *Cell*. 86, 973-983, 1996

Macela *et al.*, *FEMS Immunol.Med.Microbiol*. 13, 235-238, 1996

Matsuura and Galanos, *Infec.Immun.*, 58:935-937, 1990.

Medzhitov, Preston-Hurlburt, Janeway, *Nature*, 388:394-397, 1997.

15 Medzhitov, Preston-Hurlburt, Kopp *et al.*, *Molecular Cell*, 2:253-258, 1998.

Michalek, Moore, McGhee, Rosenstreich, Mergenhagen, *J.Infec.Dis.*, 141:55-63, 1980.

Miller *et al.*, PCT Application WO 89/06700

Modlin, Brightbill, Godowski, *N.Engl.J.Med.*, 340:1834-1835, 1999.

Muzio *et al.*, *J.Exp.Med*. 187, 2097-2101, 1998

20 Muzio, Natoli, Saccani, Levrero, Mantovani, *J.Exp.Med.*, 187:2097- 2101, 1998.

O'Brien *et al.*, *J.Immunol*. 124, 20-24, 1980.

Pace, Russell, LeBlanc, Murasko, *J.Immunol.*, 134:977-989, 1985.

Poltorak *et al.*, "Endotoxin, Lipopolysaccharide, c. Positional, Shock, Inflammation, and Sepsis," *Blood Cells Molecules & Diseases* 24:340-355, 1998.

25 Poltorak, He, Smirnova *et al.*, *Science*, 282:2085-2088, 1998b.

Poltorak, Smirnova, He *et al.*, *Blood Cells Mol.Dis.*, 24:340-355, 1998a.

Qureshi *et al.*, *10th International Mouse Genome Conference*. 311,1996(Abstract)

Qureshi, Lariviere, Leveque *et al.*, *J.Exp.Med.*, 189:1519, 1999.

Qureshi, Lariviere, Leveque *et al.*, *J.Exp.Med.*, 189:615-625, 1999.

- Rock *et al.*, "A family of human receptors structurally related to *Drosophila* Toll,"
Proc.Natl.Acad.Sci.U.S.A. 95, 588-593, 1998.
- Rommens *et al.*, In: Hochgeschwender, U., Gardiner, K., eds., *Identification of Transcribed Sequences*, New York, N.Y., Plenum Press, 1998, p. 65
- 5 Rosenstreich *et al.*, *J.Immunol.* 121, 1664-1670, 1978
- Rosenstreich *et al.*, *J.Infec.Dis.* 136, S239-S245, 1977
- Rosenstreich, Vogel, Jacques, Wahl, Oppenheim, *J.Immunol.*, 121:1664-1670, 1978.
- Rosetto *et al.*, *Biochem.Biophys.Res.Comm.* 209, 111-116, 1995
- Ryan *et al.*, *Nature.* 269, 153-155, 1977
- 10 Sambrook *et al.*, In: *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989.
- Schneider, Hudson, Lin, Anderson, *Genes Dev.*, 5:797-807, 1991.
- Shimazu, Akashi, Ogata *et al.*, *J.Exp.Med.*, 189(11):1777-1782, 1999.
- Sultz, *Nature*, 219:1253-1254, 1968.
- 15 Sultz, *Nature.* 219, 1253-1254, 1968
- Tracey *et al.*, *Science*, 234:470-474, 1986.
- Tracey, Beutler, Lowry *et al.*, *Science*, 234:470-474, 1986.
- Truffa-Bachi *et al.*, *Cell.Immunol.* 30, 1-11, 1977
- Vogel and Fultz, *Microbiol.Immunol.* 137, 165-170, 1988
- 20 Vogel *et al.*, *Infect.Immun.* 62, 4454-4459, 1994
- Vogel, Moore, Sipe, Rosenstreich, *J.Immunol.*, 124:2004-2009, 1980.
- Von Jeney *et al.*, *Infec.Immun.* 15, 26-33, 1977
- Watson *et al.*, *J.Immunol.* 118, 2088-2093, 1977
- Watson *et al.*, *J.Immunol.* 120, 422-424, 1978
- 25 Watson, Kelly, Lagen, Taylor, *J.Immunol.*, 120:422-424, 1978.
- Wright *et al.*, *Science*, 249:1431-1433, 1990.
- Wright, Ramos, Tobias, Ulevitch, Mathison, *Science*, 249:1431-1433, 1990.
- Yang *et al.*, *Nature*, 395:284-288, 1998.
- Yang, Mark, Gray *et al.*, *Nature*, 395:284-288, 1998.